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Part I 
INTRODUCTION 
Chapter 1.1 
General introduction to the topic 
Atrial natriuretic peptide, a hormone secreted by the heart, has come to be 
considered a major contributor to the hormonal control of the cardiovascular sys-
tem. Although the endocrine function of the heart was demonstrated only in 
1981, an association between the cardiac atria and renal function had been 
suspected long before. 
As early as 1935 Peters speculated on the existence of a volume controlling 
system which could 'sense the fullness of the blood stream' (1). In 1956 Henry, 
Gauer and Reeves (2) suggested that the heart could detect changes in the 
central blood volume. Inflation of a balloon in the left atrium of dogs was shown 
to increase diuresis, natriuresis and urine flow rate (3,4). Initially these findings 
were attributed to a reactive decrease in the secretion of vasopressin or a 
response of the nervous apparatus (5,6). However, the diuresis and natriuresis 
induced by volume expansion were found not to be inhibited by cardiac dener-
vation, by vagal sectioning, by destruction of the pituitary or by antidiuretic 
hormone infusion (7-9). These observations did not preclude the possibility of a 
blood-borne diuretic and natriuretic factor that could explain the observed 
phenomena. 
In 1961 deWardener and colleagues performed a series of experiments that 
strongly pointed to the presence of a circulating natriuretic factor. In these 
experiments an isolated dog kidney was perfused with blood circulating through a 
second dog in which saline volume expansion was induced. This resulted in a 
marked increase in the urine flow rate from the isolated dog kidney (10). This 
phenomenon suggested to them the existence of an unidentified 'third factor' 
affecting sodium excretion, as collateral experiments showed that the natriuresis 
resulting from sodium load occurred independently of changes in glomerular 
filtration rate (first factor) and aldosterone (second factor) (10). This 'third 
factor' assumed to be a circulating humoral mediator, came to be known as the 
natriuretic hormone. In contrast to atrial natriuretic peptide this substance, of a 
low molecular weight <1000 Da (11), considerably lower than that of atrial 
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natriuretic peptide (3081 Da), inhibits Na+/K+-ATPase activity (12) and possesses 
ouabain-like immunoreactivity (13). Its exact chemical structure has not yet been 
elucidated. 
Concurrently with the experiments which demonstrated that both volume 
expansion and increase in atrial pressure induce diuresis, possibly through the 
medium of a circulating agent, an entirely different line of research was followed 
which led to the discovery of the atrial natriuretic peptide. In 1951 Kisch and 
colleagues using an electron microscope detected granules in atrial myocytes 
which were absent in ventricular myocytes (14). Jamieson and Palade noticed the 
resemblance of these granules to secretory granules found in endocrine organs 
(15). In 1979 deBold and colleagues found that the amount of these specific 
granules in the atria was negatively correlated with the volume of extracellular 
fluid (16). The number of these granules increased by water deprivation and 
decreased by saline loading or administration of deoxycorticosterone. In 1981 
these investigators performed a crucial experiment: they injected atrial extracts 
into rats and observed massive diuresis and natriuresis. In contradistinction, 
ventricular extracts did not produce these effects (17). DeBold and colleagues 
concluded that the heart secretes a hormone which is stored in specific atrial 
granules and is involved in the volume regulation of the cardiovascular system. In 
view of its site of production, its effects and chemical structure this hormone was 
called 'atrial natriuretic peptide (ANP)'. 
In the past few years extensive biomedical research has elucidated the structure 
and function of this peptide. The next chapter gives a brief review of the current 
knowledge regarding this new peptide hormone. 
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Chapter 1.2 
Survey of the literature and 
scope of the present study 
Isolation and characterization of ANP 
Soon after the landmark experiment by deBold et al. (17) several investigators 
isolated various related polypeptides from the atrium (18,19). These polypeptides 
possess natriuretic, diuretic and vasorelaxant properties. All these peptides were 
found to derive from a common precursor peptide containing 126 amino acids 
(20) (figure 1-1). As different investigators reported isolation of these peptides, 
different names were initially given to them, which led to confusion and compli-
cated scientific communication. Therefore a nomenclature committee, established 
jointly by the International Society of Hypertension, the American Heart Asso-
ciation and the World Health Organization, has recommended that the term 
'Atrial Natriuretic Factor (or Peptide)' be adopted and that the prefix 'h' for 
human or 'r' for rat be used for species designation (21). Furthermore the 
specific amino acid composition of each peptide should be designated with 
reference to the common precursor molecule, with peptide sequence starting at 
the N-terminus. Thus the precursor form of ANP is (1-126)ANP (also known as 
7-ANP). In blood, the major circulating form of ANP is (99-126)ANP (also 
known as a-ANP), made up by the final 28 amino acids on the C-terminal end 
of (1-126)ANP (22,23). 
Evidence is accumulating that besides (99-126)hANP, other peptides deriving 
from (l-126)hANP circulate in human blood. The presence of the precursor 
peptide itself as well as cardiodilatin (corresponding to (l-98)hANP) and ß-hANP 
(an antiparallel dimer of (99-126)hANP) have been reported (24,25). Also, 
shorter fragments of (99-126)hANP have been found in human blood (26,27) 
(figure 1—2). As the incidence of these peptides seems to differ in various patho-
logical conditions (28), the possibility cannot be excluded that altered atrial pro-
cessing and secretion of abnormal forms may be involved in certain disturbances 
of sodium and fluid balance. 
The major circulating form, (99-126)hANP possesses a disulfide bridge between 
the two cysteine residues, which is essential for its biological activity (29) (figure 
1-3). 
Successive deletion of the five C-terminal residues gradually decreases the biolo-
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(l-126)hANP (or yhANP) are found. 
gical activity of ANP, while deletion or prolongation of the N-terminal residues 
seems to have little effect (30,31). Human (99-126)ANP differs from rat 
4 
Figure 1-3. Structure of the major circulating component in blood: (99-126)ANP. 
(99-126)ANP by one amino acid. Where in rat position 110 is occupied by 
isoleucine it is occupied by methionine in man. 
The gene for ANP consists of three translated sequences (exons) and two 
intervening sequences (introns) not coding for the precursor peptide (figure 1-1). 
It is of interest to note that the second intron contains a sequence for a putative 
glucocorticoid receptor-regulatory element (GcR) (32,33). This suggests that the 
synthesis of ANP may be partly regulated by glucocorticoids. Accordingly, when 
fludrocortisone or prednisolone was administered to healthy persons, treatment 
with the mineralocorticoid fludrocortisone induced volume expansion (explaining 
the rise in ANP levels) with weight gain, whereas treatment with the 
glucocorticoid prednisolone did not induce such effects. Both treatments however 
induced similar increases in ANP levels (34). When dexamethasone was added to 
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atrial myocytes in vitro, the immunoreactive ANP level in the myocytes, the 
mRNA level and the amount of ANP released from atrial myocytes all increased 
(35). 
The gene for ANP encodes for a 151 amino acids pre-pro peptide. After clea-
vage of the 25 amino acids hydrophobic signal-peptide, the (1-126)ANP pro-
peptide arises. The main storage form of ANP as found in granules in atrial 
myocytes is (1-126)ANP while the major circulatory form is (99-126)ANP (36). 
The cleavage of the Arg^ - Ser^ bond to produce the bioactive (99-126)ANP 
form probably occurs before the release of ANP into the bloodstream (37,38). 
The identification in bovine and rat atria of a protease specific for the putative 
cleavage site indicates that the atrial tissue contains the enzyme required for the 
proteolytic activation of pro-ANP (39,40). 
Under normal physiological condititions immunoreactive ANP is present in 
both atria, but predominantly in the right one (41) which also contains a greater 
number of secretory granules (42). Atrial appendectomy markedly diminishes the 
natriuretic response to volume load (43,44). 
Chronic volume overload as occurs in congestive heart failure, may lead to de-
pletion of atrial ANP and 'recruitment' of ventricular myocytes. The ratio of 
atrial versus ventricular ANP, which is normally about 1000:1, can under these 
conditions decrease to 10:1. The amount of mRNA in both atrium and ventricle 
increases and secretory granules appear in the ventricles (45-48). In the normal 
state no storage granules in ventricular myocytes are found, which implies that 
the ventricular myocytes secrete ANP via a constitutive rather than a regulatory 
secretory pathway like the atrial myocytes (48,49). 
Release of ANP 
The first indications for the existence of a blood-borne natriuretic substance 
came from the observations made by deWardener and colleagues that blood 
from a volume expanded dog could induce natriuresis (10). As mentioned above, 
these investigators attributed this phenomenon to a putative substance, 
designated 'natriuretic hormone'. It is however more likely that this phenomenon 
is mediated at least in part by the atrial natriuretic peptide. Indeed, after the 
experiment by deBold et al. in 1981 (17) it was shown, in human and animal 
studies, that volume expansion is associated with a marked rise in ANP levels 
and concomitant diuresis and natriuresis (50,51). The diuretic/natriuretic response 
to volume expansion in rats can be blocked by administering monoclonal ANP-
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antibodies, which by binding to ANP neutralize its action (52-54). The hypothesis 
that the blood volume determines the release of ANP is supported by the ob-
served positive correlation of ANP concentrations with the right atrial pressure 
(55,56). Although in general atrial pressure is a measure for atrial stretch, it is 
the stretch rather than the pressure that seems to be the main stimulus for 
release of ANP (57,58). The pivotal role played by atrial stretch implies that it is 
the central (or so-called 'effective') blood volume rather than intravascular 
volume that is the main determinant of ANP release. Manoeuvres causing a 
redistribution of intravascular fluid volume such as head down tilt, head out 
water immersion or change from the upright to the supine position increase ANP 
concentrations (59,60). The increase in ANP concentrations observed during 
infusion of pressor agents like angiotensin II or phenylephrine probably results 
from increased right atrial pressure rather than from a direct effect of angioten-
sin II or phenylephrine on ANP release (61). The amount of sodium in the diet 
influences ANP release. High sodium intake for 3 to 5 days can increase ANP 
concentrations two to fourfold. A close positive correlation was observed between 
body weight gain, fractional sodium excretion and plasma ANP concentration, 
which shows that ANP plays a role in regulating the body fluid balance (62,63). 
ANP increases during tachycardia or rapid atrial pacing in proportion to heart 
rate (64), which in all likelihood is due to atrial stretching. Interestingly, 
repeating the stimulus seems to enhance ANP release (65). 
As ANP levels reflect intracardiac pressures, high levels have been observed in 
pathological conditions associated with volume overload such as congestive heart 
failure, chronic renal failure, primary aldosteronism or the syndrome of inappro-
priate secretion of antidiuretic hormone (ADH). With normalization of 
extracellular fluid volume (e.g. by drug treatment or haemodialysis) ANP 
concentrations fall (55,66-70). The somewhat blunted response to infusion of 
ANP in congestive heart failure may be due to diminished responsiveness of 
target-organs to ANP, to intrinsic renal dysfunction or to activation of sodium-re-
taining systems offsetting the effects of ANP (71). 
After the discovery of ANP it was speculated that impaired secretion of or 
impaired response to this hormone could be involved in the pathogenesis of 
hypertension. However, both in experimental and human hypertension an 
elevation in ANP concentrations was found rather than a reduction. While 
strongly elevated ANP concentrations were measured in severe hypertension 
accompanied by left ventricle hypertrophy, positively correlating with blood 
pressure, normal or only slightly elevated concentrations were observed in mild 
essential hypertension (72,73). Infusion of synthetic ANP in humans with essential 
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hypertension has an enhanced blood pressure lowering effect, attended with 
enhanced diuresis and natriuresis (74). This does not suggest reduced organ 
responsiveness to ANP in essential hypertension. Although the above mentioned 
data do not support the idea of a dysfunction of the ANP system in hyperten-
sion, it is interesting to note that sons of hypertensive parents, as compared to 
sons of normotensive parents, exhibit a diminished ANP response to a 7 day 
high sodium diet (75). Hypertensive patients, as compared to normal persons, 
exhibit an enhanced natriuresis and an enhanced ANP response to saline infusion 
(76). Exercise increases heart rate, blood pressure and ANP release more in 
hypertensives than in normals, while the rise in ANP was found to correlate with 
the degree of left ventricular dysfunction (77,78). 
Effects of ANP 
The potent effects of ANP on the kidney led to intensive research into the 
mechanisms involved. Infusion of the synthetic peptide into animals or humans 
causes large increases in urinary sodium and chloride excretion, together with 
moderate increases in calcium, magnesium and phosphate excretion with little 
change in potassium excretion and free water clearance (79-81). The distribution 
of ANP receptor sites in the kidney suggests that ANP acts mainly on the 
glomeruli, collecting ducts and the renal vasculature (82,83). The renal effects of 
ANP seem to be largely due to its renal haemodynamic and vascular activities, in 
particular to an increase in glomerular filtration rate and filtration fraction, a 
medullary washout and a redistribution of renal blood flow away from the salt 
retaining nephrons. ANP can increase both single nephron and whole kidney 
glomerular filtration rates, probably by constriction of efferent and dilatation of 
afferent glomerular arterioles together with increased glomerular capillary 
permeability (84-87). A direct effect of ANP on the renal tubulus cannot be 
ruled out (80,88,89). 
Infusion of ANP causes a dose-dependent fall in the arterial blood pressure in 
man as well as in animals (81,90,91). This may be caused by a direct vasodilating 
effect of ANP since isolated vessels or vascular preparations partially constricted 
by the application of pressor agents relax when ANP is added (92,93). Infusion 
of synthetic ANP into humans, however, does not decrease but increases peri-
pheral resistance. This is probably due to reflex activation of the sympathetic 
nervous system. The blood pressure lowering effect of ANP may thus be due to 
a decrease in cardiac output (94,95). Such decrease cannot be explained by a 
direct negative effect of ANP on the heart, as ANP does not affect the force of 
8 
contraction nor the heart rate in isolated cardiac atria (96). Furthermore ANP 
increases coronary blood flow, and during infusion of ANP right atrial pressure 
decreases rather than increases as would be expected in the case of a negative 
inotropic effect (97,98). The reduction in cardiac output can be ascribed to a 
decrease in venous return following ANP infusion (97). Diuresis and contraction 
of the intravascular blood volume may play an additional role. ANP causes a 
reduction in the circulating blood volume due to a shift of intravascular fluid to 
the interstitial space, which shift presumably results from increased capillary 
hydraulic conductivity and postcapillary resistance (99,100). This reduction is 
reflected in a rise in haematocnt, a phenomenon which cannot be ascribed to 
increased diuresis since it is also found in anephnc rats (101). 
Yet, some investigators observed an increase in cardiac output during infusion 
of ANP (102). The change in cardiac output may depend on the degree of after-
load reduction (which increases cardiac output) and preload reduction (which de-
creases cardiac output). The contradictory observations regarding the cardio-
vascular effects of ANP may be attributable to species-related differences, to the 
level of consciousness of the experimental subject, and to the molecular form of 
ANP infused. Furthermore the dose of ANP, the mode of administration (e.g 
bolus or constant intravenous infusion, or both) and the duration of infusion 
varied widely with different experimental protocols. Besides, the medium m 
which ANP is dissolved and the study design (whether or not placebo-controlled) 
are to be taken into consideration. 
ANP can be considered to be a functional antagonist of the renin-angiotensm-
aldosterone system. It inhibits the rise in PRA after head-up tilt (103). Low dose 
ANP infusion decreases PRA secretion (80,90,91). High dose ANP may stimulate 
PRA, presumably by reflex activation of the sympathetic system. In cultured 
juxtaglomerular cells renin release was inhibited by ANP (104). Also the 
increased delivery of sodium to the distal tubulus may decrease renin secretory 
rate from the macula densa cells. Aldosterone synthesis is directly inhibited by 
ANP at a step preceding the mitochondrial metabolism of cholesterol (105). 
Plasma Cortisol was reported to decrease after administration of ANP (106) but 
not consistently (80,90). Haemorrhage- or dehydration-induced release of ADH 
was inhibited by ANP in the rat (107). Also, the rise in ADH concentrations 
after head-up tilt (103) and the osmolahty-induced ADH release (108) were in-
hibited by ANP. It was shown that ANP reduces the rate of ADH release in 
vitro (109). Several investigators did not detect any change in ADH concen-
trations in vivo (79,81), while others noted a slight decrease during infusion of 
ANP or, after it, a rebound increase implying suppression of ADH during m-
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fusion (110). 
ANP may influence the sympathetic nervous system. Low doses of ANP in hu-
mans do not affect the release of catecholamines (91,95). In dog, low doses of 
ANP lower blood pressure slightly and decrease the release of catecholamines, 
whereas higher doses of ANP tend to have a reverse effect. This implies that low 
infusion rates of ANP may inhibit the release of epinephrine from the adrenal 
medulla and also the baroreceptor reflexes that normally increase norepinephrine 
release. At larger doses of ANP the more pronounced hypotensive effects elicit a 
more powerful reflex response of the sympathetic nervous system, thereby increa-
sing norepinephrine release (94,111). 
Figure 1—4 illustrates the function of ANP in the regulation of the extracellular 
fluid (ECF) volume. Distension of atrial myocytes by increasing ECF volume 
stimulates cardiac ANP secretion. The various effects of ANP on its target-
organs (kidney, adrenal and cardiovascular system) lead to a decrease in ECF 
volume which by diminishing atrial distension decreases ANP secretion. 
Receptor and second messenger of ANP 
Autoradiographic and receptor binding studies have revealed an abundance of 
binding sites for ANP in the body. ANP binding sites are localized in the kidney, 
adrenal gland, small intestine, colon, certain brain areas and blood vessels (112-
114). This wide distribution of binding sites is not surprising in view of the role 
of ANP in controlling salt and water balance and blood pressure. 
The ANP receptor population is functionally heterogeneous. Two types of 
receptors exist: one with and one without guanylate cyclase activity. Both 
guanylate cyclase-containing and guanylate cyclase-free receptors possess similar 
molecular weights of approximately 130.000 daltons under nonreducing 
conditions. Under reducing conditions the cyclase-free receptor consists of sub-
units of about 65.000 daltons (115,116). The difference between the two types of 
receptors is also expressed in their binding capacity to ANP and its analogues: 
while the guanylate cyclase-containing receptor (called B-receptor) binds ANP 
molecules containing more than 24 amino acid residues, the guanylate cyclase-
free receptor (C-receptor) is capable of binding truncated ANP analogues with 
21 or 17 (ring) amino acid residues (117). The development of specific ANP 
analogues for the C-receptor made it possible to clarify their function. Although 
these analogues bind to more than 95 % of (99-126)ANP binding sites in the 
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Figure 1-4. Schematic drawing of the function of ANP in the regulation of 
extracellular fluid (ECF) volume. 
kidney, no cyclic guanosine monophosphate (cGMP) was produced (118). In the 
isolated rat kidney these analogues exhibit no effects on renal vasculature, 
glomerular filtration rate, filtration fraction or excretion of fluid and electrolytes. 
On the other hand, when these analogues were infused into intact animals, a 
marked diuresis and natriuresis occurred. Blood pressure decreased and 
glomerular filtration fraction increased. Concomitantly, plasma levels of 
(99-126)ANP increased. These findings indicate that the natriuretic and blood 
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pressure lowering effects of the analogues should not be ascribed to their in-
trinsic ANP nature but to their ability to increase plasma levels of endogenous 
(99-126)ANP (118). As these analogues compete with endogenous (99-126)ANP 
for binding to C-ANP receptors, it is likely that the C-ANP receptor modulates 
the metabolic clearance of ANP (119). 
After binding of ANP to its receptor the membrane-bound enzyme particulate 
guanylate cyclase is activated and cGMP is produced (120,121). Cyclic GMP, 
acting as second messenger for ANP then provokes the biological effects of ANP 
through the cGMP-dependent protein kinase (122,123). The receptor and the 
enzyme particulate guanylate cyclase are tightly coupled and probably represent 
the same entity (124,125). When the actions of ANP are blocked by antibodies 
directed against ANP, no cGMP production is observed (126,127). While addition 
of a permeable analogue of cGMP in vitro and in vivo mimicks the effects of 
ANP (128-130), prevention of cGMP production abolishes the effects of ANP 
(131,132). Cyclic GMP values can be measured in plasma as well as in urine. 
Measurement of the cGMP response to ANP may be useful to investigate the 
responsiveness of the target organs to ANP (133,134). 
ANP-peptides in the brain and the kidney 
ANP-like immunoreactive material has been found in various parts of the brain 
and the peripheral nervous system. The highest concentration of ANP, though 
3000-fold lower than in the atria, is found in the hypothalamus. Local production 
of ANP in the brain is suggested by the existence of ANP mRNA transcripts in 
rat brain, especially in the hypothalamus. In vitro, the rat hypothalamus can 
release ANP-like material (135-139). These observations point to a neuro-
transmitter or neuromodulator role of ANP in the central nervous sytem. While 
in blood the predominant form of ANP is (99-126)ANP, in rat brain the predo-
minant forms are (102-126)ANP and (103-126)ANP, which implies different 
processing and maturation of the ANP prohormone in the brain (139,140). Spe-
cific receptors for ANP have been demonstrated in brain tissue. Brain micro-
vessels constituting the blood-brain barrier also possess specific ANP receptor 
binding sites. As ANP is able to alter the rate of production of cerebrospinal 
fluid, it may participate in the constant exchange of fluid between blood and 
brain (141,142). 
Injections of ANP into the lateral ventricle of rat brain induces multiple effects 
on the regulation of water and salt balance. ANP increases urinary volume, de-
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creases salt and water intake and inhibits ADH secretion and the pressor respon-
se to angiotensin II in rats. Intracerebro-ventricular injection of antiserum to 
ANP enhances angiotensin Il-induced water intake (143-149). Thus ANP in the 
brain acts synergistically with its known effects as a cardiovascular hormone. 
Recently, a novel 26 amino acids peptide called 'Brain Natriuretic Peptide' 
(BNP, figure 1—5) was identified in porcine brain. Its structure strongly resembles 
that of ANP but it definitely is neither a precursor nor a degradation product of 
it (150-152). Correspondingly, BNP does not crossreact with ANP in a 
radioimmunoassay (153). Although the localization of BNP in rat brain seems to 
differ from the localization of ANP (154), the two peptides share the same 
receptor, as shown by receptor displacement studies (151,155). BNP, like ANP, 
acts on particulate guanylate cyclase and increases cGMP (151,156). The effects 
of BNP are similar to those of ANP: inhibition of adrenal steroidogenesis (156), 
diuretic, natriuretic, blood pressure lowering and vasorelaxant activities (150), 
antidipsinogenic action (157) and inhibition of ADH secretion (158). Interestingly, 
BNP seems to be present in the atrium as a prohormone and to be secreted into 
the circulation as a smaller molecule, resembling the ANP hormone. The amount 
of immunoreactive BNP was found to be approximately 1-5 % of the amount of 
immunoreactive ANP in porcine heart and plasma (153). 
The kidney, besides being a major target-organ for ANP, may also be influen-
ced by paracrine hormones. Urodilatin, a 32 amino acid hormone corresponding 
to (95-126)ANP, was identified in the collecting ducts of the rat kidney (figure 
1-5). Messenger RNA for pro-ANP was found in the collecting duct, which sug-
gests local production and processing of this hormone. Preliminary reports 
indicate that urodilatin administered to rats induces effects similar to those of 
ANP (159). 
It is becoming increasingly clear that the atrial natriuretic peptide hormone 
system can be regarded as antagonistic to the renin-angiotensin aldosterone 
system. The circulating atrial natriuretic peptide in blood, the paracrine hormone 
urodilatin and the brain natriuretic peptide exert functions opposite to those of 
the latter hormone system. They increase diuresis and natriuresis, lower blood 
pressure, induce vasodilation, and suppress renin, aldosterone and vasopressin 
secretion. Furthermore the existence of a circulating hormone, a paracrine 
hormone and a putative neurotransmitter point to the integrated function of this 
hormonal system in the control of body fluid homeostasis. 
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Figure 1-5. The marked similarity between atrial natriuretic peptide (ANP), porcine 
brain natriuretic peptide (BNP) and urodilatin (UNP) point to the integrated 
function of this hormonal system in the control of body fluid homeostasis. Note that 
urodilatin corresponds to (95-126)hANP. 
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Scope of the thesis 
The investigations described in the following chapters were performed with a 
view 
- to develop and validate a method for the determination of ANP concentrations 
in human blood (Part II) 
- to study the influence of various physiological and sampling conditions affecting 
the measurement and interpretation of ANP concentrations (part III) 
- to explore the physiological relevance of the higher ANP values found in 
elderly subjects as compared to those measured in young subjects, including a 
number of observations on the second messenger of the ANP hormonal 
system, cyclic guanosine monophosphate (part IV) 
- to study the involvement of the atrial natriuretic peptide system in pulmonary 
embolism and myocardial infarction (part V) 
In this thesis the abbreviation ANP is used to designate immunoreactive atrial 
natriuretic peptide in humans. 
15 

Chapter 1.3 
References 
1 Peters JP Body water The exchange of fluids in man Charles С Thomas, 1935,287 
2 Henry JP, Gauer OH, Reeves JL Evidence of the atrial location of receptors influencing 
urine now Circ Res 1956 4 85 90 
3 Lydtin H, Hamilton WF Effect of acute changes in left atrial pressure on urine flow in 
unaneslhetized dogs Am J Physiol 1964,207 530-6 
4 Gillespie DJ, Sandberg RL, Koike Tl Dual effect of left atrial receptors on excretion of 
sodium and water in the dog Am J Physiol 1973,225 706-10 
5 Gauer OH, Henry JP Circulatory basis of fluid volume control Physiol Rev 1963 43 423-81 
6 Ledsome JR, Linden RJ, O'Connor WJ The mechanisms by which distension of the left 
atrium produces diuresis in anaesthetized dogs J Physiol 1961,159 87-100 
7 Linden RJ Atrial reflexes and renal function Am J Cardiol 1979,44 879 83 
8 Pater DC, Schultz HD, Sundet WD, Mapes JS, Goctz KL Effects of left atrial stretch in 
cardiac-dcncrvated and intact conscious dogs Am J Physiol 1982,242 H1056-64 
9 Pcarce JW The effect of vagotomy and denervation of the carotid sinus on diuresis 
following plasma volume expansion Can J Biochem Physiol 1959,37 81 90 
10 DeWardener HE, Mills IH, Clapham WF, Hayter CJ Studies on the efferent mechanism of 
the sodium diuresis which follows the administration of intravenous saline in the dog Clin 
Sa 1961,21 249 58 
11 Hamlyn JM, Sehenden JA, Zyren J, Baczynskyj L. Purification and characterization of 
digitalishke factors from human plasma Hypertension 198710(suppl 1) 171-7 
12 Hamlyn JM, Ringel R, Schaeffcr J, et al A circulating inhibitor of (Na++K+)ATPase 
associated with essential hypertension Nature 1982 300 650 2 
13 Grubcr KA, Whitakcr JM, Buckalcw VM Endogenous digitalis like substance in plasma of 
volume expanded dogs Nature 1980;287 743 5 
14 Kisch В Electron microscopy of the atrium of the heart Ezp Med Surg 1956,14 99 112 
15 Jamicson JD, Paladc GE Specific granules in atrial muscle cells J Cell Biol 1964 23 151 72 
16 DeBold AJ Heart atria granularity effects of changes in water - electrolyte balance Proc 
Soc Exp Biol Med 1979,161 508 11 
17 DeBold AJ, Borenstein HB, Veress AT, Sonnenberg H A rapid and potent natriuretic res­
ponse to intravenous injection of atrial myocardial extract in rats Life Sa 1981,28 89 94 
18 Currie MG, Geller DM, Cole BR, et al Purification and sequence analysis of bioactive 
atrial peptides (atnopcptins) Science 1984 223 67 9 
19 Atlas SA, Kleinen HD, Camargo MJ, et al Purification, sequencing and synthesis of 
natriuretic and vasoactive rat atrial peptide Nature 1984,309 717-9 
20 Kangawa K, Fukuda A, Matsuo H Structural identification of ß- and -j-human atrial 
natriuretic polypeptides Nature 1985 313 397 400 
21 Dzau VJ, Baxter JD, Cantin M, et al Nomenclature for atrial peptides New Engl J Med 
1987,3161278 9 
22 Theiss G, John A, Morich F, et al a-h-ANP is the only form of circulating ANP in 
humans FEBS Lett 1987,218 159-62 
23 Sugawara A, Nakao K, Morn N, et al α human atrial natriuretic polypeptide is released 
from the heart and circulates in the body Biochem Biophys Res Commun 1985,129 439-46 
24 Iloh H, Nakao K, Sugawara A, el al 7 atrial natriuretic polypeptide (fANP) derived 
peptides in human plasma cosecretion of N-tcrminal ifANP fragment and aANP / Clin 
Endocrinol Metab 1988,67 429 37 
25 Melcagros L, Gibbs JSR, Ghatei MA, Bloom SR Increase in plasma concentrations of car-
diodilatm (amino terminal pro atrial natriuretic peptide) in cardiac failure and during re­
cumbency Br Heart J 1988,60 39-44 
17 
26 Yandle Τ, Crozier I, Nicholls G, Espiner E, Carne A, Brennan S Amino acid sequence of 
atrial natriuretic peptides in human coronary sinus plasma Biochem Biophys Res Commun 
1987,146 832-9 
27 Imura O, Shimamoto K, Ando Τ, et al Plasma levels of human atrial natriuretic peptide in 
patients with hypertensive diseases Can J Physiol Pharmacol 1987,65 1701 5 
28 Marumo F, Kurosawa T, Takcda S, Katoh Y, Hasegawa N, Ando К. Changes of molecular 
forms of atrial natriuretic peptide after treatment for congestive heart failure Kim 
Wochenschr 1988,66 675 81 
29 Misono KS, Fukumi H, Grammer RT, Inagami Τ Rat atrial natriuretic factor complete 
amino acid sequence and disulfide linkage essential for biological activity Biochem Biophys 
Res Commun 1984,119 524 9 
30 Thibault G, Garcia R, Carrier F, et al Structure activity relationships of atrial natriuretic 
factor (ANF) I Natriuretic activity and relaxation of intestinal smooth muscle Biochem 
Biophys Res Commun 1984 125 938 46 
31 Garcia R, Thibault G, Scidah NG, et al Structure activity relationships of atrial natriuretic 
factor (ANF) II Effect of chain length modifications on vascular reactivity Biochem 
Biophys Res Commun 1985126178 84 
32 Nemer M, Chambcrland M, Sirois D, el al Gene structure of human cardiac hormone pre­
cursor, pronatnodilalin Nature 1984,312 654 6 
33 Greenberg BD, Bcnccn GH, Scilhamer JJ, Lcwicki JA, Fiddes JC Nucleotide sequence of 
the gene encoding human atrial natriuretic factor precursor Nature 1984 112 656 8 
34 Weidmann Ρ, Matter DR, Matter ЕЕ, et al Glucocorticoid and mincralocorticoid 
stimulation of atrial natriuretic peptide release in man J Clin Endocrinol Metab 
1988,661213-9 
35 Gardner DG, Gert? BJ, DcSchcppcr CF, Kim DY Gene for the rat atrial natriuretic 
peptide is regulated by glucocorticoids m vitro J Clin Invest 1988 82 1275 81 
36 Thibault G, Garcia R, Gulkowska J, et al The propeptide Asn'-Tyr12* is the storage form 
of rat atrial natriuretic factor Biochem J 1987,241 265 72 
37 Michcncr ML, Gierse JK, Scctharam R, el al Proteolytic processing of atnopcplin prohor­
mone Mol Pharmacol 1986 10 552 7 
38 Gibson TR, Shields PP, Glcmbotski CC The conversion of atrial natriuretic peptide 
(ANP) (1 126) lo ANP (99 126) by rat scrum conlribution to ANP cleavage in isolated 
perfused ral hearts Endocrinology 1987,120 764-72 
39 Baxter JH, Wilson IB, Harris RB Identification of an endogenous protease that processes 
atrial natriuretic peptide at its amino terminus Peptules 1986,7407 11 
40 Imada Τ, Takayanagi R, Inagami Τ Identification of a peptidase which processes atrial na­
triuretic factor precursor to its active form with 28 amino acid residues in particulate frac­
tions of rat atrial homogenate Biochem Biophys Res Commun 1987,143 587-92 
41 Cantin M, Ding J, Thibault G, et al Immunorcaciivc atrial natriuretic factor is present in 
both alna and venlncles Mol Cell Endocrinol 1987,52 105-11 
42 Mane JP, Guillemot H, Hall PY Le degré de granulation des cardiocyles auriculaires -
Elude planimétnquc au cours de diífírcnls apports d'eau de sodium chez le rat Pathol Biol 
(Pans) 1976 24 549 54 
43 Villareal D, Freeman RH, Davis JO, Verburg KM, Van RC Effects of atrial 
appendectomy on circulating amai natriuretic factor during volume expansion in the rat 
Proc Soc Exp Biol Med 198618154 8 
44 Veress AT, Sonnenbcrg H Righi atrial appendectomy reduces the renal response to acute 
hypervolemia in the rat Am J Physiol 1984,247 R610 1 
45 Yasuc H, Obata K, Okumura K, et al Increased secretion of atrial natriuretic polypeptide 
from Ihe left ventricle in patients with dilated cardiomyopathy / Clin Invest 1989 81 46 51 
46 Edwards BS, Ackermann DM, Lee ME, Reeder GS, Wold LE, Burnett JC Identification of 
atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive 
heart failure J Clin Invest 1988,81 82 6 
47 Ding J, Thibault G, Gulkowska J, et al Cardiac and plasma atrial natriuretic factor in 
experimental congestive heart failure Endocrinology 1987,121 248-57 
18 
48 Saito Y, Nakao К, Arai H, et al Augmented expression of atrial natriuretic polypeptide 
gene in ventricle of human failing heart J Clin Invest 1989,83 298 305 
49 Bloch KO, Seidman JG, Naftilan JD, Fallon JT, Seidman CE Neonatal atria and ventricles 
secrete atrial natriuretic factor via tissue-specific secretory pathways Cell 1986,47695 702 
50 Lang RE, Thölkcn H, Ganten D, Luft FC, Ruskoaho H, Unger Τ Atrial natriuretic 
factor - a circulating hormone stimulated by volume loading Nature 1985 314 264-6 
51 Anderson JV, Donckier J, McKenna WJ, Bloom SR The plasma release of atrial 
natriuretic peptide in man Clin Sci 1986,71151-5 
52 Hirth C, Stasch JP, Kazda S, et al Blockade of the response to volume expansion by 
monoclonal antibodies against atrial natriuretic peptides Kim Wochensch 
1987,65(suppl VIH) 87 91 
53 Naruse M, Obana K, Narusc K, et al Antiscra to atrial natriuretic factor reduces urinary 
sodium excretion and increases plasma renin activity in rats Biochem Biophys Res Commun 
1985,132 954-60 
54 Sasaki A, Kida O, Kalo J, et al Effects of antiserum against α rat atrial natriuretic peptide 
in anesthetized rats Hypertension 198710308 12 
55 Raine AEG, Erne P, Burgisscr E, et al Atrial natriuretic peptide and atrial pressure in pa­
tients with congestive heart failure New Engl J Med 1986,315 511 7 
56 Hirala Y, Ishu M, Matsuoka H, et al Plasma concentrations of α-human atrial natriuretic 
polypeptide and cyclic GMP in patients with heart disease Am Heart J 1987,113 1463 9 
57 DeBold AJ, DcBold ML, Sarda IR Functional - morphological studies on in vitro 
cardionatnn release J Hypertension 1986,4(suppl 2) S3-7 
58 Edwards BS, Zimmerman RS, Schwab TR, Hcublcin DM, Burnett JC Atrial stretch, not 
pressure, is the principal determinant controlling the acute release of atrial natriuretic 
factor Circ Res 1988,62191 5 
59 Epstein M, Loutzenhiser R, Friedland E, Acelo RM, Camargo MJF, Atlas SA. 
Relationship of increased plasma atrial natriuretic factor and renal sodium handling during 
immersion-induced central hypervolemia in normal humans / Clin Invest 1987,79 738 45 
60 Solomon LR, Atherton JC, Bobinski H, Green R Effect of posture on plasma 
immunoreaclive atrial natriuretic peptide concentrations in man Clin Sci 1986 71 299 305 
61 Shcnker Y, Bates ER, Egan BH, Hammoud J, Grckin RJ Effect of vasopressors on atrial 
natriuretic factor and hemodynamic function in humans Hypertension 1988,12 20 5 
62 Holhslcr AS, Tanaka I, Imada Τ, el al Sodium loading and posture modulate human atrial 
natriuretic factor plasma levels Hypertension 1986 8(suppl II) II106-11 
61 Solomon LR, Atherton JC, Bobinski H, Green R Effect of dietary sodium chloride and 
posture on plasma immunoreaclive atrial natriuretic peptide concentrations in man Clin 
Sa 1987,72 201 8 
64 Tsai RC, Yamaji T, Ishibashi M, el al Atrial natriuretic peptide during supraventricular 
tachycardia and relation to hemodynamic changes and renal function Am J Cardiol 
1988,61 1260 4 
65 Haufe MC, Weil J Gerzer R, Ernst JE, Theiscn K. Effects of repeated increments m right 
atrial pressure on secretion of atrial natriuretic factor Am J Cardiol 1988,61 932 4 
66 Anderson JV, Woodruff PWR, Bloom SR The effect of treatment of congestive heart 
failure on plasma atrial natriuretic peptide concentration a longitudinal study Br Heart J 
1988,59 207-11 
67 Wilkins MR, Wood JA, Adu D, Lote CJ, Kendall MJ, Michael J Change in plasma im­
munoreaclive atrial natriuretic peptide during sequential ultrafiltration and hemodialysis 
Clm Sci 1986,71 157 60 
68 Shenker Y, Port FK, Swartz RD, Gross MD, Grckin RJ Atrial natriuretic hormone secre­
tion in patients with renal failure Life Sci 1987,41 1635 44 
69 Cogan E, Debieve MF, Pcpcrsack Τ, Abramow M Natriuresis and atrial natriuretic factor 
secretion during inappropriate antidiurcsis Am J Med 1988,84 409 18 
70 Pednnelli R, Bruschi G, Graziadei L, et al Dietary sodium change in primary 
aldosteronism - atnal natriuretic factor, hormonal, and vascular responses Hypertension 
1988,12 192-8 
19 
71 Cody RJ, Atlas SA, Laragh JH Atrial natriuretic factor in normal subjects and heart 
failure patients - Plasma levels and renal, hormonal, and hemodynamic responses to 
peptide infusion / CIm Invest 1988,78 1362-74 
72 Wambach G, Bonner G, Stimpel M, Kaufmann W Relationship between plasma atrial na­
triuretic peptide and left atrial and left ventricular involvement in essential hypertension 
/ Hypertension 1988,6 573-7 
73 Schiffnn EL, St Louis J, Essiambrc R Platelet binding sites and plasma concentration of 
atrial natriuretic peptide in patients with essential hypertension / Hypertension 1988 6 565-
72 
74 Weidmann Ρ, Gnàdinger MP, Ziswilcr HR, et al Cardiovascular, endocrine and renal 
effects of atrial natriuretic peptide in essential hypertension / Hypertension 1986, 
4(suppL2) S7I-83 
75 Ferner С, Weidmann Ρ, Hollmann R, Dietlcr R, Shaw S Impaired response of atrial 
natriuretic factor to high salt intake in persons prone to hypertension New Engl J Med 
1988,319 1223-4 
76 Sorenscn SS, Daniclsen H, Amdiscn A, Pederscn EB Atrial natriuretic peptide and 
exaggerated natnuresis during acute hypertonic volume expansion in essential hypertension 
J Hypertension 1989,7 21-9 
77 Saito Y, Nakao K, Sugawara A, et al Exaggerated secretion of atrial natriuretic 
polypeptide during dynamic exercise in patients with essential hypertension Am Heart J 
1988,116 1052-7 
78 Sudhir K, Woods RL, Jennings GL, Nelson LA, Laufer E, Körner PI Exaggerated atrial 
natriuretic peptide release during acute exercise in essential hypertension J Hum Hyperten-
sion 1988 1 299 304 
79 Weidmann Ρ, Haslcr L, Gnädinger MP, et al Blood levels and renal effects of atrial 
natriuretic peptide in normal man / Clin Invest 1986 77 734 42 
80 Solomon RL, Atherlon JC, Bobinski H, Hillicr V, Green R Effect of low dose infusion of 
atrial natriuretic peptide on renal function in man Clm Sci 1988,75403 10 
81 Richards AM, Nicholls MG, Ikram H, Webster MWI, Yandle TG, Espincr EA. Renal, hac-
modynamit, and hormonal effects of human alpha atrial natriuretic peptide in healthy vo 
lunteers Lancet 1985,i 545 8 
82 Chai SY, Sexton PM, Allen AM, Figdor R, Mendelsohn FAO In vitro autoradiographic 
localization of ANP receptors in rat kidney and adrenal gland Am J Physiol 1986,250 
F753-7 
83 Healy DP, Fancstil DD Localization of atrial natriuretic peptide binding sues within the 
rat kidney Am J Physiol 1986,250 F573-8 
84 Ohishi K, Hishida A, Honda N Direct vasodilalory action of atrial natriuretic factor on 
canine glomerular afferent arterioles Am J Physiol 1988,255 F415 20 
85 Camargo MJF, Atlas SA, Maack Τ Role of increased glomerular filtraiion rate in atrial 
natriuretic factor-induced natnuresis in the rat Life Sci 1986,38 2197 404 
86 Fried TA, McCoy RN, Osgood RW, Stein JH Effect of atriopcptin II on determinants of 
glomerular filtration rale in the in vitro perfused dog glomerulus Am J Physiol 1986,250 
F11I9-22 
87 Seymour AA, Mazack EK. Renal effects of atrial natriuretic factor during control of the 
remn-angiolcnsin system in ancslhctucd dogs Circ Res 1988,62 506-14 
88 Sonncnberg H, Honrath U, Chong CK, Wilson DR Atrial natriuretic factor inhibits 
sodium transport in medullary collecting duct Am J Physiol 1986,250 F963-6 
89 Fried TA, Osgood RW, Stem JH Tubular sitc(s) of action of atrial natriuretic peptide in 
the rat Am J Physiol 1988,255 F313-6 
90 Oelkcrs W, Kleiner S, Bahr V Effects of incremental infusions of atrial natriuretic factor 
on aldosterone, renin, and blood pressure in humans Hypertension 1988,12 462-7 
91 Richards AM, McDonald D, Fitzpatnck MA, et al Atrial natriuretic hormone has 
biological effects in man at physiological plasma concentrations J Clin Endocrinol Metab 
1988,671134-9 
92 Winquist RJ Possible mechanism underlying the vasorelaxant response to atrial natriuretic 
factor Fed Proc 1986,45 2371 5 
20 
93 Hughes A, Thom S, Goldberg Ρ, Martin G, Sever Ρ Direct effect of α-human atrial 
natriuretic peptide on human vasculature in vivo and in vitro Clin Sa 1988,74 207-11 
94 Eben TJ, Skelton MM, Cowley AW Dynamic cardiovascular responses to infusions of 
atrial natriuretic factor in humans Hypertension 1988,11 537 44 
95 Мопсе A, Pcpkc Zaba J, Loysen E, et al Low dose infusion of atrial natriuretic peptide 
causes salt and water excretion in norman man Clin Sci 1988,74 359 63 
96 Hiwatari M, Satoh К, Angus JA, Johnston CI No effect of atrial natriuretic factor on car­
diac rate, force and transmitter release Clin Exp Pharmacol Physiol 198613 163 8 
97 Brcuhaus BA, Sanen HH, Brandt MA, Chimoskey JE. Atnopeptin II lowers cardiac output 
in conscious sheep Am J Physiol 1985,249 R776-80 
98 Laxson DD, Dai XZ, Schwartz JS, Bache RJ Effects of atrial natriuretic peptide on 
coronary vascular resistance in the intact awake dog J Am Coll Cardiol 1988,11 624 9 
99 Huxley VH, Tucker VL, Verbürg KM, Freeman RH Increased capillary hydraulic 
conductivity induced by atrial natriuretic peptide CITC Res 1987,60 304-7 
100 Tnppodo NC, Cole FE, Fröhlich ED, MacPhee AA. Atrial natriuretic peptide decreases 
circulatory capacitance in areflexic rats Ore Res 1986,59 291 6 
101 Fluckiger JP, Waeber B, Matsueda G, Delaloye B, Nussberger J, Brunner HR Effect of 
atnopeptin III on hematocrit and volemia of nephreclomized rats Am J Physiol 1986,251 
H880 3 
102 Hynyncn M, Kupari M, Salmcnperä M, et al Hemodynamic effects of α-human atrial 
natriuretic peptide in healthy volunteers J Cardiovasc Pharmacol 1988 11 711-5 
103 Williams TDM, Walsh KP, Lightman SL, Sutton R Atrial natriuretic peptide inhibits pos­
tural release of renin and vasopressin in humans Am J Physiol 1988,255 R368 72 
104 Kurtz A, Bruna RD, Pfeilschiftcr J, Taugner R, Bauer С Atrial natriuretic peptide inhibits 
renin release from juxtaglomerular cells by a cGMP-mediated process Proc Natl Acad Sci 
USA 1986,83 4769-73 
105 Goodfnend TL, Elliott ME, Atlas SA Actions of synthetic atrial natriuretic factor on 
bovine adrenal glomerulosa Life Sci 1984,351675 82 
106 Ohashi M, Fujio N, Kato K, Nawata H, Ibayashi H, Matsuo H Effect of human α-atrial 
natriuretic polypeptide on adrenocortical function in man J Endocrinol 1986110 287-92 
107 Samson WK. Atrial natriuretic factor inhibits dehydration and hemorraghc induced 
vasopressin release Neuroendocnnology 1985,40 277-9 
108 Allen MJ, Ang VTY, Bennett ED, Jenkins JS Atrial natriuretic peptide inhibits 
osmolality-induced arginine vasopressin release in man Clin Sci 1988,75 35 9 
109 Obana K, Naruse M, Inagami T, et al Atrial natriuretic factor inhibits vasopressin 
secretion from rat posterior pituitary Biochem Biophys Res Commun 1985,132 1088 94 
110 Fujio N, Ohashi M, Nawata H, et al α-human atrial natriuretic polypeptide reduces the 
plasma arginine vasopressin concentration in human subjects Clin Endocrinol 1986,25 
181 7 
111 Kuchcl O, Debinski W, Racz K, et al An emerging relationship between peripheral sym­
pathetic nervous activity and atrial natriuretic factor Life Sa 1987,401545-51 
112 Bianchi С, Guikowska J, Thibault G, Garcia R, Genest J, Cantin M Radioautographic 
localization of I2SI-atrial natriuretic factor (ANE7) in rat tissue Histochemistry 1985,82 441-
52 
113 Lynch DR. Braas KM, Snyder SH Atrial natriuretic factor receptors in rat kidney, adrenal 
gland, and brain autoradiographic localization and fluid balance dependent changes Proc 
Natl Acad Sa USA 1986,83 3357 61 
114 Mantyh CR, Kruger L, Brecha NC, Manlyh PW Localization of specific binding sites for 
atrial natriuretic factor in the central nervous system of rat, guinea pig, cat and human 
Bram Res 1987,412 329-34 
115 Olins GM, Patton DR, Bovy PR, Mehta PP A linear .analog of atrial natriuretic peptide 
(ANP) discriminates guanylate-cyclase coupled ANP receptors from non-coupled receptors 
ƒ Biol Chem 1988,263 10989 93 
116 Leitman DC, Andresen JW, Catalano RM, Waldman SA, Tuan JJ, Murad F Atrial 
natriuretic peptide binding, cross-linking, and stimulation of cyclic GMP accumulation and 
particulate guanylate cyclase activity in cultured cells J Biol Chem 1988,263 3720-8 
21 
117. Bovy PR, O'Neal JM, Olins GM, Palton DR. Identification of structural requirements for 
analogues of atrial natriuretic peptide (ANP) to discriminate between ANP receptors subty­
pes. / Med Chem 1989;32:869-74. 
118. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial 
natriuretic factor. Science 1987;238:675-8. 
119. Almeida FA, Suzuki M, Scarborough RM, Lcwicki JA, Maack T. Clearance function of 
type С receptors of atrial natriuretic factor in rats. Am J Physiol 1989;256:R469-75. 
120. Tremblay J, Gerzer R, Vinay P, Pang SC, Beliveau R, Hamel P. The increase of cGMP by 
atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase. 
FEBS Lea 1985;181:17-22. 
121. Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates 
paniculate guanylate cyclase and elevates cyclic GMP in rat tissue. J Biol Chem 
1984;259:14332-4. 
122. Fiscus RR, Rapoport RM, Waldman SA, Murad F. Atriopeptin II elevates cyclic GMP, 
activates cyclic GMP-dependent protein kinase and causes relaxation in rat thoracic aorta. 
Biochim Biophys Acta 1985;846:179-84. 
123. O'Grady SM, De-Jonge HR, Vaandrager AB, Field M. Cyclic nucleotide-dcpcndcnt protein 
kinase inhibition by H-8:effects on ion transport. Am J Physiol 1988;254:C115-21. 
124. Chinkers M, Garbers DL, Chang MS, et al. A membrane form of guanylate cyclase is an 
atrial natriuretic peptide receptor. Nature 1989;338:78-83. 
125. Ishido M, Fujita T, Shimonaka M, et al. Inhibition of atrial natriuretic peplidc-induced 
cyclic GMP accumulation in the bovine endothelial cells with anti-atrial natriuretic peptide 
receptor antiserum. J Biol Chem 1989;264:641-5. 
126. Hamet P, Tremblay J, Pang SC, et al. Effect of native and synthetic atrial nalriurclic factor 
on cyclic GMP. Biochem Biophys Res Commun 1984;123:515-27. 
127. Stasch JP, Hirth C, Kazda S, Wohlfeil S. The elevation of cyclic GMP as a response to 
acute hypervolemia is blocked by a monoclonal antibody directed against atrial natriuretic 
peptides. Eur J Pharmacol 1986;129:165-8. 
128. Huang CL, Ives HE, Cogan MG. In vivo evidence that cGMP is the second messenger for 
atrial natriuretic factor. Proc Natl Acad Sci USA 1986;83:8015-8. 
129. Zeidcl ML, Silva Ρ, Brenner BM, Seiftcr JL. cGMP mediates effect of atrial peptides on 
medullary collecting duel cells. Am J Physiol 1987;252:F551-9. 
130. Sen I, Roy P. Atrial natriuretic factor induced phosphorylation of human placental 
membrane protein: an effect mimicked by guanosinc 3':5'-cyclic monophosphate. Biochem 
Biophys Res Commun 1986;139:431-8. 
131. Henrich WL, McAllister EA, Smith PB, Campbell WB. Guanosinc S'.S'-cyclic 
monophosphate as a mediator of inhibition of renin release. Am J Physiol 1988;255:F474-8. 
132. Ohlslcin EH, Berkowitz BA. Cyclic guanosine monophosphate mediates vascular relaxation 
induced by atrial natriuretic factor. Hypertension 1985;7:306-10. 
133. Hamct P, Tremblay J, Pang SC, cl al. Cyclic GMP as mediator and biological marker of 
atrial nalriurclic factor. J Hypertension 1986;4(suppl.2):S49-56. 
134. Heim JM, Gottmann К, Weil J, Haufe MC, Gerzer R. Is cyclic GMP a clinically useful 
marker for ANF action ? Ζ Kardial 1988;77(suppl.2):41-6. 
135. Tanaka I, Misono KS, Inagami T. Atrial natriuretic factor in rat hypothalamus, atria and 
plasma: determination by specilic radioimmunoassay. Biochem Biophys Res Commun 
1984;124:663-8. 
136. Gardner DG, Vlasuk GP, Baxter JD, Fiddes JC, Lcwicki JA. Identification of atrial 
natriuretic factor gene transscripts in the central nervous system of the rat. Proc Natl Acad 
Sci USA 1987;84:2175-9. 
137. Debinski W, Gulkowska J, Kuchcl O, el al. ANF-likc pcptidc(s) in the peripheral 
autonomic nervous system. Biochem Biophys Res Commun 1986;134:279-84. 
138. Shibasaki T, Naruse M, Naruse K, el al. Atrial natriuretic factor is released from rat hypo­
thalamus in vitro. Biochem Biophys Res Commun 1986;136:590-5. 
139. Glcmbotski CC, Wildey GM, Gibson TR. Molecular forms of immunoreactive atrial 
natriuretic peptide in the rat hypothalamus and atrium. Biochem Biophys Res Commun 
1985;129:671-8. 
22 
140 Shiono S, Nakao К, Morn Ν, el al Nature of atrial natriuretic polypeptide in rat brain 
Biochem Biophys Res Commun 1986,135 728-34 
141 Chabner PE, Roubcrt P, Plas Ρ, Braquet Ρ Blood brain barrier and atrial natriuretic 
factor Can J Physiol Pharmacol 1988 66 276-9 
142 Stcardo L, Nathanson JA. Brain barrier tissues end organs for alnopeptins Science 1987, 
235 470-3 
143 Fitts D A Thunhorst RL, Simpson JB Diuresis and reduction of salt appetite by lateral 
ventricular infusions of atriopcptin II Brain Res 1985,348 118-24 
144 Lcc J, Feng JQ, Malvan RL, Huang BS, Grckin RJ Centrally administered atrial 
natriuretic factor increases renal water excretion Am J Physiol 1987,252 Fl011-5 
145 litake K, Share L, Croflon JT, Brooks DP, Ouchi Y, Blaine EH Central atrial natriuretic 
factor reduces vasopressin secretion in the rat Endocrinology 1986,119 438 40 
146 Nakao K, Morn N, Itoh H, et al Atrial natriuretic polypeptide in brain - implication of 
central cardiovascular control Klin Wochenschr 1987,65(suppl8) 103-8 
147 Katsuura G, Nakamura M, Inouye K, Kono M, Nakao K, Imura Η Regulatory role of 
atrial natriuretic polypeptide in water drinking in rats Eur J Pharmacol 1986,121 285 7 
148 Itoh H, Nakao K, Yamada T, et al Central imeraction of the brain atrial natriuretic poly­
peptide (ANP) system and the brain angiotensin system in ANP secretion from heart - evi­
dence for possible brain heart axis Can J Physiol Pharmacol 1988,66 255 61 
149 Shimizu T, Katsuura G, Nakamura M, et al Effect of intraccrcbroventricular atrial 
natriuretic polypeptide on blood pressure and urine production in rats Life Sci 1986, 
39 1263 70 
150 Sudoh T, Kangawa K, Minammo Ν, Matsuo Η A new natriuretic peptide in porcine brain 
Nature 1988 ??2 78-81 
151 Song DL, Kohsc KP, Murad F Brain natriuretic factor augmentation of cellular cyclic 
GMP, activation of particulate guanylatc cyclase and receptor binding FEBS Lett 1988,232 
125 9 
152 Mdckawa K, Sudoh T, Furusawa M, et al Cloning and sequence analysis of cDNA 
encoding a precursor for porcine brain natriuretic peptide Biochem Biophys Res Commun 
1988157 410 6 
154 Sano Y, Nakao К, Itoh H, et al Brain natriuretic peptide is a novel cardiac hormone Bio­
chem Biophys Res Commun 1989 158 360 8 
154 Saper CB, Hurley KM, Moga MM, et al Brain natriuretic peptides differential localization 
of a new family of neuropeptides Neurosa Lett 1989,96 29 34 
155 Torda Τ, Naiarali AJ, Saavedra JM Brain natriuretic peptide receptors in the rat 
peripheral sympathetic ganglia Biochem Biophys Res Commun 1989,159 1012 8 
156 Hashiguchi T, Higuchi K, Ohashi M, ci al Porcine brain natriuretic peptide, another 
modulation of bovine adrenocortical steroidogenesis FEBS Lett 1988,216 455 61 
157 Itoh H, Nakao K, Yamada T, el al Antidipsinogcnic action of a novel peptide, 'brain 
natriuretic peptide', in rats Eur J Pharmacol 1988,150193 6 
158 Yamada T, Nakao K, Itoh H, et al Intraccrcbroventricular injection of brain natriuretic 
peptide inhibits vasopressin secretion in conscious rats Neurosa Leu 1988,95 223-8 
159 Schulz-Knappe Ρ, Forssmann К, Herbsl F, Hock D, Pipkorn R, Forssmann WG Isolation 
and structural analysis of "urodilatm", a new peptide of the cardiodilatin-(ANP) family, ex­
tracted from human urine Ют Wochenschr 1988,66 752 9 
23 

Part II 
MEASUREMENT OF ANP 
CONCENTRATIONS 
In part I of this thesis a brief analysis of the literature regarding the function 
of the atrial natriuretic peptide is given. The atrial natriuretic peptide (ANP) 
hormonal system can be regarded as antagonistic to the renin-angiotensin-
aldosterone system, its main function being to protect the body from car-
diovascular volume overload. As ANP values reflect the volume of the 
intravascular compartment, measurement of ANP concentrations can be of value 
to determine the role of ANP in the endocrine control of the cardiovascular 
system and in various pathophysiological states in man. In this part of the thesis 
two methods for measurement of ANP concentrations are described and 
compared. Furthermore, using high pressure liquid chromatography analysis an 
approach to determine the molecular forms of immunoreactive ANP in human 
plasma is described. As cyclic guanosine monophosphate (cGMP) functions as 
the second messenger for ANP, the cGMP concentration in plasma reflects the 
biological effectiveness of ANP. Therefore a method for measurement of cGMP 
concentrations in human plasma was developed. 
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Chapter 2.1 
Extraction method 
Introduction 
Soon after the sequence analysis of ANP and the first radioimmunoassay of 
ANP in plasma (1), synthetic (99-126)hANP and antibodies directed against ANP 
became commercially available. This enabled various investigators to establish a 
method for measurement of ANP in human blood. 
These methods vary widely; both direct assays (2-5) and assays using an extrac-
tion step have been described. Prior extraction of plasma can be achieved using 
Vycor-glass (6), Sepharose-coupled antiserum (7-9) or silica cartridges (10-15). In 
order to develop a method for measurement of ANP concentrations in man we 
immunized sheep to obtain a specific antibody directed against (99-126)hANP. 
As the obtained antibodies were specific for the non-oxidized form of 
(99-126)hANP, a suitable non-oxidized tracer was obtained after comparing two 
different iodination procedures. Using these antibodies and tracer a sensitive and 
reliable method for measurement of ANP based on prior extraction of the 
plasma on Seppak C-18 columns was developed. 
Materials and methods 
Materials 
Synthetic (99-126)hANP (for constructing standard curve and iodination), 
(103-126)hANP, (105-126)hANP, (lll-126)hANP, (116-126)hANP, and 
(99-109)hANP were purchased from Peninsula Laboratories Ine, England; rat 
(99-126)ANP was a gift from Dr. B. Penke, University of Szeged, Hungary; 
alpha-MSH, (Arg)-vasopressin and ACTH were obtained from INCSTAR, Still-
water, MN, USA; Na;25I was from Amersham Int, Amersham, UK; aprotinin 
(Trasylol) was from Bayer, Leverkusen, FRG; sheep IgG, Bovine Serum Albumin 
(BSA Cohn fraction V) and Triton X—100 were from Sigma Chemicals Corp, St. 
Louis, MO, USA; PEG-6000, EDTA, HjBOj and NaOH were obtained from 
Merck, Darmstadt, FRG; Protag-125, ethanol, acetonitrile (HPLC-grade), acetic 
acid, methanol (HPLC-grade), distilled water (HPLC-grade) and trifluor acetic 
acid (TFA, HPLC-grade) were obtained from Baker Fine Chemicals, USA. 
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Complete Freund's adjuvant was purchased from Hoechst, The Netherlands. All 
reagents were of analytical grade, except where mentioned otherwise. To obtain 
a tracer with preferable binding characteristics, as compared to a chloramine-T 
product, a Protag iodination was performed. 
Blood collection 
Blood samples (3 ml) were collected by venepuncture into EDTA vacuum 
tubes, kept on ice, centrifuged as soon as possible (1500 g, 40C, 10 minutes), and 
stored in polystyrene tubes containing 200 KIU of aprotinin (Trasylol, Bayer AG, 
FRG)/ml plasma at -SCPC until used for extraction. 
Extraction 
Seppak C-18 cartridges (Waters Associates, Milford, MA, USA) were pre-
treated by subsequently washing with 5 ml acetic acid(96 %)-ethanol(86 %) 
(4:% v/v), 5 ml methanol, 5 ml distilled water and 5 ml acetic acid(96 %)-
distilled water (4:96 v/v). One ml plasma was acidified with 3 ml acetic acid 
(96 %)-distilled water (4:96 v/v) in a polystyrene tube and applied to the 
cartridge. After washing twice with 3 ml distilled water, the ANP was eluted in 
polystyrene tubes with 3 ml acetic acid(96 %)-ethanol(86 %) (4:96 v/v) (modified 
from Lang et al. (16)). The eluant was evaporated under a stream of nitrogen 
for 1 hour at 3700. The walls of the tubes were rinsed with 1 ml ethanol 
(100 %) and evaporated to dryness. The residue was dissolved in 0.50 ml RIA-
buffer (0.2 mol/1 sodium borate (pH 8.4), 10 mmol/1 of EDTA, 0.1 % Triton 
X-100 detergent and 2 g/l BSA) and radioimmunoassayed. Extraction efficiency 
was assessed by recovery experiments in which different amounts of 
(99-126)hANP were added to four different plasmas. The effect of evaporation 
was assessed by evaporating six samples of pure standard in either elution 
solvent or standard added to plasma or plasma extracts. Comparisons were made 
using the Wilcoxon two-sample test. 
Antibodies against (99-126)liANP 
The immunogene used for production of antibodies against (99-126)hANP was 
kindly provided by INCSTAR, Stillwater, USA. It was prepared by conjugation of 
synthetic (99-126)hANP to keyhole limpet haemocyanin using carbodiimide as the 
coupling agent (17). Two mg of the conjugate was dissolved in 1 ml saline and 
emulsified with an equal volume of complete Freund's adjuvant. Two Texel white 
sheep (S—31 and S—32) were immunized subcutaneously in two places on their 
back. Every 2 weeks, booster injections were given with the same composition as 
the first immunization. At the same time, blood was drawn for determination of 
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the antiserum-titre and for study of the cross-reactivities. 
Antibodies against sheep-IgG 
Horses were immunized subcutaneously with 2 mg sheep-IgG, which was dissol­
ved in 1 ml saline and emulsified with 1 ml complete Freund's adjuvant. Every 2 
weeks booster injections of the same composition were given and blood was 
drawn for titre measurements. 
Preparation of [12SI]-monoiodotyrosyl-(99-126)hANP 
Two methods of preparation of [/25I]-(99-126)hANP were compared; the 
Protag-125 iodination method according to Guenther et al. (18) and the 
chloramine—Τ method, modified from Greenwood et al. (19). Synthetic 
(99-126)hANP was iodinated with Na'2 5I using either Protag-125 or 
Chloramine—T. Subsequently the iodination mixture was loaded onto a 3 ml 
silica C—18 column (Baker Fine Chemicals, USA), which was previously 
prewashed using 4 ml methanol, 4 ml distilled water and 4 ml phosphate buffer 
(67 mmol/1, pH 7.4). After washing with 3 ml solvent A (methanol-distilled 
water-TFA 20:80:0.1 v/v/v), elution was carried out with 1 ml solvent В 
(methanol-distilled water-TFA 80:20:0.1 v/v/v). The eluate was purified by high 
pressure liquid chromatography (HPLC) using a micro-Bondapack column (20 
cm), with a flow rate of 2 ml/min. The initial solvent composition was 
acetonitrile-distilled water-TFA (20:80:0.1 v/v/v). A linear gradient from 20 to 
50 % acetonitrile was performed to elute the different iodinated forms of ANP. 
[í25I]Monoiodotyrosyl-(99-126)hANP eluted at 30 % acetonitrile. 
Radioimmunoassay 
One hundred microlitres of plasma-extract or standard in RIA-buffer was 
mixed with 200 μΐ of sheep anti-ANP serum (S-32, final dilution in RIA-buffer 
1:2.5 χ IO") at 40C in polystyrene tubes. The mixture was allowed to incubate for 
18 hours at 4CC. Two hundred microlitres of tracer solution (9500 dpm) was ad­
ded, and incubated for a further 24 hours at 4CC. Separation of bound and free 
hormone was achieved by addition of 1.0 ml horse anti-sheep precipitating 
complex (1 μΐ normal sheep serum, 15 μΐ horse anti-sheep-IgG serum and 30 mg 
PEG-6000 per ml sodium borate buffer (20 mmol/1, pH 8.4, 2 g/1 BSA)) at room 
temperature for 30 minutes. Finally the suspension was centrifuged for 30 
minutes at 1000 g at room temperature. The tubes were decanted and the 
radioactivity of the pellet was counted in a gamma counter. Parallelism was 
assessed by assaying 0.25, 0.50 (both made up to 1.0 ml with RIA-buffer) and 1.0 
ml of different plasma samples. 
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Results 
Antibodies against (99-126)hANP 
Both sheep produced antibodies with very high titres (up to 1:2.5 χ 10* final 
dilution). After two months, no further increase in titre was found. In the final 
assay procedure, the antibody designated S—32 was used, which was collected 
after 5 months of immunization from sheep S-32. The other antibody, S-31, 
was used in the direct assay for ANP (see chapter 2.2). In table I I - 1 the cross-
reactivities of the S—31 antibody (direct method), the S-32 antibody (extraction 
method) and a commercially available antibody from Peninsula are shown. The 
antibodies S—31 and S—32 recognize only the ANP peptides possessing an intact 
disulfide bridge. Complete cross-reactivity was found with ß-hANP. No cross-
Table II-l. C r o s s - r e a c t i v i t i e s of the S-31, the S-32 and the Peninsula 
an t ibodies (percentages v s . (99-126)hANP). 
(99-126)hANP 
(99-126)rANP 
(103-126)hANP 
(105-126)hANP 
(101-126)hANP 
(99-109)hANP 
(111-126)hANP 
(116-126)hANP 
ß-hANP 
(l-30)hANP 
(31-67)hANP 
a-M5H 
ACIH(l-39) 
Ary8-Vascpres. 
S-31 
100 
1.5 
104 
117 
107 
<0.2 
<0.2 
<0.2 
-
-
-
<0.2 
<0.2 
<0.2 
S-32 
100 
2.2 
109 
127 
127 
<0.2 
<0.2 
<0.2 
100 
<0.2 
<0.2 
<0.2 
<0.2 
<0.2 
Peninsula 
100 
100 
90 
95 
125 
<0.2 
65 
55 
-
-
-
<0.2 
<0.2 
<0.2 
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reactivity was observed with different parts of (l-126)hANP not containing the 
(99-126)hANP fragment. In contrast to the Peninsula antibody, both the S-31 
and the S-32 antibodies have no affinity to rat (99-126)ANP, which differs from 
human (99-126)ANP by only one amino acid on position 110 (see figure 1-3). 
Knowing that methionine on position 110 of human (99-126)ANP is easily oxi­
dized to the methionine sulfoxide form and that the antibodies used are highly 
specific for this methionine, a non-oxidized tracer for these antibodies had to be 
developed. 
Iodination 
In order to develop a suitable tracer, two methods of iodination were 
compared: a method in which a mild oxidizing agent, namely Protag, was used 
and a second method using chloramine—T, which is a more aggressive agent. 
Figure II—1 shows the elution profiles of both iodination procedures. With the 
cpm (x104) 
О Protag iodination 
Щ CAT. iodination 
r ·, , — - . · ,
 r
- .,.,,, , _ . 
25 30 35 ¿0 ¿5 50 
Fractions (0.5 min) 
Figure II-l. Elution profile of iodinated (99-126)hANP tracer using two different 
iodination procedures, namely the Protag method and the chloramine-T (СЛ.Т.) 
method. 
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Protag method, two major (peaks 1 and 2) and two minor peaks (peaks 3 and 4) 
were observed while with the chloramine—Τ (C.A.T.) procedure, only two major 
peaks (peaks 1 and 3) were found. As chloramine—Τ is a more aggressive 
method, thus causing more oxidation, we wondered whether peak 1 and peak 3 
could be the oxidized forms of peak 2 and peak 4, respectively. Therefore we 
oxidized fraction 37 (peak 2) and fraction 46 (peak 4) obtained from the Protag 
iodination with HjO^ This resulted in a shift on the HPLC profile to the 
retention times of peaks 1 and 3, respectively, thereby confirming our hypothesis. 
Thus peak 1 corresponds to monoiodotyrosyI-(99-126)hANP-methionine sulfoxide, 
peak 2 to monoiodotyrosyl-(99-126)hANP, peak 3 to diiodotyrosyl-(99-126)hANP-
methionine sulfoxide and peak 4 to diiodotyrosyl-(99-126)hANP. Good and 
reproducible binding was observed with fraction 37 (peak 2, corresponding to the 
non-oxidized monoiodotyrosyl-(99-126)hANP form). When the tracer of this 
fraction was diluted, aliquoted and lyophilized it was stable for at least 6 weeks. 
As a low binding of the S—32 antibody was observed with the tracers obtained 
from peaks 1 and 3 which correspond to the oxidized forms of the iodinated 
(99-126)hANP tracer, it can be assumed that this antibody is more specific for 
the non-oxidized form of (99-126)hANP. No difference in binding was observed 
between the oxidized and the non-oxidized tracers when the antibody of Penin­
sula was used (figure II—2). 
B/T (·/.)• 
4 5 -
3 0 
S-32 
4 5 
304 
PENINSULA 
monoiodo-ANP 
monoiodo-ANP sulfoxide 
dnodo-ANP sulfoxide 
1 0 100 
( p g / tube ) 
Figure II-2. Various standard curves using both the oxidized and the non-oxidized 
(99-126)hANP tracers with the S-32 as weil as the Peninsula antibody. 
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Extraction procedure and radioimmunoassay 
The extraction procedure is summarized in table II—2. When the eluate of the 
Seppak C-18 column is air-dried conversion of ANP to the oxidized form might 
occur, which would then be recognized to a minor extent by the S—32 antibody. 
Figure I I - 3 shows ANP values of pure (99-126)hANP standard measured 
directly in the radioimmunoassay (first column). Air-drying of pure standard in 
elution solvent resulted in a lowering of immunoreactivity (second column), 
confirming our hypothesis. However, air-drying of standard added to plasma 
extracts (third column) or to plasma (fourth column) did not significantly lower 
ANP immunoreactivity. This implies that plasma exerts a protective effect on the 
oxidation of ANP. Furthermore instead of air-drying a nitrogen stream is used 
routinely to minimize oxidation of ANP during the evaporation procedure. 
A typical standard curve of the radio-immunoassay is shown in figure II-4. 
Table 11-2. Flow diagram of e x t r a c t i o n procedure and radioimmunoassay. 
Col lec t blood samples (3 ml) in EDTA-tubes on crushed i c e 
Centrifuge within 1 hour and s t o r e in a l i q u o t s conta ining 
200 КТО aprotinin/ml plasma a t -80°С 
Extract ion on SeppaJc C-18 c a r t r i d g e s 
Subsequently p r e t r e a t with: 
- 5 ml 4 % a c e t i c acid in 86 % ethanol 
- 5 ml methanol 
- 5 ml distilled water 
- 5 ml 4 % acetic acid 
Acidify 1.0 ml plasma with 3 ml 4 % acetic acid and apply the 
acidified plasma to the cartridge 
Wash twice with 3 ml distilled water 
Elute with 3 ml 4 % acetic acid in 86 % ethanol 
Evaporate under a stream of nitrogen during 1 hour at 37°С 
Add 1 ml of ethanol 100 %, mix and evaporate to dryness 
Dissolve in 500 μΐ RIA-buffer 
Radioimmunoassay in polystyrene tubes: 
- take 100 μΐ plasma extract or standard 
- add 200 μΐ antiserum 
- mix and cover tubes with parafilro 
- incubate 18 hours at 4°C 
- add 200 μΐ tracer and mix well 
- cover tubes with parafilm 
- incubate 24 hours at 4°C 
- add 1 ml sheep antiservnu/PEG at 20°C and mix 
- incubate for 30 minutes at 20°С 
- centrifuge 30 minutes at 20°С 
- decant supernatant and count pellet 
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Figure II-3. Ήιε effect of evaporation on ANP immunoreactive levels. 
The initial binding as determined in 6 consecutive assays was 28 ± 0.5 % 
(mean ± SD). In these assays a nonspecific binding was obtained of 
4.4 ± 1.1 %. The detection limit (defined as B0 - 3 χ SD) was 0.8 ± 0.2 pg/tube, 
corresponding to 4 pg/ml plasma when 1.0 ml plasma was extracted. The 50 % 
intercept was at 9 pg/tube, with a working range from 0.8 to 100 pg/tube. ANP 
levels as assessed when 1.0, 0.50 and 0.25 ml of plasma were extracted are 
shown in table II—3. These results prove that this assay gives a good parallelism. 
The recovery of synthetic (99-]26)hANP added to plasma is constant (95 %) in 
the range from 25 to 149 pg/ml (table II-4). The intra- and inter-assay coef­
ficients of variation were 8.6 % (n = 7) at a level of 12.6 pg/ml and 11.6 % 
(n = 6) at a level of 21.7 pg/ml, respectively. 
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Table II-3. Parallelism of the extraction method (ANP, pg/ml) 
Sançile 
n o . 
1 
2 
3 
4 
5 
6 
7 
1.00 0.50 0.25 
m i l l i l i t e r s used for extract ion 
21.8 
16.6 
15.7 
25.0 
43 .1 
46.2 
32.3 
27 .1 
17.3 
14.0 
26.6 
42.2 
47.4 
32.0 
23.4 
18.0 
14.7 
27.6 
41.6 
45.2 
35.2 
Table II-4. Recovery of the extraction method (ANP, pg/ml and 
percentage of recovery) 
pg ANP added 
t o d i f f erent 
plasmas 
0 
12.5 
25.0 
50.0 
100.0 
1 
46.2 
56.3 
70 .1 
95.0 
142.7 
ANP 
(96) 
(98) 
(99) 
(98) 
(pg/ml) (and % ANP mrovered) 
2 
32.3 
41.7 (93) 
56.2 (98) 
74.1 (90) 
128.3 (97) 
3 
25.0 
34.1 (91) 
46.4 (93) 
66.3 (88) 
121.4 (97) 
4 
43 .1 
55.3 
63.1 
81.2 
148.9 
(99) 
(93) 
(87) 
(104) 
Recovery: mean ± SD = 95 ± 5 % (range 87 to 104 %) 
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Figure II-4. Standard curve of the extraction method. 
Using this extraction method, ANP levels were measured in 66 healthy indivi-
duals without a history of cardiovascular, renal or endocrine disorders. Blood was 
obtained between 930 and MP0 a.m. after 30 minutes in the sitting position and 
after at least 3 hours of fasting. ANP values in these subjects ranged from 8.3 to 
86.8 pg/ml (mean ± SD = 35.3 ± 16.2 pg/ml). 
In summary, this chapter describes the development and validation of a 
sensitive and specific method for measurement of ANP concentrations in human 
blood. This assay, being able to detect both elevated ANP levels and ANP levels 
below the normal range, can be used for routine measurements of ANP concen-
trations in man. 
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Chapter 2.2 
Direct method 
Introduction 
As outlined in the previous chapter, the methods to assess ANP levels in 
plasma can be divided into direct assays (2—5) as opposed to assays using an 
extraction step (6—15). In chapter 2.1 an extraction method for measurement of 
ANP is described. This method, though giving reliable results, is quite laborious 
and costly. Therefore a simple, easy to perform direct assay for ANP was 
developed. The results obtained with this direct assay are compared to those 
obtained with the extraction method, including the effect of exercise stimulating 
cardiac ANP secretion. 
Materials and methods 
Materials 
Synthetic (99-126)hANP (for constructing standard curve and iodination) was 
purchased from Peninsula Laboratories Ine, England; aprotinin (Trasylol) was 
from Bayer, Leverkusen, FRG. Sheep IgG, Bovine Serum Albumin (BSA Cohn 
Fraction V) and Triton X-100 were from Sigma Chemicals Corp, St. Louis, MO, 
USA; PEG-6000, EDTA, Н,В0 3 and NaOH were obtained from Merck, Darm­
stadt, FRG. All reagents were of analytical grade, except where mentioned 
otherwise. The extraction method was performed as described in chapter 2.1. 
Blood sampling 
Blood samples were collected by venepuncture in EDTA vacuum tubes, kept 
on ice, centrifuged within one hour (1500 g, 40C, 10 minutes) and stored in 
aliquots containing 200 KIU of aprotinin/ml plasma at -80*41 until used. 
Direct method 
For the direct assay, the antibody S—31 was used. For characterization of the 
antibody, see table II—1. One hundred microlitres of plasma or standard (in 
RIA-buffer with 6 % human serum albumin) was mixed with 200 μΐ of sheep 
anti-ANP serum (S-31, final dilution in RIA-buffer 1:1.75 χ IO") at 40C in poly-
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styrène tubes. After an incubation period of 8 hours at 40C, 200 μΐ of tracer 
solution (9500 dpm of non-oxidized monoiodotyrosyl tracer obtained with the 
Protag iodination method) was added and the mixture was incubated for 24 
hours at 40C. Separation of bound and free hormone was achieved by adding 1.0 
ml horse anti-sheep precipitating complex (1 μΐ normal sheep serum, 15 μΐ horse 
anti-sheep-IgG serum and 30 mg PEG-6000 per ml RIA-buffer) at room 
temperature (КУС) for 30 minutes. After centrifuging for 30 minutes at 1500 g 
(20oC) the tubes were decanted and the bound fraction was counted in a 
gamma-counter. Recovery of ANP was studied after addition of 62.5, 125, 250 
and 500 pg/ml plasma of synthetic (99-126)hANP to 4 different plasma samples. 
Parallelism was studied by assaying 5 dilutions of 6 different plasma samples. 
Exercbe 
The effect of exercise on a bicycle ergometer on ANP levels was studied on 
three males and one female (aged 20 to 28 years). Blood samples were collected 
before exercise, after a five minutes period of exercise (at 75 % of maximum 
workload, as determined via a previous submaximal exercise test) and after an 
one-hour rest period. ANP was measured both with the direct assay and with the 
extraction assay. Plasma adrenaline (Adr) and noradrenaline (NAdr) were deter­
mined as described previously (20). 
Statùtical analysis 
Statistical analysis was performed using the Spearman rank correlation test. 
Significance was assessed at the a=0.05 level. Data are expressed as 
mean ± SD, except where mentioned otherwise. 
Results 
Radioimmunoassay 
The cross-reactivities of the antibody S—31 are presented in table II—1. As the 
S—31 antibody is specific for the non-oxidized form of methionine on position 
110 of (99-126)hANP, a non-oxidized monoiodotyrosyl-(99-126)hANP tracer as 
obtained with the Protag iodination method was used in the assay. In figure I I -5 
a typical standard curve for the direct assay is shown. The detection limit 
(defined as B0 - 3 χ SEM) was 1.34 ± 0.10 pg/tube (mean ± SEM, for 10 con­
secutive assays), corresponding to 13.4 pg/ml plasma. The 50 % intercept was at 
220 pg/ml, giving a working range of approximately 13 to 1000 pg/ml. Five 
dilutions from 6 plasma samples (ANP values ranging from 45 to 709 pg/ml) 
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Figure II-5. Standard curve of the direct method. 
showed good parallelism (table II-5). The intra- and inter-assay coefficients of 
variation were 3.1 % (n = 6) and 5.5 % (n = 6), respectively, at an endogenous 
level of 125 pg/ml. Recovery, as determined by addition of synthetic 
(99-126)hANP ranged from 90 % to 115 % (mean ± SD = 99 ± 7 %, table 
II-6). 
Plasma ANP values in 41 normal persons with a non-standardized sodium 
intake were 59 ± 25 pg/ml (mean ± SD, η = 41, range 15 to 111 pg/ml). These 
values are in range with those reported by other workers in the field (2—15). 
Thirty-three samples from both normal persons (NP) and patients with 
congestive heart failure (CHF) were measured using both the direct and the ex­
traction method. The results are shown in figure II-6. The direct assay and the 
extraction method correlated well; correlation coefficient г = 0.60 (p<0.01). 
However, when only the values of the normal individuals (extraction values 
ranging from 14 to 70 pg/ml) were studied, the correlation coefficient was 0.34 
(p = NS, figure II—6 inset). This discrepancy cannot be ascribed to the use of 
two different antibodies, as will be shown in chapter 2.3. 
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Table II-5. Parallelism of the direct method (ANP, pg/ml) 
Sanple 
no. 
1 
2 
3 
4 
5 
6 
100 80 
microlitres 
493 
709 
411 
68 
45 
104 
490 
698 
428 
66 
40 
88 
60 
used for radio 
538 
740 
463 
72 
38 
84 
40 20 
imnunoassay 
517 
850 
408 
78 
43 
101 
515 
840 
560 
45 
-
106 
Table II-6. Recovery of the direct method 
pg ANP added 
to different 
plasmas 
0 
62.5 
125 
250 
500 
1 
27 
83 
145 
289 
574 
AMP 
(90) 
(94) 
(105) 
(109) 
(pg/ml) (and % 
2 
25 
83 (93) 
149 (99) 
313 (115) 
499 (95) 
ANP rRcovered) 
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Recovery: mean ± SD = 99 ± 7 % (range 90 to 115 %) 
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Figure II-6. ANP values of both normal persons and patients with congestive heart 
failure, measured directly as well as after extraction. Tfie Spearman correlation coef-
ficient was 0.60 (p<0.01). Inset: ANP values of normal persons only (correlation-
coefficient 0.34, ρ = NS). 
Exercise 
ANP values, both measured with and without extraction, increased during 
exercise on the bicycle ergometer. One hour after exercise, ANP levels were not 
different from levels prior to exercise (figure II-7). ANP extraction values 
correlated excellently with values measured with the direct assay (r = 0.89, 
p<0.001). Both adrenaline and noradrenaline levels were higher during exercise 
(table II-7). 
Discussion 
The correlation of the results from the previously described extraction assay 
(see chapter 2.1) and the direct assay under discussion was good, with one 
exception. When ANP values in normal subjects and patients with CHF were 
pooled (extraction values ranging from 14 to 560 pg/ml), linear regression analy­
sis revealed a good correlation (p<0.01). In contrast, no statistically significant 
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Time 
Figure /7-7. ANP values of four normal persons before (time 1), during (time 2) and 
after (time 3) exercise, measured both with the direct assay (o—o) and with the ex-
traction assay ( · — · ) . 
Table 11-7. Exercise-test on bicycle ergometer 
ANPe (pg/ml) 
ANW (pg/ml) 
NAdr (nmol/1) 
Adr (nmol/1) 
Pre 
exercise 
38.6 ± 14.0 
64 ± 29 
2.28 ± 0.42 
0.17 ± 0.03 
During 
exercise 
106.3 ± 42.1 
141 ± 49 
9.78 ± 3.67 
0.81 ± 0.18 
Post 
exercise 
29.9 ± 5.7 
58 ± 28 
2.50 ± 0.48 
0.09 ± 0.01 
Results of AMP, measured directly (ANPd) and after extraction 
(ANPs), adrenaline (Adr) and noradrenaline (NAdr). Results 
are expressed as mean ± SD. 
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correlation was found when only ANP values in normal subjects (extraction 
values ranging from 14 to 70 pg/ml) were considered. This discrepancy is in 
agreement with findings reported by other workers that the correlation of direct 
results and extraction results decreases at concentrations lower than 100 to 120 
pg/ml (13,21-23). Poole et al. (24) compared the results of 23 different 
laboratories who measured ANP values in the same three plasma samples con-
taining low, medium and high ANP immunoreactivity. Although ANP values 
among the different laboratories varied considerably, all laboratories using an 
extraction method consistently ranked the three plasma samples in the right 
sequence .whereas the laboratories using a direct method did not. Evidently, in 
unextracted plasma there are factors whose influence becomes the greater as 
measured ANP concentrations decrease, and which render direct values in the 
normal range meaningless. 
Nevertheless, the direct assay for ANP fulfills some of the criteria of a valid 
method, such as the parallelism between serial dilutions of plasma and standard 
curve and the recovery curves of ANP added to plasma. Also, ANP values rose 
consistently during exercise, in accordance with ANP values measured in ex-
tracted plasma (25—27). Other workers using a direct assay have found high 
levels of ANP in patients with cardiac disease, liver cirrhosis and renal disease 
(21,28-30). ANP values rose during exercise (28,30), saline infusion (21) and fell 
after haemodialysis in end-stage renal failure (2,21,28). 
Part of the discrepancy in ANP immunoreactivity observed between direct and 
extraction methods may be explained by the existence of a high molecular weight 
component which is not retained on the Seppak C—18 column (21,31). This high 
molecular weight component is clearly different from (1-126)ANP and possesses 
ANP-binding capacities. Possibly this high molecular weight component 
represents a binding protein for ANP. The ANP value obtained using the direct 
assay then represents total ANP immunoreactivity while the ANP value obtained 
using the extraction method represents the free ANP concentration (32). 
In conclusion, direct measurements of ANP, being simple and easy to perform, 
could well be of value to detect high ANP levels in patients and to follow trends 
in ANP concentrations in individual subjects. The more laborious extraction 
method however is necessary for accurate measurements of ANP and to detect 
small differences in ANP values. 
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Chapter 2.3 
Validation of the antibody 
Introduction 
To date, various investigators have described methods for measurement of 
ANP in human plasma. With these methods, widely different normal ANP 
concentrations have been reported. This may be due to differences of method or 
technique, or to other factors. Evidence is accumulating that besides the 28 
amino acids polypeptide (99-126)hANP other immunoreactive ANP-related forms 
circulate in human blood (33,34). Different cross-reactivities of the chosen 
antibody for these as yet unidentified components could partly explain the dif­
ferent outcomes. The antibodies S—31 and S—32 possess different cross-reac­
tivities to several ANP-fragments, as compared to those of the commercially 
available antibody from Peninsula. To validate the use of the S-32 antibody for 
the extraction method, plasma extracts were assayed using both the S—32 and 
the Peninsula antibodies. Furthermore, as the S-32 antibody is used routinely in 
the extraction method and the S-31 antibody in the direct method, the inter-
changeability of these two antibodies was studied. 
Materials and methods 
For the comparison of the S—32 antibody and the Peninsula antibody, 1.0 ml 
of 56 plasma samples was extracted using the procedure described in chapter 2.1. 
The plasma-extracts were dissolved in 500 ді RIA-buffer and subsequently radio-
immunoassayed using both the S-32 and the Peninsula antibodies. For com­
parison of the S-31 and the S-32 antibodies in the extraction method, both 
antibodies were applied to 17 plasma extracts. Both antibodies were also applied 
on 30 plasma samples using the direct assay. 
Statistical analysis 
For comparison of ANP values obtained using the different antibodies the 
paired t-test (Student) was used. Furthermore the Spearman rank correlation test 
was used for determination of the correlation coefficient. Significance was 
assessed at the α=0.05 level. 
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Results and discussion 
Figure II—8 shows ANP levels as determined with the S—32 antibody and the 
antibody from Peninsula on 56 plasma extracts (S-32 values ranging from 8 to 
94 pg/ml). An excellent correlation between these two antibodies was observed, 
г = 0.88, ρ < 0.001. When the Peninsula antibody was used generally higher ANP 
values were found as compared to those found when using the S—32 antibody 
(p<0.01). Linear regression analysis resulted in the following equation (mean 
± SEM): S-32 value = 0.81 (± 0.06, p<0.001) χ Peninsula-value - 3.73 (± 3.20, 
ρ = NS) pg/ml. The observed discrepancy can be explained by different cross-
reactivities of the S—32 and the Peninsula antibodies towards various fragments 
of (99-126)hANP as displayed in table I I - 1 . As high pressure liquid chro­
matography analysis indicates the existence of at least three distinct ANP-related 
components in human blood (chapter 2.4) different crossreactivities of the two 
antibodies towards these components might easily result in different ANP values. 
In figure II—9 the results of both the S—31 and the S—32 antibodies on 17 
plasma extracts (S—32 values ranging from 13 to 62 pg/ml) are shown, while in 
figure II—10 the results of both antibodies on 30 plasma samples in the direct 
Renins (pg/ml ) 
100 
60 100 
S-32 ( p g / m l ) 
Figure II-8. ANP values and regression line obtained when both the S-32 and the 
Peninsula antibodies were used for determination of ANP concentrations in 56 
plasma extracts. 
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S-31(pg/ml) 
60 
S-32lpg/ml) 
Figure 11-9. Results obtained when both the S-31 and the S-32 antibodies were used 
in the extraction method (n = 17). 
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Figure 11-10. Results obtained when both the S-31 and the S-32 antibodies were 
used in the direct method (n = 30). 
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assay (S—31 values ranging from 15 to 143 pg/ml) are shown. Values obtained 
using both antibodies correlated well both when the extraction method was used 
(r = 0.97, p<0.01) and when the direct method was used (r = 0.87, p<0.01). 
Use of both antibodies resulted in similar ANP values in either assay (paired 
t-test, extraction method: t = -0.22, ρ = 0.83, direct method: t = 0.33, 
ρ = 0.75). These results therefore cannot explain the discrepancy between ANP 
values obtained with the extraction method (S-32 antibody) and with the direct 
method (S—31 antibody) on the same plasma samples from normal persons, as 
described in chapter 2.2. These results also demonstrate the possibility of in­
terchanging both antibodies for the two methods to determine ANP 
Concentrations described in this thesis. Mainly for reasons of economy the S-32 
antibody is used routinely in the extraction method while the S-31 antibody is 
used routinely in the direct assay. 
The correlation observed between the S-32 antibody and a widely used 
commercially available antibody from Peninsula justifies the use of the former 
antibody for use in routine measurements of ANP in human blood. 
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Chapter 2.4 
Immimoreactivity of ANP in human plasma 
Introduction 
The exact molecular forms of atrial natriuretic peptide in human plasma are 
not yet known. One method to investigate these molecular forms is separation of 
ANP-immunoreactivity on a high pressure liquid chromatography (HPLC) 
column. 
Nakaoka et al. (35) using an extraction method, found elevated levels of ANP 
in patients with congestive heart failure. This finding was soon confirmed by 
various other workers (36,37). However, it is questionable whether these elevated 
levels of immunoreactive ANP can be attributed solely to the (99-126)hANP 
form, or that other immunoreactive forms are measured also. 
To investigate this possibility plasma from 11 patients with congestive heart 
failure (CHF) and plasma from 5 normal persons (NP) were applied to HPLC-
analysis. As besides (99-126)hANP two other immunoreactive forms were de­
tected in human blood, the functional relevance of these immunoreactive forms 
was studied by HPLC-analysis of plasma obtained both in the basal state and 
during stimulated cardiac ANP release. 
Materials and methods 
Blood was collected into EDTA tubes on ice, and centrifuged immediately (10 
minutes, 1500 g, 40C). Prior to HPLC-analysis, the plasma was extracted on Sep-
pak silica C—18 cartridges (Waters Associates, Milford, MA, USA), subsequently 
eluted using an acetic acid (96 %)-ethanol(86 %) (4:96 v/v) solution, evaporated 
under a nitrogen stream and dissolved in RIA-buffer (pH 8.4, 0.2 mol/1 sodium 
borate buffer). HPLC-analysis was performed using a Supelco C-18 (5 μιτι)-
column (25 cm) with a flowrate of 2 ml/min. The initial solvent composition was 
acetonitrile-distilled water-TFA (20:80:0.1 v/v/v). A linear gradient was used from 
20 to 34 % acetonitrile at 30 minutes, and to 80 % acetonitrile at 40 minutes 
after injection of 200 ді extract. Fractions were collected each minute. 
(99-126)hANP eluted at 28 % acetonitrile (fraction 16). Subsequently, these 
fractions were radioimmunoassayed using two different antibodies: the S-32 
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antibody and the Peninsula antibody. Cross-reactivities of these two antibodies 
are displayed in table II—1. 
The plasma samples were assayed both directly and after extraction, measuring 
total immunoreactivity, and after application to the HPLC-column. Plasma for 
HPLC-analysis was obtained from 11 patients with chronic congestive heart 
failure (Killip classification score III and IV (38)) due to various diseases, and 
from 5 normal persons without any signs of cardiovascular, renal or endocrine 
disorders. 
To study the influence of cardiac ANP secretion on the immunoreactive ANP-
related forms blood was obtained from 5 healthy young persons before and 
during exercise at 90 % of maximal capacity on a bicycle ergometer. Also, from 
1 healthy young person blood was obtained before and after stimulation of ANP 
by volume loading (750 ml 0.9 % NaCl during 60 minutes). The study protocol 
of the exercise test is described in detail in chapter 3.6 and the volume loading 
study is described in chapter 4.4. 
To study the correlation between the various methods and the two antibodies, 
the Spearman rank correlation test was used. Differences in contents of peaks A, 
В and С expressed as percentages of total ANP immunoreactivity measured in 
peaks А, В and С on the HPLC-profile were studied using the Wilcoxon two-
sample test. Differences between values obtained with the Peninsula antibody 
and with the S-32 antibody were investigated using the Wilcoxon signed rank 
test. Significance was assessed at the о=0.05 level. Data are expressed as 
mean ± SD, except where mentioned otherwise. 
Results 
After HPLC-analysis, a large amount of immunoreactive material did not elute 
on the position of (99-126)hANP (peak C, fractions 15 to 17). Figure 11-11 
shows typical HPLC-profile patterns of plasmas from a NP and a CHF person. 
Both types of plasma showed besides the major (99-126)hANP peak (peak C), 
two minor peaks preceding peak С Peak A eluted at positions 8, 9 and 10 while 
peak В eluted at positions 12, 13 and 14. These three peaks were observed both 
when the S—32 antibody was used and when the Peninsula antibody was used. 
When the content of peak C, measured with the S—32 antibody, was expressed 
as percentage of the total ANP immunoreactivity measured in peaks А, В and C, 
peak С contained 46 to 73 % of total immunoreactivity in the CHF plasma, and 
40 to 58 % in the plasmas of NP. Using the Peninsula antibody, the comparable 
ranges were 23 to 60 % and 35 to 49 %, respectively (table II-8). The contents 
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Figure II-ll. Representative HPLC profiles of both a normal person (NP, upper 
panel) and of a patient with congestive heart failure (CHF, lower panel) measured 
with the S-32 as well as the Peninsula antibody. 
of peaks А, В and С did not differ between NP and CHF, neither when using 
the Peninsula antibody nor when using the S-32 antibody. When the NP and the 
CHF persons were taken together, the percentage content of peak A as 
measured with the Peninsula antibody was significantly greater than the 
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Table II-8. Contents of iiranunoreactive peaks in t h e HPIJC p r o f i l e 
(expressed as percentage of t o t a l immunoreactivity of peaks A, В and 
C) measured with t h e Peninsula antibody and with t h e S-32 antibody. 
Mean ± SD (range) % 
Peninsula S-32 
peak A 
Œ F peak В 
peak С 
peak A 
NP peak В 
peak С 
32.3 ± 12.3 18.7 ± 6.4 
(20 - 60) (10 - 29) 
24.1 ± 5.8 22.2 ± 5.2 
(17 - 34) (14 - 32) 
43.7 ± 10.6 59.2 ± 9.4 
(23 - 60) (46 - 73) 
26.8 ± 4.7 23.1 ± 3.1 
(21 - 34) (19 - 27) 
30.1 ± 4.3 28.8 ± 4.7 
(26 - 37) (23 - 35) 
43.2 ± 5.2 48.0 ± 7.6 
(35 - 49) (40 - 58) 
percentage content of peak A as measured with the S—32 antibody. For peak B, 
these percentages did not differ, while the percentage content of peak С was less 
for the Peninsula antibody. 
Also, the total ANP immunoreactivity after extraction of the plasma was mea­
sured. Taken these percentages into account, the (99-126)hANP levels (cor­
responding to peak C) ranged from 72 to 330 pg/ml in CHF as measured with 
the S-32 antibody, and from 45 to 380 pg/ml as measured with the Peninsula 
antibody. The ranges in NP were 12 to 35 pg/ml and 9 to 34 pg/ml, respectively. 
When ANP concentrations as measured with the direct assay, the extraction 
method and as content of peak С on the HPLC-profile were correlated using the 
S-32 and the Peninsula antibodies, overall results correlated well (table II-9 
and figure 11—12). Figure 11 — 13 shows representative HPLC-profiles of plasmas 
obtained both in the basal state and during stimulation (bicycle exercise or vol­
ume loading). Under both basal and stimulated conditions, the predominant im-
munoreactive component as secreted by the heart corresponds to (99-126)hANP. 
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Figure 11-12. ANP immunoreactivity measured with the direct assay, the extraction 
assay, and as content of peak С on the HPLC profile, using both the S-32 and the 
Peninsula antibodies. 
Discussion 
Early reports on ANP-immunoreactivity, based on separation of plasma by 
HPLC-chromatography, indicated that the main immunoreactive form in human 
plasma corresponds to (99-126)hANP. However, several investigators using 
various HPLC-techniques observed besides (99-126)hANP also other immuno­
reactive moieties. These other immunoreactive forms may represent smaller frag­
ments of (99-126)hANP like (103-125)hANP, (102-126)hANP, (103-126)hANP or 
(105-126)hANP. AJso the existence of ß-hANP, (l-126)hANP (the prohormone) 
and (l-98)hANP has been postulated (33,34,39-41). The differences in 
techniques used, in specificity of the antibody used and the complexity of the 
HPLC-technique may explain these discrepancies. In this respect the Peninsula 
antibody recognized the ANP moiety eluting at peak A of the HPLC-profile to a 
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Table II-9. Spearman c o r r e l a t i o n c o e f f i c i e n t s between AMP values 
measured with t h e d i r e c t method, t h e e x t r a c t i o n method and as 
content (pg/ml) of peak С on t h e HPLC p r o f i l e using both t h e 
S-32 and t h e Peninsula a n t i b o d i e s . All c o r r e l a t i o n s were highly 
s i g n i f i c a n t (p<0.01). 
Speannan r 
η = 16 
direct 
S-32 extraction 
HFEC 
direct 
0.96 
0.77 
0.77 
Peninsula 
extractie«! 
0.76 
0.96 
0.93 
HPIC 
0.81 
0.95 
0.97 
greater extent than the S-32 antibody. Consequently, the percentage content of 
peak С recognized by the Peninsula antibody decreased and was less than the 
percentage content of peak С recognized by the S—32 antibody. 
Using HPLC-analysis and amino-acid sequence analysis, Yandle et al. (33) 
found that both (99-126)hANP, (106-126)hANP and a peptide made up of 
(99-105)hANP and (106-126)hANP circulate in human blood. The results 
obtained with our HPLC-technique confirm that besides (99-126)hANP, other 
immunoreactive forms circulate in plasma of both normal persons and patients 
with congestive heart failure. The existence of these immunoreactive forms 
cannot be ascribed to the use of the S-32 antibody, as these three peaks on the 
HPLC-profile were also found when using the commercially available and widely 
used Peninsula antibody. As both antibodies are specific for ANP or ANP-related 
components and do not cross-react with other peptide hormones (see table II-1) 
peak A and peak В probably represent parts of the (l-126)hANP hormone. 
Various fragments and extended forms of (99-126)ANP are biologically active 
(42—44). Therefore it is quite probable that the ANP immunoreactive forms 
representing peaks A and В are also biologically active. 
Both volume loading and exercise stimulate cardiac ANP secretion. As shown 
in this chapter, the predominant form secreted by the heart corresponds to 
(99-126)hANP. This implies that, although other ANP-related forms also circulate 
in human blood, the predominant form of ANP-immunoreactivity both basal and 
in the stimulated state, is (99-126)hANP. Whether the other two unknown 
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Figure 11-13. Representative HPLC profiles of two healthy subjects, both in the basal 
state and during stimulation by exercise (upper panel) or volume loading (lower 
panel). 
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immunoreactive peaks observed in this study may represent some kind of pre-
cursor or degradation products of (99-126)hANP and whether they are of 
physiological importance, remains to be elucidated. 
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Chapter 2.5 
Determination of cGMP concentrations 
Introduction 
Cyclic guanosine monophosphate (cGMP) acts as the second messenger for the 
atrial natriuretic peptide hormonal system (45,46). Extracellulair cGMP vaiues 
correlate well with intracellular cGMP values (47). Therefore determination of 
cGMP concentrations in plasma reflect the biological effectiveness of ANP 
(48,49). As combined assessment of both ANP and cGMP concentrations in 
plasma can provide insight into the functioning of the ANP hormonal system, a 
method for measurement of cGMP concentrations in human plasma was 
developed. 
Materials and methods 
Cyclic GMP was measured by radioimmunoassay following ethanol precipitation 
of plasma proteins. To correct for procedural losses, 100 μ\ (10,000 dpm) of Ή -
cGMP in ethanol (S^H-guanosine 3',5'-cyclic monophospate (Amersham Interna­
tional, England) of specific activity 910 GBq/mmol) was dried in borosilicate glass 
tubes under a stream of nitrogen. The residues were then incubated with 0.5 ml 
of plasma for 10 minutes. To each sample, 1.0 ml of ethanol (Merck 983, 
Darmstadt, FRG) was added. The tubes were vortexed and centrifuged at 2000 g 
for 10 minutes. The supernatants were then decanted and dried at 50oC under a 
stream of nitrogen. The residues were redissolved in 0.5 ml of assay buffer 
(50 mM Tris, 4 mM EDTA (Merck, Darmstadt, FRG) of pH 7.5 with 0.625 % 
(v/v) of beriglobuline (Behringwerke, Marburg, FRG)) and centrifuged at 2000 g 
for 5 minutes. Of these samples, 200 μΐ was counted for recovery and two 100 μΐ 
aliquots were taken for radioimmunoassay. A standard curve (0 to 100 nmol/1) 
was set up in duplicate. To each standard, control and unknown, 100 μΐ (10,000 
dpm) of JH-cGMP, 200 μΐ of sheep anti-cGMP serum in assay buffer and 200 μΐ 
of assay buffer were added. Following overnight incubation at 40C, antibody 
bound and free cGMP were separated by addition of 150 μΐ of dextran coated 
charcoal (1.6 % w/v of charcoal and 0.2 % w/v of dextran T70 in 50 mM Tris-
buffer). After 6 minutes at 40C the tubes were centrifuged at 2000 g. The 
supernatants were then decanted and counted for radioactivity. The cGMP an-
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tibody was raised in Texel white sheep against cGMP coupled to keyhole limpet 
haemocyanin. 
Results and discussion 
After immunization of sheep with cGMP, an antibody with a titre of 1:3000 
was obtained and used for routine measurements of cGMP concentrations in 
human plasma. The cross-reactivity of the antibody with cAMP was 4 %. The 
cGMP values are corrected for the individual recovery of the plasma sample. 
The mean (± SD) recovery of 25 plasma samples after ethanol precipitation of 
B/BQC/. I 
\ 
\ 
!
 ι 1 1 1 1 1 H 
01 0 25 05 1 25 5 10 
nmol /tube 
Figure 11-14. Standard curve of the radioimmunoassay for cGMP with dilution 
curves of two different plasma samples. 
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plasma proteins was 75.4 (± 6.8) %. Dilution of plasma samples showed good 
parallelism. In figure 11—14 a representative standard curve of the 
radioimmunoassay is shown. The sensitivity of the assay, defined as the least 
amount of cGMP distinguishable from zero at a 95 % confidence limit was 0.07 
pmol per tube, corresponding to 1.0 nmol/1 of plasma. The intra- and inter-assay 
coefficients of variation were 7.1 % (n = 6) and 14.2 % (n = 10), respectively, 
at a level of 11.5 nmol/1. 
These results demonstrate that cGMP concentrations can be measured 
accurately and reproducably in human plasma. Assessment of cGMP values may 
be useful to evaluate the biological effect of ANP. 
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Part III 
INFLUENCE OF VARIOUS 
PHYSIOLOGICAL AND SAMPLING 
CONDITIONS ON ANP 
CONCENTRATIONS 
To date, various workers have described methods for measurement of plasma 
ANP values in humans. Plasma ANP values as obtained with a method using an 
extraction step of the plasma are generally considered to be reliable (1,2). Yet, 
even when using the same extraction method and the same antibody, ANP values 
obtained in various laboratories differ considerably (1). Part of these differences 
can be ascribed to different blood collection procedures. In addition physiological 
conditions during the blood sampling procedure may influence cardiac ANP 
secretion. In this respect one has to consider the position of the patient, a 
diurnal rhythm, and the influence of exercise. In the following chapters, the 
influence of the aforementioned factors, along with the influence of venepuncture 
stress, the menstrual cycle and intra-individual variations on ANP concentrations 
are analyzed. 
71 

Chapter 3.1 
Blood sampling and handling of 
plasma samples 
Introduction 
No uniform agreement exists regarding the procedure for collection of blood 
samples for determination of ANP concentrations. Various workers use either 
EDTA or heparin as an anti-coagulant. Also, the necessity of putting the blood 
sampling tubes on ice has been questioned. Richards et al. (2) reported that, 
using a direct method, ANP-immunoreactivity varied with the number of platelets 
present in plasma. Since this number is greatly dependent on the mode of 
centrifugation, the effect of different modes of centrifugation on plasma ANP 
levels is described in this chapter. Plasma samples for determination of ANP 
values are usually not assayed immediately. Before assaying the samples, they are 
stored at -SCFC for periods up to some months. Occasionally, samples have to be 
assayed once again. Therefore the influences of both storage (for a period up to 
six months at either -20oC or at -80°C) and repeated thawing of plasma samples 
before assay were studied. 
Methods 
Blood collection procedure 
To compare various blood sampling conditions, blood samples from two 
persons were collected into either EDTA, heparin or citrate glass tubes (kept on 
ice). After centrifugation of the blood sample (1500 g, 10 minutes, 4°C), 200 
KIU of aprotinin (Trasylol, Bayer AG, FRG) was added for each milliliter of 
plasma. Each sample was measured in sixfold. 
The analytical stability of ANP was studied by centrifuging blood samples ob-
tained from one person after 0, 1 and 3 hours at either room temperature 
(20°€) or stored in ice (0oC). Each sample was measured in sixfold. All samples 
of each person were measured consecutively in the same assay to minimize intra-
and inter-assay variations. For determination of ANP, the extraction method 
with the Peninsula antibody was used. 
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Centrifugation of blood samples 
From three persons, sufficient blood was collected to centrifuge blood samples 
(9 ml each) respectively 5, 10 and 15 minutes at 1500 g and 15 minutes at 
3000 g. Also, following centrifugation for 15 minutes at 1500 g, the aspirated 
plasma was recentrifuged for 15 minutes at 20,000 g. After centrifugation the 
plasma columns were aspirated in four portions from the top to the buffy coat 
(separating the plasma from the red cells). Before storage at —80°C, an aliquot 
(25 μΐ) was removed for counting of the platelets. The samples were measured 
consecutively in the same assay run. Both the extraction method (with the S—32 
antibody) and the direct method (with the S—31 antibody) were used for 
determination of ANP values. 
Storage and thawing of plasma samples 
The effect of prolonged storage (up to 5 months) at - S ^ C was studied on 
one plasma sample, measured repeatedly (14 times) during this period. Also, 
from two subjects plasma (with aprotinin 200 KIU/ml plasma added) was stored 
either at —20oC or at —80oC for a period up to six months. The ANP levels 
(consisting of six measurements each) were compared with the ANP level (six 
measurements) in plasma assayed within one week (stored at —80oC). To study 
the influence of thawing, plasma from 3 persons was thawed once (which is the 
routine procedure), twice or three times before assay. Each plasma sample was 
measured six times for each of the thawing procedures. Samples of each person, 
regardless of the thawing procedure, were measured in the same assay run within 
one week after blood collection. The extraction method using the S-32 antibody 
was used. 
Statistical analysis 
Statistical analysis of the various blood collection procedures was performed 
using the Wilcoxon two-sample test. To correlate the amount of platelets present 
in the plasma with the corresponding ANP value the Spearman rank correlation 
test was used. For evaluation of the different modes of centrifugation, one-way 
analysis of variance followed by the t—test (Student) with Bonferroni's correction 
was used. Differences in ANP immunoreactivity after storage at — 20CC or at 
—SCC and after several times thawing were studied using one-way analysis of 
variance followed by the t-test (Student) with Bonferroni's correction. Sig­
nificance was assessed at the a=0.05 level. Data are expressed as mean ± SD, 
except where mentioned otherwise. 
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Results 
Blood collection procedure 
Collection of blood in heparin or citrate glass tubes gave consistently lower 
values than collection in EDTA glass tubes (table HI—1, percentage and p—value 
as compared to blood sampling in EDTA glass tubes on ice, 0 hours). Obviously, 
collection in citrate resulted in much greater variations. The amount of immuno-
reactive ANP decreased when blood was kept either on ice or at room tempera­
ture for some time before centrifugation. However, when blood kept on ice was 
centrifuged within one hour, immunoreactivity remained at 90 % of basal. Based 
on these results, the following routine procedure was adopted as standard proce­
dure for blood collection: sampling into EDTA-glass tubes kept on ice, 
Table III-l. ANP concentra t ions found a f t e r d i f f e r e n t t rea tments of 
blood samples 
Subject 
A 
В 
С 
Sanple 
treatment 
EDTA, in ice, 0 h 
Heparin, in ice, 0 h 
Citrate, in ice, 0 h 
ІША, in ice, 0 h 
Heparin, in ice, 0 h 
Citrate, in ice, 0 h 
EDTA, in ice for: 
0 h 
1 h 
3 h 
ШЕА, at КГ for: 
0 h 
1 h 
3 h 
ANP ι (ra/mi) 
mean ± SD 
25.0 
20.2 
12.0 
35.8 
30.5 
25.8 
25.0 
22.5 
20.8 
22.5 
19.5 
18.0 
+ 
+ 
+ 
+ 
± 
± 
+ 
± 
± 
± 
± 
+ 
1.7 
1.5 
4.7 
2.2 
2.4 
4.7 
1.7 
1.6 
1.5 
1.0 
1.4 
1.3 
%* 
100 
80 
48 
100 
85 
72 
100 
90 
83 
90 
78 
72 
p-value 
p<0.01 
p<0.01 
_ 
p<0.01 
p<0.01 
-
p<0.05 
p<0.01 
p<0.05 
p<0.01 
p<0.01 
Numbers a r e for s i x d i f f e r e n t samples from each sub jec t . 
RT: room temperature (20°C). In i c e : 0°C. P-value: v s . EDTA in 
i c e , 0 hours (h) for t h e same person. 
* ANP concentrat ion found expressed as % ANP concentra t ion for 
t h e same plasma in EDTA, in i c e , 0 h. 
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centrifugation as soon as possible (within one hour) and storage at —SCPC before 
assay. 
Centrifugation of blood samples 
From each person (n = 3), a blood sample (9 ml) was centrifuged using five 
ANP (*/» of reference value ) 
120 
100 
8 0 -
direct method 
ч«.. 
120-1 
100-
8 0 -
100 200 
extraction method 
100 300 
"TOO 
700 
Platelet count (x10 s /l) 
Figure III-l. Relationship between the platelet count in the plasma and the 
corresponding ANP value, measured with the direct assay (upper panel) and after ex­
traction (lower panel). ANP values are expressed as percentages of the ANP 
concentrations in plasmas of the same person containing less than 10 χ l(f 
platelets/L 
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different methods, yielding different amounts of platelets in the plasma. Further­
more, each plasma column was divided into four equal parts with increasing 
platelet count from the top of the plasma column to the buffy coat. In figure 
I I I - l the ANP values of all individuals are plotted against the corresponding 
platelet counts. The values that were measured in plasma containing less than 
10 χ IO9 platelets/1, were taken as reference value (= 100 %) for each person. 
No significant correlation was found between platelet count and ANP value as 
measured with or without extraction. Pooling of the values of the four portions 
of the plasma columns together, the results of the various procedures of 
centrifugation are shown in figure III-2. No differences in ANP levels were 
observed between the various centrifugation procedures. 
ANP(7o of reference value ) 
5 10 15 15 15 mm 
1500 1500 1500 3000 20.000 g 
Methods of centrifugation 
Figure Ш-2. ANP values found directly (open bars) and after extraction (closed 
bars) in relation to different centrifugation modes. Bars denote mean ± SD. Values 
are expressed as percentages of the ANP concentrations in plasmas of the same 
person containing less than 10 χ l(f platelets/l. 
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Storage and thawing of plasma samples 
Storage of plasma from one person at — SCPC during a period of up to five 
months did not significantly influence ANP immunoreactivity (figure III-3). How­
ever, comparison of storage temperatures revealed that storage at — 2(fC 
markedly decreased ANP immunoreactivity as compared to storage at — SOPC. 
Storage at — 80oC for a period up to six months did not significantly influence 
ANP immunoreactivity (figure III-4 and table III-2). In contrast, repeated 
thawing of plasma prior to extraction and radioimmunoassay markedly decreased 
the ANP level (figure III-5 and table III-3). 
Discussion 
Various factors can influence ANP levels, thereby explaining part of the differ­
ences in reference values found among various laboratories. An additional factor 
contributing to these discrepancies in reference values could very well be that 
blood sampling and handling of the plasma samples differed considerably. As 
shown by the preceding experiments, the choice of anticoagulant can exert a sub­
stantial influence on ANP immunoreactivity. Storage of blood samples, even 
( p g / m l ) 
mean = 22,6 pg/ml 
SD = 2,37 pg ml 
CV =10,5 'lo 
x _ x ^ χ _x 
x ~* *~
 χ
 x χ χ 
τ 1 1 1 1 — 
1 2 3 4 5 ( months ) 
Figure Ш-3. Stability of ANP immunoreactivity in plasma during storage at —8(ГС 
(η = 14). 
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storage condition 
Figure III-4. Storage of plasma at -2(ГС or at -8(fC for a period up to six 
months. While storage at —2(fC decreased ANP levels, storage at -8(fC did not 
influence ANP levels (Ref = reference ANP values in plasma assayed within one 
week). Values are mean ± SD. ρ = ρ—value vs. reference. 
Table III-2. Storage of plasma of two subjects at -20°С or at 
-80°С Values represent the mean (± SD) of six measurements. 
Reference = ANP levels in plasma assayed within one week. 
Storage 
Peferenubi 
3 months 
-80° С 
-20° С 
6 months 
-80° С 
-20° С 
subjects 
À 
32.2 ± 1.0 
32.3 ± 2.3 
24.9 ± 1.4*# 
32.4 ± 1.7 
26.3 ± 1.3*# 
В 
33.0 ± 2.0 
33.6 ± 2.8 
30.8 ± 3.3 
32.6 ± 2.0 
29.9 ± 2.4 
* p<0.05 vs. -80°C stored for the same period 
# p<0.05 vs. reference 
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Figure III-5. Influence of repeated thawing of plasma samples from three persons on 
ANP levels. Bars denote mean ± SD. ρ = ρ—value vs. 1 χ thawing. 
Table Ш-3. Influence of repeated thawing of plasmas from 
t h r e e s u b j e c t s . The ANP value of each thawing procedure r e ­
p r e s e n t s t h e mean (± SD) of s i x measurements. 
times 
thawing 
1 X 
2 χ 
3 χ 
subjects 
A 
32.2 ± 1.0 
21.5 ± 1.3* 
12.5 ± 1.1*# 
В 
33.0 ± 2.0 
25.8 ± 1.3* 
17.5 ± 1.3*# 
С 
31.9 ± 3.4 
33.9 ± 3.9 
24.7 ± 2.3*# 
* p<0.05 vs. 1 χ thawing 
# p<0.05 vs. 2 χ thawing 
when kept on ice, for more than one hour decreases ANP immunoreactivity 
more than 10 %. This figure is higher than that reported by Hartter et al. (3). 
However, these investigators used labelled ANP as standard for measuring the 
amount of degradation, while we determined the endogenous remaining 
immunoreactivity, which could explain the difference. 
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Richards et al. (2) reported that platelets interfere with the direct assay for 
ANP, causing an elevation of ANP concentrations proportional to the number of 
platelets present in the plasma. Such an effect was not found in our study. How-
ever, these blood samples were centrifuged at 1500 g for 5, 10 and 15 minutes, 
whereas Richards eC al. centrifuged their samples only at 1000 g for 10 minutes. 
To analyze whether this could explain the difference, from one person blood was 
also centrifuged at 1000 g for a 10 minutes period. No significant difference with 
the other centrifugation methods could be detected (data not shown). These 
findings imply that in using the methods of measuring ANP as described in this 
thesis, no special precautions with regard to the amount of platelets are required. 
Storage of plasma at — 80oC for up to six months did not decrease ANP-immu-
noreactivity. This is consistent with findings reported by other workers, who did 
not observe a decrease in ANP levels when plasma was stored at —80oC or even 
at — 20oC (3,4). However, in our study storage at — 20oC decreased ANP values 
markedly in one person. These results imply that plasma should be preferentially 
stored at — 80oC to avoid loss of ANP immunoreactivity. As thawing of plasma 
markedly decreased ANP-immunoreactivity, samples should be thawed only once 
before extraction and radioimmunoassay. Other workers have also observed a de-
crease in ANP-immunoreactivity when plasma was thawed repeatedly (5). To cir-
cumvent repeated thawing of plasma when samples have to be assayed more 
than once, we recommend to divide the plasma after centrifugation over two or 
more plasma collection tubes. 
Considering the results discussed in this chapter, the standard routine for 
handling blood samples for ANP should be: collection into EDTA-glass tubes on 
ice, centrifugation within one hour (1500 g, 10 minutes, 4°C), addition of 200 
KIU of aprotinin/ml plasma and storage at -80°C. Plasma samples should be 
thawed only once before assay. All samples used to determine ANP values in 
this thesis were handled consistently in the above-mentioned method. 
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Chapter 3.2 
Venepuncture stress and menstrual cycle 
Introduction 
It has been reported that in animal studies stress can elevate ANP levels (6,7). 
This elevation is probably due to the increase of circulating catecholamine levels 
(8,9). As venepuncture stress can markedly elevate these levels, venepuncture 
stress may also influence ANP concentrations. 
Progesterone, by antagonizing the binding of aldosterone to its receptor on the 
distal tubulus of the kidney, acts as a natriuretic agent (10,11). Therefore it 
cannot be excluded that ANP levels in the follicular phase differ from those in 
the luteal phase of the menstrual cycle. 
These issues were analyzed in the present study. 
Methods 
To determine if stress caused by venepuncture can influence ANP levels, a 
catheter was inserted into an antecubital vein of 9 healthy young male subjects 
who were in the recumbent position for thirty minutes before insertion of the 
catheter. Blood samples were obtained immediately after insertion of the 
catheter and 30 minutes thereafter. 
For measurement of ANP in two phases of the menstrual cycle, 16 healthy 
women (aged 18 to 45 years) who were not taking oral contraceptives, were 
studied on day 4 to 6 (follicular phase) and on day 18 to 19 (luteal phase) of the 
menstrual cycle. Blood samples were obtained between 9iW and T45 a.m. and 
between 1530 and 1610 p.m. of the same day. 
ANP was determined using the extraction method with the Peninsula antibody. 
All samples from each person were measured in the same assay run. Statistical 
analysis was performed using the paired t-test (Student). Significance was 
assessed at the α=0.05 level. Values are expressed as mean ± SD, except where 
mentioned otherwise. 
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Results and discussion 
In figure III-6 the ANP values immediately after venepuncture (25.4 ± 7.9 
pg/ml) and 30 minutes thereafter (29.6 ± 7 . 1 pg/ml) are shown. No significant 
decrease was observed between values obtained after 0 and after 30 minutes, 
suggesting that venepuncture stress does not elevate ANP levels. However, in 
some persons a disturbing discrepancy was found between the ANP values 
obtained after 0 minutes and the values obtained 30 minutes later, which cannot 
be attributed solely to assay variations. As the plasma half life of (99-126)hANP 
in man is approximately 3.5 minutes (see chapter 4.2), the possibility arises that 
ANP is not continuously secreted by the heart, but in a pulsatile way. 
As shown in figure III-7, ANP levels in the follicular phase tended to be 
ANP ( p g / m l ) , 
50 -
4 0 
3 0 
2 0 
10 
I I 
О 30 ( m m ) 
Figure III-6. Influence of venepuncture stress on ANP values in blood sampled at 0 
minutes and 30 minutes after insertion of an intravenous catheter. No significant 
difference was found. 
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Figure Ш-7. ANP values (mean ± SEM) in the follicular (foil) and luteal (lut) 
phase of the menstrual cycle. Blood was sampled in the morning (a.m.) and in the 
afternoon (p.m.). NS = not significant. 
somewhat higher than those in the luteal phase of the menstrual cycle; the 
difference however was not statistically significant. In contrast, ANP levels 
obtained in the morning were higher than the corresponding levels obtained in 
the afternoon (follicular phase: 36.3 ± 13.5 vs. 27.9 ±11.6 pg/ml; ρ < 0.05, luteal 
phase: 32.1 ± 11.3 vs. 26.9 ± 10.4 pg/ml; ρ = 0.06). Taken the values of both 
menstrual phases together, the difference between morning and afternoon values 
was significant (34.2 ± 12.4 vs. 27.4 ± 10.8 pg/ml, p<0.01). 
In conclusion, both venepuncture stress and the phase of the menstrual cycle 
do not influence ANP values. A difference however exists between morning and 
afternoon concentrations of ANP. 
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Chapter 3.3 
Diurnal rhythm 
Introduction 
As described in chapter 3.2, ANP values obtained in the morning were higher 
than those obtained in the afternoon. Therefore it could be that ANP, like other 
hormones, possesses a diurnal rhythm. To explore this possibility, ANP was 
monitored in 7 ambulant subjects to study the variations during daytime. In 
addition, ANP was measured three times during a 24 hours period in nine 
hospitalized patients. 
Methods 
To study the variation in ANP over the day, an intravenous catheter was inser-
ted into an antecubital vein in five healthy and two pregnant (4 and 8 months) 
ambulant female volunteers. Blood sampling (from 700 a.m. till Ì500 p.m., sitting 
position) was more frequent in the morning. The subjects awoke at approx-
imately 600 a.m., had breakfast at ± 630 a.m. and lunch at ± 13°° p.m. Statistical 
analysis was performed using the Spearman rank correlation test on ANP values 
from each person. 
In nine hospitalized patients (7 males, 2 females) without any cardiovascular, 
renal or endocrine disorders, blood was obtained at 700 a.m., 1530 p.m. and at 
2330 p.m., at least two hours after a meal. The patients were in the supine posi-
tion during the entire study period. Statistical analysis was performed using 
analysis of variance for repeated measurements followed by the paired t-test 
(Student). Significance was assessed at the α=0.05 level. ANP was determined 
using the extraction method with the Peninsula antibody. All samples from each 
person were measured in the same assay run. 
Results 
The variations in ANP levels in a mixed group of ambulant female subjects 
throughout the day is shown in figure III—8. A statistically significant fall in ANP 
levels was observed (mean Spearman correlation coefficient ± SEM = -0.75 
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Figure III-8. Variation in ANP levels throughout the day. 
± 0.05, p<0.01) in all subjects, including the identical twin and the pregnant wo­
men. The decline was most prominent between 700 a.m. and 8'° a.m., thereafter 
no significant fall was observed. In the hospitalized patients who were recumbent 
during the study period, ANP values varied widely intra-individually. In these pa­
tients, no consistent trend in ANP concentrations could be detected (figure 
III-9). 
Discussion 
The observed fall in ANP concentrations in the early morning in ambulant sub­
jects is in accordance with the results reported by Weil et al. These investigators 
found higher levels of both ANP and cGMP in the morning (12). As a fall in 
ANP has been described in association with change from the supine to the up­
right position (see chapter 3.5) and venous pooling of the blood into the lower 
extremities occurs in the morning (13), this mechanism may be responsible for 
the observed morning-decline of ANP. The absence of a similar fall in ANP 
concentrations between Ί30 a.m. and 15да p.m. in the recumbent patients is in 
agreement with this hypothesis. Donckier et al. (14) reported a nightly peak of 
ANP at 400 a.m. in the diurnal rhythm of ANP. No variation during daytime was 
observed in these ambulant subjects. Richards et al. (15) found higher ANP 
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Figure III-9. ANP values sampled in nine patients who were in the supine position 
during the study period. No consistent pattern in ANP concentrations could be detec-
ted. 
levels during l l 0 0 a.m. and 1300 p.m. and lower levels between Yl00 and 1900 p.m. 
In contrast, other workers (16-18) did not report a diurnal rhythm of ANP. The 
inconsistent results reported in these studies can be attributed to the frequency 
and timing of blood sampling, whether ambulant or recumbent subjects were 
studied, and to the method used to determine ANP concentrations. 
In conclusion, ANP values may vary dependent on the time of the day. This 
factor should be borne in mind when interpreting ANP concentrations. 
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Chapter 3.4 
Intra-individual variation 
Introduction 
As described in chapters 3.2 and 3.3, a considerable intra-individual variation in 
ANP levels was observed in some subjects, which could indicate that the heart 
secretes ANP in a pulsatile way rather than continuously. In order to assess the 
significance of a possible biological variation in ANP levels, ANP was measured 
serially during a 521/2 minutes period to study the intra-individual variation. 
Methods 
Fifteen healthy volunteers (8 males, 7 females, aged 20 to 25 years), gave 
informed consent and, after having fasted overnight, participated in the study. 
The subjects were not permitted to drink coffee or to smoke cigarettes. After 
having rested for at least 30 minutes in the supine position, blood (7 ml) was 
sampled 8 times during a 52 г minutes period (in periods of І г minutes each) 
starting at 900 a.m. ANP was measured using the extraction method with the 
S—32 antibody. All samples from each person were assayed in the same run. In 
order to obtain an accurate estimate of the intra-assay coefficient of variation for 
ANP, the coefficients of variation of 18 different plasma samples (endogenous 
ANP levels ranging from 12.5 to 55.8 pg/ml, each sample was processed sixfold 
in the same assay) were determined. The coefficients of variation ranged from 
3.0 to 11.4 % (mean ± S.D. = 7.0 ± 2.5 %, median value 6.6 %), and were 
approximately normally distributed (Shapiro-Wilk normality test ρ = 0.6). 
To study the intra-individual variation, the mean and the coefficient of 
variation (C.V.) of each person were calculated. In order to show the existence 
of additional variations besides the intra-assay variation, the hypothesis that the 
intra-individual coefficients of variation belong to the same distribution as the 
intra-assay coefficients of variation, was tested using the one-sided Wilcoxon two-
sample test. Besides, for each subject it was examined whether the subjects's 
intra-individual coefficient of variation exceeded the intra-assay coefficient of 
variation using the one-sided t-test (Student). To assess any significant changes in 
ANP during the study period, differences between the initial and successive ANP 
values were tested using the paired t-test (Student) with Bonferroni's correction. 
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Results 
ANP levels were measured consecutively eight times at fixed intervals during a 
52V2 period in 15 healthy volunteers. The mean, standard deviation (SD) and the 
coefficient of variation (C.V.) were calculated for the data on each individual. 
The results are depicted in table III—4. The coefficients of variation in these 
subjects varied widely, from 5.4 % to 23.1 %. Using the one-sided Wilcoxon two-
sample test, the hypothesis that the intra-individual coefficients of variation 
belong to the same distribution as the intra-assay coefficients of variation (7.0 ± 
2.5 %) could be rejected at the α = 0.001 level. The C.V. in 9 subjects sig­
nificantly (at the a = 0.05 level) exceeded the intra-assay variation, indicating 
that the intra-individual variation observed in these subjects could not be 
explained by assay variations alone. During the study period, no consistent 
Table III-4. I n t r a - i n d i v i d u a l v a r i a t i o n of ANP l e v e l s in man. 
The c o e f f i c i e n t of v a r i a t i o n (C.V.) i n 9 out of 15 sub jects 
s i g n i f i c a n t l y exceeded t h e in t ra-assay v a r i a t i o n (7 %) (sex: 
m = male, f = female, p-value: NS = p>0.10). 
Person 
A 
В 
С 
D 
E 
F 
G 
H 
I 
J 
К 
L 
M 
N 
О 
sex 
m 
f 
m 
f 
m 
m 
m 
f 
m 
f 
m 
m 
f 
f 
f 
mean ANP value 
(pg/ml, mean ± SD) 
81.7 
16.5 
15.4 
26.0 
55.5 
48.1 
33.2 
48.4 
23.4 
56.0 
33.8 
39.5 
61.1 
60.1 
51.1 
+ 
+ 
+ 
+ 
+ 
± 
± 
± 
+ 
± 
± 
± 
± 
± 
± 
17.7 
3.5 
1.4 
4.1 
10.4 
11.1 
1.8 
3.4 
2.9 
3.3 
3.8 
7.2 
8.2 
5.5 
6.1 
C.V. (%) 
21.7 
21.1 
8.8 
15.7 
18.7 
23.1 
5.4 
6.9 
12.6 
6.3 
11.4 
18.2 
13.5 
9.1 
11.9 
p-value 
<0.001 
<0.001 
NS 
0.002 
<0.001 
<0.001 
NS 
NS 
0.022 
NS 
0.054 
<0.001 
0.011 
NS 
0.038 
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change of ANP with time was found. 
Discussion 
In chapter 3.2, the influence of venepuncture stress on ANP levels was studied. 
From each person, two blood samples within a period of 30 minutes were collec­
ted. Although no consistent change in ANP was observed, some subjects dis­
played a disturbing discrepancy in ANP values during this 30 minutes period. 
The study described in this chapter extends these observations. All plasma 
samples from the same person were assayed in the same run, thereby limiting 
assay variations. Furthermore, a period of "ЫУг minutes with blood sampling each 
IVT. minutes was chosen to limit the possible influence of a diurnal rhythm of 
ANP. The total amount of blood collected during this period was approximately 
60 ml, while haemorrhage of 500 ml did not significantly influence ANP levels 
(19). The study started at 9°° a.m. and the subjects were in the supine position 
during the entire study period. The possible influence of breakfast was excluded 
by fasting overnight, while coffee and cigarettes (possibly influencing blood 
pressure) were not permitted. Despite these precautions, in 9 out of 15 subjects 
the observed variation in ANP levels could not be attributed to intra-assay 
variations alone. As no consistent change in ANP levels during this period was 
observed, the variation cannot be attributed to a diurnal rhythm, the effects of 
haemorrhage, the effect of assuming the supine position, or to the effect of ha­
ving had a meal. The only other factor that could possibly explain the observed 
intra-individual variation, is the existence of endogenous fluctuations in ANP 
levels. Therefore one should keep this endogenous variation in mind when 
interpreting ANP concentrations. 
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Chapter 3.5 
Posture and ANP 
Introduction 
From data obtained during cardiac catheterization in patients with congestive 
heart failure, it was found that ANP levels are correlated with the right atrial 
pressure. Increasing the atrial pressure by inflating a balloon in the pulmonary 
artery concomitantly increases ANP concentrations (20), while decreasing the 
right atrial pressure by inflating a balloon in the vena cava decreases cardiac 
ANP secretion (21). In man, the plasma ANP concentration rises after manoeu-
vres which increase extracellular volume and right atrial pressure (22,23). 
Furthermore ANP levels have been reported to increase after head-up water 
immersion, head-down tilt and during ingestion of a high salt diet (24-26). The 
first two of these manoeuvres are not usually encountered in daily life and the 
significance of these observations remains uncertain. In particular it is not known 
whether changes in right atrial pressure, which might occur in normal day to day 
life, are sufficient to stimulate cardiac ANP secretion. Assuming the upright 
posture causes venous pooling of blood in the lower parts of the body and hence 
reduces venous return and right atrial pressure, and this is associated with a re-
duction in renal blood flow, diuresis and natriuresis, and plasma renin activity 
(27,28). Inversely, assumption of the supine posture increases central blood 
volume, venous return, right atrial pressure and renal salt and water excretion. 
To investigate the effects of changes in right atrial pressure occurring during 
daily life, the influence of three posture positions (supine, sitting and upright 
positions) on ANP secretion was studied. Also, plasma renin activity (PRA) and 
aldosterone was measured to study the interrelationships between these three 
volume-regulating hormones. 
Methods 
A catheter was inserted into an antecubital vein in 19 healthy subjects (12 
males, 7 females, aged 20 to 27 years). Blood for measurement of ANP, PRA 
and aldosterone was withdrawn after one hour in the supine position, 15 minutes 
later in the sitting position and 15 min thereafter when the subjects were stan-
ding upright. Additionally, in 9 of these subjects blood was also sampled 15 
95 
minutes later when the subjects were in the supine position again. As the plasma 
half life of ANP in man is approximately 3.5 minutes (chapter 4.2) a period of 
15 minutes was considered to be adequate to detect posture-induced changes in 
ANP. 
ANP was measured using the extraction method with the S—32 antibody. PRA 
was measured using the Phadebas Angiotensin I test (Pharmacia Diagnostics, 
Sweden) and plasma aldosterone was measured as described previously (29). All 
plasma samples from each person were assayed consecutively in the same assay 
run. Statistical analysis was performed using the Wilcoxon signed rank test and 
the Spearman rank correlation test. Significance was assessed at the α=0.05 
level. Values are expressed as mean ± SD, except where mentioned otherwise. 
Results 
Change of position from supine to sitting significantly decreased ANP levels, 
while PRA levels did not differ. In contrast, changing from the sitting to the up­
right position did not further decrease ANP while PRA markedly rose (figure 
III—10). Plasma aldosterone did not differ in any of the three positions (table 
III—5). No correlation was observed between the percentual decrease in ANP 
from the supine to the upright position, and the corresponding percentual in­
creases in PRA (r = —0.24, ρ = NS) or aldosterone (r = 0.09, ρ = NS). Also, 
the percentual changes in PRA and aldosterone did not correlate (r = -0.09, 
ρ = NS). 
In a subset of nine subjects, hormone levels were also measured after changing 
from the upright to the supine position again. The results of these subjects are 
shown in table III—6 and figure III-11. While PRA decreased after changing 
from the upright to the supine position, no significant change neither in ANP nor 
in aldosterone was observed. In none of the four positions did ANP values corre­
late with PRA or aldosterone values. PRA values correlated only in the initial 
supine position (r = 0.59, η = 19, p<0.01) and in the sitting position (r = 0.65, 
η = 19, p<0.01) with plasma aldosterone values. 
Discussion 
This study describes the effects of posture on three hormones influencing the 
body fluid regulation. ANP can be regarded as a counterregulatory hormone, 
with effects opposite to those of PRA and aldosterone. In the upright position, 
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Table III-5. Plasma concentrations of atrial natriuretic peptide 
(ANP), plasma renin activity (PRA) and aldosterone (Aldo) in 
the supine, sitting and upright position. Values are expres­
sed as mean ± SD (n = 19). 
ANP 
(pg/ml) 
PRA 
(nmol/l/h) 
Aldo 
(nmol/l) 
* p<0 
** p<0 
VS. SU] 
positi 
Position 
supine sitting 
36.5 ± 14.8 27.5 ± 12.2** 
1.31 ± 1.20## 1.32 ± 1.06** 
0.40 ± 0.20 0.44 ± 0.25 
.05 # p<0.05 
.01 ## p<0.01 
pine vs. upright 
on position 
upright 
26.7 ± 12.9** 
2.12 ± 1.56** 
0.46 ± 0.32 
Wilcoxon signed rank test 
ANPIpg/ml) 
» NS NS 
PRA(nmol/l h) 
ι — ; 
- Aldosterone(nmol/l] 
, N5 
NS NS NS 
¿5 
35 
2 5 -
15 
• 
-
ΓΊ 
-
Я * 
-, 1 
2 5 -
2 0-
1 5 -
1 0 
0 5 -
¿1 
r 
J , 
JL 
0 6 
о и 
0 2 
I 
sup sit up sup 
« p<0 05 
sup sit up sup sup sit up sup 
Figure III-ll. Position-induced changes in ANP and PRA. Aldosterone levels were 
not influenced by the position of the subjects (n = 9). Sup = supine, sit = sitting 
up = upright position. Bars indicate mean + SEM. 
Table III-6. Plasma concentrations of atrial natriuretic peptide 
(AMP), plasma renin activity (PRA) and aldosterone (Aldo) in 
9 subjects, measured in the supine, sitting and upright 
position, and after assuming the supine position again. 
Values are expressed as mean ± SD. 
ANP 
(ra/mi) 
VSA 
(ппюІ/1/h) 
Aldo 
(nmol/l) 
supine 
42.5 ± 12.5 
0.97 ± 0 . 6 1 # 
0.35 ± 0.20 
P o s i t i o n 
s i t t i n g 
32.1 ± 13.8* 
1.08 ± 0 . 6 5 # 
0.40 ± 0.30 
upric^it 
31.7 ± 15.4* 
1.92 ± 0.96* 
0.51 ± 0.46 
supine 
28.7 ± 8.7* 
1.45 ± 0.71*fl 
0.56 ± 0.35 
* p<0.05 # p<0.05 
vs initial vs upright 
supine position position 
Wilcoxon signed rank test 
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lower ANP concentrations were measured as compared to those obtained in the 
supine position (30,31). Solomon et al. (32), using a tilt-table, increased venous 
return to the heart and observed an increase in ANP concentrations. This 
increase was markedly attenuated by inflation of antishock-trousers, which apply 
positive pressure to the legs and lower abdomen thereby diminishing the increase 
in venous return. 
In the study described in this chapter, ANP decreased when the volunteers 
changed from the supine to the sitting position. However, no further change in 
ANP was observed when the upright position was assumed. Possibly, more than 
15 minutes would be needed for a further decrease in ANP. As infusion of ANP 
inhibits the postural release of renin (33), an increase in PRA after changing 
from the supine to the sitting position would be expected. In contrast, PRA 
increased only when changing from the sitting to the upright position. Assuming 
the supine position again after standing upright decreased PRA levels while ANP 
did not change. The lack of correlation between the percentual changes in ANP 
and PRA is a further indication that during short-term physiological changes the 
regulation of these two hormones is not reciprocally related. 
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Chapter 3.6 
Exercise and ANP 
Introduction 
Both in animal studies and in studies performed in humans, ANP levels in 
peripheral venous blood were found to correlate with intracardiac pressures 
(5,20). During supraventricular tachycardia and during tachycardia induced by 
ventricular pacing, elevated ANP levels have been found which returned to 
baseline after termination of the tachycardia (34,35). Exercise is associated with 
an increase in heart rate and intra-cardiac pressures (36). Furthermore exercise 
stimulates adrenaline and noradrenaline levels, which have been found to elevate 
ANP levels (8,9). To study the influence of exercise on cardiac ANP secretion, a 
standardized bicycle exercise test was performed on 7 healthy volunteers and its 
influence on ANP, its second messenger cyclic guanosine monophosphate 
(cGMP) and various other hormones were investigated. 
Methods 
The influence of exercise on cardiac ANP secretion was studied on 7 healthy 
volunteers (4 males, 3 females aged 20 to 28 years). On a separate day prior to 
the final exercise test, the subjects performed a stepwise graded bicycle exercise 
test (sitting position) till maximal exhaustion as determined from the expected 
maximal heart rate for a given age (37). Heart rate was monitored continuously 
and used to calculate 50 % and 90 % of the maximal workload. On the day of 
the exercise test, blood was sampled at rest (time = 1), after three minutes of 
exercise at 50 % of the maximal workload (time = 2), after three minutes of 
exercise at 90 % of the maximal workload (time = 3) and 15 (time = 4) and 60 
(time = 5) minutes after the exercise test. The exercise test started at 1400 p.m., 
ending at Ì430 p.m. 
All samples from each person were measured consecutively in the same assay 
run. ANP was measured using the extraction method and the S-32 antibody. Cy-
clic GMP was measured as described in chapter 2.5. Plasma renin activity (PRA) 
was measured using the Phadebas Angiotensin I test (Pharmacia Diagnostics, 
Sweden), aldosterone (29), Cortisol (38), adrenaline and noradrenaline (39) were 
measured as described previously. All plasma samples of each person were 
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measured m the same assay run. 
Statistical analysis was performed using the Wilcoxon signed rank test and the 
Spearman rank correlation test. Significance was assessed at the a=0.05 level. 
Data are expressed as mean ± SD except where indicated otherwise. 
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Figure III-12. Influence of exercise on plasma levels of ANP, cGMP, PRA, 
aldosterone (Aldo), Cortisol, adrenaline (Adr) and noradrenaline (NAdr) (n = 7). 
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Results 
Standardized bicycle exercise stimulated both adrenaline and noradrenaline al­
ready at 50 % of the maximal effort of the individual subject. PRA and aldoste­
rone increased only at 90 % exercise, while Cortisol decreased (figure III-12 and 
table III—7). ANP levels increased slightly at 50 % exercise, with a marked in­
crease at 90 % exercise. Cyclic GMP values were significantly elevated at 90 % 
exercise and were positively correlated with the corresponding ANP values (r = 
0.39, p<0.05). 
Table III-7. Plasma concentrat ions of ANP (pg/ml), c y c l i c guanosine 
monophosphate (cGMP, ranol/l),noradrenaline (NAdr, nmol/1), adrena­
l i n e (Adr, nmol/l), plasma renin a c t i v i t y (PRA, nmol/l/h), a l d o s ­
terone (Aldo, nmol/l), Cor t i so l (Cor, μπιοΐ/ΐ), h e a r t r a t e (HR, 
beats/min) and s y s t o l i c a r t e r i a l pressure (SAP, mm Hg) a t r e s t 
(time 1) , a t 50 % exerc i se (time 2) , a t 90 % exerc i se (time 3) and 
15 (time 4) and 60 (time 5) minutes a f t e r e x e r c i s e . Values a r e ex­
pressed as mean ± SD (η = 7 ) . 
ANP 
CCMP 
NAdr 
Adr 
РВА 
Aldo 
Cor 
HR 
SAP 
Time 
1 
32.6 ±10.3 
18.8 ±2.7 
2.21 ±0.55 
0.22 ±0.12 
1.62 ±0.74 
0.50 ±0.20 
0.28 ±0.07 
80.3 ±10.6 
102.7 ±12.6 
40.7 
20.4 
4.44 
0.43 
1.84 
0.55 
0.24 
34.7 
134.3 
2 
± 1 3 . 5 * # 
± 2 . 6 # 
± 1 . 2 1 % 
± 0 . 1 7 % 
± 0 . 6 5 # 
± 0 . 2 4 # 
±0.07* 
± 9 . 0 % 
± 1 1 . 0 % 
106.8 
24.6 
15.3 
0.88 
3.80 
0.83 
0.23 
182.1 
160.3 
3 
±48.2* 
± 2 . 3 * 
±9.28* 
±0.45* 
±1.58* 
±0.29* 
±0.07* 
±8.5* 
±13.7* 
4 
44.0 ±11-7% 
19.9 ± 2 . 6 5 # 
2.59 ± 1 . 1 5 # 
0.30 ± 0 . 1 1 % 
2.06 ±1.17 # 
0.76 ±0.21* 
-
-
-
30.7 
18.7 
1.47 
0.13 
1.88 
0.47 
0.19 
5 
± 1 0 . 8 # 
± 2 . 4 # 
±0.47*^ 
±0.08* 
± 1 . 7 0 # 
± 0 . 2 0 # 
±0.05* 
-
-
* p<0.05 # p<0.05 
vs. baseline vs. 90 % exercise 
(time = 1) (time = 3) 
Wilooxon signed rank t e s t 
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Discussion 
The data presented demonstrate that ANP, released during exercise, is capable 
of exerting biological effects as cGMP values, reflecting the biological 
effectiveness of ANP (40,41) consistently increase during exercise. In view of the 
known effects of ANP one would expect a natriuresis and diuresis. During 
exercise, the opposite phenomenon is observed (42,43). This phenomenon can be 
attributed to concomitant activation of antinatriuretic and antidiuretic systems 
such as the sympathetic nervous system and the renin-aldosterone system, which 
effects override the natriuretic and diuretic effects of the ANP hormonal system. 
At 90 % of the maximal exercise effort of the individual subject, both PRA and 
aldosterone rose probably due to activation of the sympathetic nervous system as 
shown by the increase in adrenaline and noradrenaline. 
Rather unexpectedly (44), plasma Cortisol decreased during exercise. Odink et 
al. (45) and Gumming et al. (46) also found no change or a slight decrease in 
Cortisol values during exercise, rising shortly after exercise. As no Cortisol values 
were measured shortly after exercise, their observations could not be confirmed. 
In patients with ischaemic heart disease, a disproportionate elevation of ANP 
during exercise was found as compared to patients without ischaemic heart 
disease (47,48). This may be due to a disproportionate elevation of intracardiac 
pressures during exercise in the former group. Furthermore ANP levels were cor-
related to maxima] creatine kinase levels and were inversely correlated to the left 
ventricular ejection fraction (47) and to the maximal oxygen uptake, which 
uptake is an index for the remaining ventricular function (49). 
In conclusion, levels of both ANP and its second messenger cGMP consistently 
increase during a standardized bicycle exercise test in healthy volunteers. This 
test may be useful as a noninvasive method for evaluating cardiac function. 
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Part IV 
AGE-DEPENDENCY OF ANP 
In elderly subjects higher plasma ANP concentrations have been reported as 
compared to those found in young subjects (1,2). One explanation for these 
higher levels in elderly subjects could be a difference in clearance of ANP. 
Therefore synthetic (99-126)hANP was infused in both young and elderly subjects 
and the pharmacokinetic parameters were compared. The physiological significan-
ce of the higher ANP concentrations in elderly subjects is not yet known. Two 
possibilities arise: the sensors governing ANP release by the heart are more 
sensitive in elderly subjects, or a down-regulation of ANP target-organ 
responsiveness occurs in these subjects with a compensatory increase in ANP 
secretion. As the secretion of ANP is dependent on the intravascular volume, the 
influences of dehydration (causing a slight volume contraction) and volume 
loading (causing volume expansion) on ANP concentrations in young and elderly 
subjects were studied. Furthermore, in order to assess directly the influence of 
age on haemodynamic and endocrine effects of ANP, (99-126)hANP was infused 
both in young and in elderly subjects and the effects in both groups were 
compared. Cyclic guanosine monophosphate (cGMP) functions as the second 
messenger for ANP. As cGMP levels can be measured in plasma, the 
comparison between young and elderly subjects was extended by using cGMP 
levels as an index of the biological effectiveness of ANP. 
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Chapter 4.1 
Age and immunoreactive ANP concentrations 
Introduction 
Various investigators have observed higher basal concentrations of 
immunoreactive ANP in elderly subjects as compared to young subjects (1,2). 
However, in these studies ANP concentrations found in one group of elderly 
subjects were compared with those found in one group of young subjects. 
In order to obtain normal values for ANP, blood was sampled from 66 healthy 
subjects varying in age from 22 to 79 years. Within this study group a linear 
correlation was found between the age of the person and the corresponding 
ANP concentration. As this finding confirms the assumption that immunoreactive 
ANP concentrations increase with advancing age and the ANP immunoreactive 
profile in healthy persons is heterogeneous (chapter 2.4), one may wonder 
whether the higher ANP concentrations in elderly subjects can be attributed to 
different circulating forms of ANP as compared to young subjects. Therefore the 
ANP immunoreactive profiles of one young and one elderly person were studied, 
both in the basal state and after stimulation by volume loading. 
Methods 
To study the influence of age on plasma levels of ANP, blood was obtained 
from 66 healthy persons on free sodium intake, without a history of 
cardiovascular, renal or endocrine disorders, between 9?° and IO00 a.m. after 30 
minutes in the sitting position and after at least 3 hours of fasting. None of the 
volunteers used any medications, oral anticonceptives included. The age of the 
volunteers (29 females, 37 males) varied from 22 to 79 years. Care was taken 
that the sex and number of volunteers was evenly distributed over all age classes. 
Systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and heart rate 
were recorded. Mean arterial pressure (MAP) was calculated as MAP = DAP + 
(SAP - DAP)/3. ANP was measured using the extraction method and the S-32 
antibody. Correlations were made using the Spearman rank correlation test. 
Significance was assessed at the α=0.05 level. Blood from one young and one 
elderly person (both basal and after stimulation by volume loading, see chapter 
4.4) for HPLC analysis was collected into EDTA tubes on ice and centrifugea 
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immediately. HPLC analysis was performed as described in chapter 2.4. 
Results 
The values obtained from 66 healthy volunteers ranged from 8.3 to 86.8 pg/ml 
(mean ± SD = 35.3 ± 16.2 pg/ml). Although a wide range of ANP values was 
observed, the ANP concentration correlated positively with the subject's age 
(Spearman г = 0.57, p<0.01, figure IV—1). Both mean arterial pressure and sys­
tolic arterial pressure correlated positively with the ANP concentration (r = 0.27, 
p<0.05 and г = 0.28, p<0.05, respectively). However, these correlations disap­
peared when a correction for age was applied. Neither heart rate nor diastolic 
arterial pressure correlated with the ANP value. 
In figure IV-2 the HPLC profiles of one young and one aged person are 
shown. The HPLC profile of the aged person was similar to that of the young 
person. Both in the basal state and after stimulation the predominant 
immunoreactive form corresponds to (99-126)hANP. 
ANP extraction value [pg/ml) 
I 1 1 1 1 1 r 
20 ¿0 60 80 
Age(yrs) 
Figure IV-1. ANP values in 66 healthy subjects ranged from 8.3 to 86.8 pglml 
(mean ± SD = 35.3 ± 16.2 pglml). ANP values correlated significantly with age 
(r = 0.57, p<0.01). 
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Figure IV-2. HPLC-profile of immunoreactive ANP before and after volume loading 
in one young person (upper panel) and one aged person (lower panel). The main 
immunoreactive component corresponds to (99-126)hANP (= a-ANP). 
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Discussion 
ANP concentrations as assessed in blood from 66 healthy subjects ranged from 
8 to 87 pg/ml. Blood was obtained under standardized conditions. To minimize 
external factors that might influence the endogenous ANP level, blood was sam-
pled in the moming between 930 a.m. and IO00 a.m., after half an hour in the 
sitting position. Furthermore, care was taken that both sexes and all age classes 
were evenly represented. As these subjects were recruited from the general 
population, this wide range of ANP values can be regarded as a measure of 
ANP concentrations found in the normal population. Within this study group, a 
significant correlation between the ANP value and the age of the subject was 
observed, with plasma levels in elderly subjects (70 years and older) being almost 
twice that of younger subjects (20 to 25 years). These results indicate that ANP 
concentrations increase progressively with advancing age and that the higher 
ANP levels observed in elderly subjects do not represent alterations in ANP 
production/metabolism present only in this age group. The generally higher ANP 
levels in elderly subjects may not be attributable to different forms of ANP 
released by the heart as the HPLC profile of the aged person was similar to that 
of the young person. The predominance of the (99-126)hANP form both before 
and during stimulation is in agreement with the hypothesis that this molecular 
form of ANP is the most important circulating form of ANP in humans (3,4). 
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Chapter 4.2 
Clearance of ANP 
Introduction 
As described in chapter 4.1, ANP concentrations in healthy subjects increase 
with advancing age. One explanation for these higher levels could be a 
diminished clearance of ANP in elderly subjects as compared to young subjects. 
To investigate this possibility the pharmacokinetic parameters of ANP were 
determined in 8 healthy young and in 9 healthy elderly subjects. 
Methods and study design 
Study design 
The study protocol was approved by the local Hospital Ethical Committee. 
After giving informed consent, 8 healthy young (aged 18 to 25 years, 4 males and 
4 females) and 9 healthy old (aged 71 to 84 years, 4 males and 5 females) 
subjects not using any medications, participated in the study. Prior to the study a 
physical examination was performed to exclude any existing cardiovascular, renal 
or endocrine disorders. (99-126)hANP was purchased from Bissendorf Peptide 
GmbH, Wedermark, FRG. After a 60 minutes equilibration period in the supine 
position, ANP (dissolved in Haemaccel) was infused into an antecubital vein for 
60 minutes at a rate of 2.0 ng/min. Blood for determination of ANP was 
sampled 30 minutes and just before infusion, at 15, 30, 45 and 60 minutes of 
infusion, and 1, 3, 5, 7, 10, 15, 20, 30, 40 and 60 minutes after termination of 
infusion. 
Methods 
ANP was measured using the extraction method and the S-32 antibody. As-
suming that elimination of ANP is a first-order process, the plasma half-life (t'/s) 
was calculated using linear regression analysis on logarithmic ANP values after 
termination of the infusion. The total body clearance (C\TB) was calculated divi-
ding the dose by the area under the curve (determined from the ANP concentra-
tion at t = 0 until the ANP concentration at t = 120 minutes using a linear 
trapezoidal method). The volume of distribution (V^) was calculated by dividing 
the CXJB by the elimination constant K^ (calculated as Inl/tVi). The endogenous 
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Creatinine clearance (ECC) was calculated from the serum creatinine level (5) 
and normalized for the body surface area (6). 
Statistical analysis 
The pharmacokinetic parameters of the young and the elderly subjects were 
compared using the Wiicoxon two-sample test and the Spearman rank correlation 
test. Significance was assessed at the α=0.05 level. All values are expressed as 
mean ± SD, except where mentioned otherwise. 
Results 
As shown in table IV-1, no differences in height, weight or quetelet-index 
(QI) were found between the young and the elderly subjects. The endogenous 
Table IV-1. Pharmacokinetic parameters of young v . s . e l d e r l y 
s u b j e c t s . Values are expressed as mean ± SEM. For abbre­
v i a t i o n s see t e x t . Ρ - value between groups: 
* p<0.05 ** p<0.01 NS = non-s ign i f icant . 
Age (years) 
Height (cm) 
Weight (kg) 
QI (kg/m2) 
EOC (ml/miry 1.73 
ΑΝίγ^,, (pg/ml) 
ANPijtf (pg/ml) 
th (min) 
CLpB (1/min) 
Vd ( l i t e r ) 
m
2) 
young 
n=8 
23.3 
175.0 
68.9 
22.4 
109.6 
33.8 
562 
3.72 
6.02 
32.8 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
± 
1.0 
3.1 
5.5 
1.5 
5.2 
4.0 
89 
0.34 
1.45 
9.0 
Ρ 
NS 
NS 
NS 
** 
* 
** 
NS 
* 
* 
e l d e r l y 
n=9 
75.3 
163.1 
66.3 
24.9 
49.7 
51.3 
1055 
3.52 
2.86 
1 4 . 1 
± 1.4 
+ 4.6 
± 4.0 
± 1.2 
± 3.7 
± 4 . 1 
± 130 
± 0.37 
± 0.33 
± 1.9 
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creatinine clearance (ECC), normalized for the body surface area, was markedly 
lower in the elderly subjects (values ranging from 31.5 to 64.1 ml/min/1.73 m2) as 
compared to the young subjects (values ranging from 78.7 to 125.5 
ml/min/1.73 m2). Both baseline ANP values (ANP^, mean of the values obtained 
30 minutes before and just prior to the start of the infusion) and the values at 
the end of the infusion (ANP^) were significantly higher in the elderly (figure 
IV-3). The plasma half-life (Ι'Λ) of ANP was similar in both groups (young: 
range 1.89 to 4.57 minutes, aged· range 1.96 to 5.18 minutes, ρ = NS). In 
contrast, the total body clearance (C]TB, young: range 3.11 to 14 36 1/min, aged: 
range 1.09 to 4.36 1/min, p<0 05) and the volume of distribution (V ,^ young: ran­
ge 8.5 to 89.4 liter, aged: range 5.2 to 24.9 liter, ρ < 0.05) were markedly 
diminished in the elderly subjects (table IV-1) 
Within the elderly, but not within the young subjects a positive correlation 
(young: r = 0 50, ρ = NS, aged, г = 0.95, p<0 01) was observed between the 
ECC and the C17B (figure IV-4). Basal ANP values were not related to the 
ECC, neither within the young (r = 0.43, ρ = NS) nor within the elderly (r = 
-0.48, ρ = NS) subjects. 
ANP(pg/ml) 
1000 π 
100 
• young subjects 
о elderly subjects 
ANP 2jjg/min 
30 0 30 60 90 120 
Time (min) 
Figure IV-3. ANP values (log scale) before, during and after infusion of 
(99-126)hANP (2.0 ßg/min) in young and elderly subjects. Values are mean ± SEM. 
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Finire 1V-4. Relationship between the total body clearance of ANP (Clfß) and the 
endogenous creatinine clearance (ECC), representing glomerular filtration rate, in 
young (r = 0.50, ρ = NS) and elderly (r = 0.95, p<0.01) subjects. 
Discussion 
Using a one-compartment model and first-order pharmacokinetics, a similar X.V-1 
but a markedly diminished Cljjj and consequently a diminished
 а
 was observed 
in the aged persons. This decreased V^ could explain the higher ANP levels 
generally found in elderly subjects. The \}/г, C\TB and Vd found in this study are 
well in line with those found in other studies (7-9). Ohashi et al. (10), using bolus 
injections of ANP, observed a prolonged second phase of (99-126)hANP disap­
pearance and a decreased metabolic clearance rate in elderly subjects. These 
investigators used a biexponential equation for their calculations. As ANP is an 
endogenously secreted hormone, the assumption of a biexponential disappearance 
curve may not be entirely correct. Furthermore in their study ANP was measured 
using a direct assay. The direct assay is subject to interference from plasma 
components, giving less reliable results than an assay based on prior extraction of 
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plasma (11,12). 
As ANP is degraded by the kidney (13-16) and not excreted in the urine, the 
Сітз probably represents metabolic clearance rather than renal clearance of 
ANP. Marumo et al. (17) using a direct assay, detected immunoreactive ANP in 
human urine. This immunoreactivity is probably caused by the presence of uro-
dilatin, a 32 amino acids containing polypeptide corresponding to (95-126)ANP 
which is produced locally in the kidney and secreted into the urine (18). 
In man, the lung, liver and kidney contribute substantially to the metabolic re­
moval of ANP from the circulation (19). Luft et al. (20) showed that the XVi of 
ANP was markedly prolonged in anephric rats as compared to control rats. 
Hollister et al. (21) observed in hypertensive humans a high ANP extraction ratio 
of the kidney but, due to the lower blood flow, a lower clearance rate of ANP 
as compared to the lung and the liver. Also, a positive correlation was found 
between endogenous creatinine clearance and ANP clearance. More than 95 % 
of ANP receptors in rat kidney are biologically silent (22). Binding of ANP to 
these receptors (called C-ANP receptors) does not result in a functional response 
or in cGMP production, in contrast to the B-ANP receptors mediating the 
biological effects of ANP through its second messenger cGMP. When these 
C-ANP receptors are specifically blocked by ring-deleted ANP analogues the 
endogenous plasma ANP concentrations increase thereby suggesting that these 
C-ANP receptors possess an important ANP clearance function (22). 
In elderly subjects the endogenous creatinine clearance (ECC), an estimate of 
the glomerular filtration rate, corresponds to the number of functioning nephrons 
(23). The excellent correlation observed between the Cl
r B and the ECC in these 
subjects therefore supports the assumption that the kidney is a major 
determinant of ANP clearance. 
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Chapter 4.3 
Dehydration and ANP 
Introduction 
The primary stimulus for secretion of atrial natriuretic peptide (ANP) by the 
heart is stretch of cardiac myocytes (24,25). Immunoreactive ANP levels in 
human blood rise after volume expansion induced by saline infusion (26,27). 
Even small changes in central blood volume caused by water immersion, head-
down tilt or during ingestion of a high salt diet are able to stimulate cardiac 
ANP secretion (28-31). 
Dehydration is associated with contraction of the body fluid volume. One 
would therefore expect a decrease in ANP levels. As in particular elderly 
subjects are prone to dehydration the effect of mild dehydration by restricting 
fluid intake to 25 % of normal on plasma levels of ANP and antidiuretic 
hormone (ADH) in relation to renal concentrating capacity was studied in young 
as well as elderly subjects. 
Methods and study design 
Dehydration study 
Thirteen young (8 males, 5 females, mean age ± SD = 21.8 ± 1.8 years, 
range 18 to 25 years) and 10 elderly (4 males, 6 females, mean age ± SD = 
76.3 ± 4 . 1 years, range 72 to 86 years) subjects without renal, cardiovascular or 
endocrine disorders, gave informed consent and participated in the study. On two 
separate days preceding the study, the fluid intake of each subject was measured 
and noted by diary. On the day prior to the study, a 24 hour urinary collection 
was made for measurement of urinary osmolality, free water clearance and 
osmolar clearance. Thereafter the subjects were restricted to 25 % of their 
normal fluid intake for one day, and a 24 hour urinary collection was made. 
Both before and after the study, blood was sampled for determination of plasma 
osmolality, haematocrit, ANP, and antidiuretic hormone (ADH). 
Hormonal and other measurements 
ANP was measured using the extraction method and the S—32 antibody. After 
prior precipitation of plasma proteins with ethanol, ADH levels were measured 
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using the Vasopressin-Rapid assay from Bühlmann Laboratories AG, Switzerland. 
Osmolar clearance (Cl^J was calculated as Cl,^ = U ^ χ V / Р ^ ( Ц ^ , = 
urinary osmolality, V = urinary volume, Ρ ^ = plasma osmolality). Free water 
clearance (С1
ш о
) was calculated as C1 W 2 0 = V - C^. 
Δ weight (kg 
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Figure IV-5. Changes in weight, antidiuretic hormone (ADH), plasma osmolality 
(Posm)> urinary osmolality (U^, free water clearance (ClH20) and osmolar clearance 
(Cl^J during the dehydration study in young and elderly subjects. Values are mean 
± SEM. 
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Statistical analysis 
Differences before and after dehydration were compared using the Wilcoxon 
two-sample test and the Wilcoxon signed rank test. Significance was assessed at 
the α=0.05 level. All values are expressed as mean ± SD except where men­
tioned otherwise. 
Results 
Restriction of fluid intake to 25 % of normal significantly increased urinary os­
molality (Ц^,) in both the young and the aged persons, while body weight de­
creased. Free water clearance (С1
И
20) decreased in both groups non-significantly 
and osmolar clearance (Cl
ojm) decreased significantly (figure IV—5). Plasma anti­
diuretic hormone (ADH) levels tended to increase in the elderly and tended to 
decrease in the young. The difference between the young and the elderly groups 
was significant. ANP levels did not show a consistent change during the dehydra­
tion study neither in the young nor in the elderly subjects (figure IV-6). Both 
before and after the study, ANP levels were significantly higher in the elderly 
persons as compared to the younger persons (table IV—2). In contrast, basal 
ADH levels were higher in the young persons. 
Discussion 
Restriction of fluid intake to 25 % of normal increased plasma and urinary os­
molality and decreased free water clearance in both groups. Also, a relative 
underfilling of the cardiovascular compartment occurred, as shown by the 
decrease in osmolar clearance. These results are in agreement with other reports 
on the influence of dehydration on the water and salt homeostasis (32,33). 
Interestingly, ADH showed a tendency to increase in the elderly and to decrease 
in the young subjects, while the ability of the kidney to retain salt and water was 
similar in both groups. This may point to decreased responsiveness of the kidney 
to ADH with advancing age (32). In hyperosmolar volume states, neither the 
ADH concentration nor the plasma osmolality but rather the volume of the 
intravascular compartment determines cardiac ANP release (34,35). In view of 
the volume contraction during dehydration, one would expect ANP levels to 
decrease. However, neither in the young nor in the elderly subjects a consistent 
change of ANP occurred during the dehydration study. Within the elderly 
subjects ANP values even tended to rise. Several investigators showed that acute 
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Figure IV-6. Individual changes (and mean ± SEM) in ANP values during the dehy-
dration study. Neither in the young nor in the elderly subjects a significant change 
was observed. 
volume depletion induced by furosemide administration lowers ANP levels 
(36,37). The absence of a decrease in ANP levels in our study may be explained 
by the following. It is possible that the dehydration induced by restriction of fluid 
intake to 25 % of normal did not cause sufficient volume contraction or that 
despite the volume contraction, counterregulatory mechanisms prevented a 
decrease in central (or so-called "effective") blood volume which is the main 
determinant for release of ANP. In either case, these results show that mild 
dehydration does not affect ANP concentrations in humans. 
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Table IV-2. Values before and after dehydration (mean ± SD), the 
difference and the p-value for differences between groups (young 
vs. elderly). For abbreviations see text (P
osnl = plasma 
osmolality. Ht = haematocrit). * p<0.05 ** p<0.01 vs. 
elderly persons. 
Young persons 
Weight (kg) 
p
osm ^tJtun/yq) 
Uosm (mosm/kg) 
C1H 2O (ml/day) 
C-osm ("Vday) 
Ht (1/1) 
АШ ( р ю і / і ) 
ANP (pg/ml) 
Before 
68.5 
285.5 
637.2 
-1538 
3123 
0.40 
7.70 
36.5 
± 
± 
+ 
± 
+ 
± 
+ 
+ 
5 . 4 
3 . 8 
259.7 
937 
623 
0.03 
1.83* 
18.2** 
Aftpr 
67.9 
287.5 
890.0 
-1797 
2705 
0.40 
6.88 
31.9 
+ 
± 
+ 
+ 
+ 
+ 
± 
+ 
5 . 5 
4 . 8 
170.2 
411 
475 
0.03 
1.00 
15.5 
Difference 
-0.58 
2.00 
253 
-259 
-418 
0.004 
-0.90 
-4 .6 
+ 
+ 
± 
+ 
± 
+ 
± 
± 
0.28 
3.67 
247 
700 
447 
0.02 
1.6* 
10.8 
Ρ 
p<0.01 
MS 
p<0.01 
MS 
p<0.01 
NS 
MS 
NS 
Elderly persons 
Weight (kg) 
p
osm (inosrvTcg) 
Uosn, (ncsivTig) 
C 1 H 2 0 (ml/day) 
Ciosm Oö/day) 
Ht (1/1) 
АШ (pnol/1) 
ANP (pg/ml) 
Before 
74.9 
287.8 
494.3 
-1083 
2699 
0.38 
5.91 
86.0 
± 
+ 
± 
± 
+ 
± 
± 
+ 
8 . 6 
3 . 1 
135.7 
5 4 1 
655 
0.04 
0.97 
46.2 
After 
74.2 
291.2 
710.9 
-1183 
2031 
0.38 
7.30 
89.3 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
8 . 6 
4 . 5 
115.1 
323 
469 
0.03 
2.45 
34.0 
Difference 
-0.39 
3.40 
216.6 
-100.3 
-668 
-0.006 
1.39 
3.31 
+ 
± 
+ 
± 
+ 
+ 
+ 
+ 
0.28 
5.85 
142.7 
530.8 
548 
0.009 
2.29 
31.4 
Ρ 
p<0.01 
NS 
p<0.01 
NS 
p<0.05 
NS 
NS 
NS 
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Chapter 4.4 
Volume loading and ANP 
Introduction 
In healthy subjects a positive correlation between the ANP concentration and 
the age of the subject was observed (chapter 4.1). One possible explanation for 
the higher ANP concentrations found in elderly subjects could be an increased 
sensitivity of the volume regulating sensors governing ANP release. As the 
secretion of ANP is dependent on the circulatory volume of the intravascular 
compartment the influence of volume expansion (750 ml 0.9 % NaCl in 60 
minutes) on ANP levels in young as well as elderly subjects was studied. Cyclic 
guanosine monophosphate (cGMP) functions as the second messenger for the 
ANP hormonal system (38,39). As cGMP concentrations can be measured in 
human plasma, determination of cGMP levels roughly reflects the biological 
effectiveness of ANP (40,41). 
Methods and study design 
The study protocol was approved by the local Hospital Ethical Committee. All 
subjects gave informed consent and underwent a thorough clinical examination 
(including electrocardiography and a chest X-ray) to exclude renal, cardiovascular 
or endocrine disorders. None of the subjects used any medications and refrained 
from alcohol, coffee and cigarettes for 24 hours preceding the study. 
Volume loading 
Eight young (4 males, 4 females, mean age ± SD = 22.5 ± 0.8 years, range 
21 to 23 years) and 8 elderly (4 males, 4 females, mean age ± SD = 73.1 ± 5.5 
years, range 65 to 84 years) subjects participated in the study. The study started 
at 8 J 0 a.m. After having fasted overnight, the subjects rested for one hour in the 
recumbent position. Thereafter 750 ml 0.9 % NaCl was infused into an ante-
cubital vein during one hour. Blood for determination of ANP, cGMP, plasma 
renin activity (PRA) and aldosterone was sampled 15 minutes before and just 
prior to the saline infusion, at 30, 45 and 60 minutes of infusion, and 30, 60 and 
90 minutes after termination of the infusion. Plasma volume expansion was calcu­
lated according to the formula [TP; - ΎΡ2]ίΥ?, χ 100% where ΤΡ ; is the total 
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protein content in plasma before and TP2 is the total protein content in plasma 
after saline infusion. The percentual change in ANP values was calculated accor­
ding to the formula [ANP^, - ANP^J/ANP^ χ 100% where ANP^, is the 
maximal ANP concentration during the study period and A N P ^ is the mean of 
the ANP values obtained 15 minutes before and just prior to the saline infusion. 
A similar formula was used to calculate the percentual change in cGMP values. 
Hormonal measurements 
ANP was measured using the extraction method and the S-32 antibody. Cyclic 
GMP was measured as described in chapter 2.5. PRA was measured using the 
Phadebas Angiotensin I test (Pharmacia Diagnostics, Sweden), plasma 
aldosterone was measured as described previously (42). 
Statistical analysis 
The responses of the various hormones to saline infusion were studied using 
analysis of variance for repeated measurements followed by the paired t-test 
(Student). Differences in plasma volume expansion were analyzed using the 
Wilcoxon two-sample test and correlations were made using the Spearman rank 
correlation test. To assess differences in rise time to the maximum ANP and 
cGMP values, the Wilcoxon two-sample test and the Wilcoxon signed rank test 
were used. Significance was assessed at the α=0.05 level. All values are expres­
sed as mean ± SD except where mentioned otherwise. 
Results 
Basal ANP values were higher in the elderly persons. Volume loading 
increased ANP only in the elderly subjects, while no significant change occurred 
in the younger persons. PRA decreased only in the younger subjects while 
plasma aldosterone did not change in either group (figure IV—7 and table 
IV—3). Basal cGMP levels did not differ between the young and the aged 
persons. During volume loading, cGMP increased in both groups with a more 
pronounced rise in the elderly subjects. The difference between the two groups 
however, was not statistically significant (two-way repeated measurements analysis 
of variance). No correlation was observed between basal cGMP and ANP values 
(young: г = -0.09, ρ = NS, aged: г = 0.33, ρ = NS), nor between the 
percentual change in cGMP and the percentual change in ANP values in either 
group (young: r = 0.52, ρ = NS, aged: r = 0.01, ρ = NS). 
During the saline infusion study, a significant plasma volume expansion 
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F/gure IV-7. Time courses of ANP, PRA, aldosterone (Aldo) and cGMP during the 
volume loading study. Values are mean ± SEM. ANP significantly increased in the 
aged subjects while PRA decreased in the young subjects. 
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Table IV-3. Values obtained before (0 min), at the end of saline in­
fusion (60 min), and 30 (90 min) and 90 (150) minutes thereafter. 
Values are expressed as mean ± SD. For abbreviations see text (TP = 
total protein). 
* pXO.OS ** ρκΟ.01 vs. values at 0 min. 
# p<0.05 young vs. aged subjects 
young 
ANP 
aged 
ycung 
ERA 
aged 
young 
Aldo 
aged 
young 
oOlP 
aged 
young 
TP 
aged 
0 min 
40.0 ± 
61.4 ± 
0.71 ± 
0.33 ± 
0.39 ± 
0.41 ± 
19.3 ± 
19.6 ± 
65.8 ± 
65.6 ± 
10.3# 
14.4 
0.49# 
0.17 
0.19 
0.33 
7.3 
4.5 
1.8 
6.8 
60 min 
43.7 ± 
96.5 ± 
0.46 ± 
0.31 ± 
0.35 ± 
0.28 ± 
19.9 ± 
23.5 ± 
62.9 ± 
61.4 ± 
18.2* 
34.3* 
0.27* 
0.16 
0.12 
0.17 
3.6 
6.8** 
1.4* 
6.5* 
90 min 
45.7 ± 
87.3 ± 
0.37 ± 
0.27 ± 
0.31 ± 
0.24 ± 
20.4 ± 
23.7 ± 
65.4 ± 
63.4 ± 
18.0* 
27.9 
0.23* 
0.11 
0.15 
0.14 
3.5 
5.7** 
2.7 
5.2 
150 min 
38.9 ±14.1* 
67.8 ±23.5 
_ 
"" 
_ 
~ 
20.9 ± 2.1" 
23.0 ± 6.9' 
_ 
" 
occurred as shown by the values for total protein (table IV—3). Plasma volume 
expansion did not differ between the young (4.3 ± 2.4 %) and the elderly (6.4 ± 
3.6 %) subjects. In neither group was the percentual change in ANP related to 
the change in plasma volume (young: r = 0.12, ρ = NS, aged: r = 0.48, ρ = 
NS). In the elderly subjects peak concentrations of ANP occurred at 66 ± 16 
minutes after the start of the infusion whereas peak concentrations of cGMP 
were reached at 101 ± 32 minutes. The difference was statistically significant 
(p<0.05). For the young subjects, the corresponding values were 83 ± 21 
minutes for ANP and 113 ± 35 minutes for cGMP (p = 0.12). The rise time to 
maximum ANP and cGMP concentrations between the two groups was not 
statistically significant. 
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Discussion 
Ohashi et al. (43) infused hypertonic saline into young and aged men and ob-
served an increase in both ANP and cGMP levels in the young as well as in the 
aged men. ANP rose from 11 to 36 pg/ml in the young and from 84 to 147 
pg/ml in the aged men while cGMP rose similarly in both groups. Using isotonic 
saline solution at a dose insufficient to increase ANP levels in the young subjects, 
we observed a pronounced increase in the elderly subjects. The absence of a 
decrease in PRA in the elderly is in agreement with decreased responsiveness of 
the renin-aldosterone system with advancing age (44,45). The pronounced rise in 
ANP in the aged subjects can partly be explained by the decrease in clearance of 
ANP with advancing age (chapter 4.2). A given stimulus for secretion of ANP 
then results in an exaggerated and prolonged rise in ANP concentrations. 
Another explanation may be that the sensitivity of the ANP release system is 
increased in aged subjects. Indeed, Ruskoaho et al. (46) observed a greater 
increase in plasma ANP levels for a similar increase in right atrial pressure 
following volume expansion in aged rats as compared to young rats. 
Aged subjects exhibit delayed natriuresis after saline infusion (47). One may 
speculate that this phenomenon causes a relative overfilling of the cardiovascular 
system in the aged subjects in comparison to the young subjects. As ANP release 
is governed by the filling of the intravascular volume one would then expect 
maximum ANP concentrations to be reached at a later time in the elderly. 
However, in our study the peak ANP levels occurred at 66 minutes after start of 
the infusion in the aged, and at 83 minutes in the young subjects. Furthermore 
volume expansion, as determined from the values for total protein, did not differ 
between the two groups. These results suggest that the delayed natriuresis in the 
elderly cannot explain the exaggerated ANP response in this group. Inversely, as 
peak concentrations of both ANP and cGMP occurred earlier in the elderly, this 
hormonal system does not seem to be responsible for this phenomenon. 
One may wonder whether the exaggerated ANP response to a volume load in 
elderly subjects has a specific physiological significance. It may well be that this is 
a compensatory mechanism for decreased responsiveness of the target-organs. 
Indeed, although basal ANP levels were higher, basal cGMP levels in the elderly 
subjects were similar to those of the young subjects. Volume loading increased 
cGMP to a similar extent in both groups. As cGMP is considered to be the 
second messenger of ANP and cGMP concentrations in blood reflect the cellular 
response to ANP (40,41), we tentatively propose that with advancing age the res-
ponsiveness of the target-organs to ANP decreases. The ANP system functions at 
a higher level, both basal and after stimulation to compensate for this decreased 
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responsiveness. Consequently, elderly subjects possess a similar capacity of the 
atrial natriuretic peptide hormonal system to compensate for volume changes of 
the intravascular compartment. 
Interestingly, volume loading did not significantly increase ANP levels in the 
young subjects but nevertheless induced a significant rise in cGMP levels. This 
may be an indication that even small changes in ANP concentrations exert bio-
logical effects. Furthermore the time lag between the rise in ANP and the rise in 
cGMP levels demonstrate that the maximal ANP levels as determined in blood 
samples drawn from a peripheral vein do not necessarily coincide with the 
maximal biological effect. This observation may also explain the time lag 
observed by Singer et al. (48) between the rise in ANP levels and the natriuresis 
and diuresis after volume loading. 
In conclusion: the relationship between cardiac ANP secretion and advancing 
age was studied. Volume loading stimulated ANP only in the elderly subjects. 
Both the similar basal cGMP levels and the comparable increase during volume 
loading are indications of decreased responsiveness of the ANP target-organs 
with advancing age. This decreased responsiveness may be compensated by the 
higher ANP concentrations in elderly subjects, both in the basal state and after 
volume loading. 
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Chapter 4.5 
Infusion of ANP 
Introduction 
As outlined in part I, the atrial natriuretic peptide (ANP) hormonal system is 
considered to function antagonistically to the renin-angiotensin-aldosterone 
system. When synthetic ANP is infused in humans a profound diuresis, natriuresis 
and blood pressure lowering effect is observed (49-54). Furthermore ANP sup-
presses renin release and aldosterone production, and exerts an inhibitory effect 
on the sympathetic nervous system (55-58). Many of these effects however, have 
been observed when synthetic ANP was infused in a high, possible pharmaco-
logical dose. It remains to be elucidated whether ANP can exert biologically 
important effects during low dose infusion. Therefore the haemodynamic and 
endocrine effects of (99-126)hANP infusion in both low dose and high dose were 
studied. The low dose was calculated to result in ANP values in the upper 
normal range while the high dose would result in ANP values comparable to 
those observed in disease states associated with chronic volume overload such as 
congestive heart failure (59,60). 
In chapter 4.4, the effect of volume expansion on cardiac ANP secretion was 
compared in young and elderly subjects. Although ANP levels increased only in 
the aged group, cGMP values, reflecting biological effectiveness of ANP (38-41) 
rose to a similar extent thereby suggesting receptor down-regulation with di-
minished target organ responsiveness in the elderly. In order to assess directly 
whether ANP effector organs are down-regulated in elderly subjects, cGMP con-
centrations were measured during infusion of both low and high dose of synthetic 
(99-126)hANP. Furthermore the effects of ANP on the cardiovascular system and 
on various hormonal systems were compared. The study design was randomized, 
double-blind and placebo-controlled. 
Methods and study design 
Study design 
The study protocol was approved by the local Hospital Ethical Committee. 
Two groups of healthy volunteers, 8 young (4 males, 4 females aged 18 to 25 
years) and 8 elderly (4 males, 4 females aged 71 to 84 years) subjects recruited 
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from the general population, were studied. All subjects gave informed consent 
and were submitted to clinical examination before admission to the study. Physi­
cal examination revealed no cardiovascular, renal or endocrine disorders. None 
of the subjects smoked, used any drugs (oral contraceptives included) nor abused 
alcohol. The subjects were instructed to eat their usual diet, not to drink any 
coffee or tea and to refrain from hard labor during 24 hours preceding the 
study. (99-126)hANP was purchased from Bissendorf Peptide GmbH, Wedemark, 
FRG and dissolved in 48.0 ml Haemaccel (Behringwerke AG, Marburg, FRG) 
solution before use. 
The studies were performed during three days separated by at least one week, 
in a climatized room (temperature: 24.6 ± 0.2oC, humidity: 54.7 ± 2.1 %, 
mean ± SD, η = 48). After having fasted for at least two hours, a catheter was 
inserted into an antecubital vein and placebo (Haemaccel) or (99-126)hANP was 
infused at random order in a double blind manner. The subjects remained in the 
supine position throughout the study period of 3 hours, including short periods 
for passing urine. 
After one hour of acclimatization (supine position) either placebo or ANP (low 
dose: 0.25 jug/min, high dose: 2.0 μg/min) was infused during 60 minutes. In a 
preliminary study these infusion rates resulted in a two-fold rise of plasma ANP 
levels during the low, and in a twenty-fold rise during the high dose infusion. 
Dissolution of iodinated (99-126)hANP in Haemaccel resulted in 20 % loss of 
radioactivity to the infusion system, as compared to 50 % loss when ANP was 
dissolved in 0.9 % saline. 
Haemodynamic measurements 
Blood pressure was monitored with a semiautomatica! arteriosonde. Electrocar­
diographic monitoring for assessment of heart rate was performed continuously. 
Forearm blood flow (FBF) was measured by venous occlusion plethysmography 
at 10 cm above heart level using mercury-in-rubber strain gauges. The skin 
circulation was excluded during FBF measurements by inflation of a wrist cuff to 
50 mm Hg. The mean arterial pressure (MAP) was calculated as the sum of the 
diastolic pressure (DP) and 1/3 of the pulse pressure (systolic pressure (SP) -
diastolic pressure). The forearm vascular resistance (FVR) was calculated as the 
quotient of MAP and FBF. Every 15 minutes two measurements were 
performed. The mean of these two measurements was used for data analysis. 
Haemoglobin and haematocrit values were measured just prior to infusion, at 45 
and 60 minutes of infusion, and 60 minutes after termination of infusion. 
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Hormonal measurements 
ANP was measured using the extraction method and the S-32 antibody, cGMP 
was measured as described in chapter 2.5. Plasma renin activity (PRA) was 
measured using the Phadebas Angiotensin I test (Pharmacia Diagnostics, 
Sweden), aldosterone (42), Cortisol (61), adrenaline and noradrenaline (62) were 
measured as described previously. Blood was sampled from an antecubital vein 
(intravenous catheter inserted 60 minutes before infusion). On each study day 
approximately 120 ml blood was sampled. From one aged person blood could 
not be sampled on the placebo day. PRA, aldosterone, Cortisol, adrenaline, 
noradrenaline and cGMP concentrations were measured in plasma obtained just 
prior to infusion (basal values), at 45 and 60 minutes of infusion and 30 minutes 
after infusion. ANP was measured in plasma obtained 30 minutes and just prior 
to infusion, at 15 (only high dose), 30, 45 and 60 minutes of infusion, and 15 
(only high dose), 30 and 60 minutes after termination of infusion. 
Statistical analysis 
Results are expressed both as absolute values and as percentual changes from 
baseline values (haemodynamic data: the values measured just prior to infusion, 
hormonal data: concentrations assessed in blood obtained just prior to infusion, 
for ANP: mean of values in blood obtained 30 minutes and just prior to 
infusion). As plasma ANP values at 45 and 60 minutes of infusion did not differ 
during either infusion dose, the mean of haemodynamic and hormonal values 
measured at 45 and 60 minutes of infusion were considered to represent the 
values at steady state ANP infusion. As during placebo infusion significant 
changes did occur, the net percentual changes at steady state were calculated by 
subtracting the percentual change during placebo infusion from the correspon­
ding percentual changes during low/high dose ANP infusion for each person. 
Differences between basal and steady state values and between young and 
elderly subjects were studied using the Wilcoxon signed rank test and the 
Wilcoxon two-sample test. Significance was assessed at the α=0.05 level. All 
values are expressed as mean ± SD, except where mentioned otherwise. 
Results 
In table IV—4 the group characteristics of the young and the elderly subjects 
are shown. Basal ANP levels were higher in the elderly while basal cGMP levels 
did not differ. During infusion of (99-126)hANP, immunoreactive ANP levels 
increased considerably in both groups reaching higher steady state values in the 
141 
Table IV-4. Group characteristics and humoral parameters measured 
under basal conditions. Values are mean ± SEM. ECC = endogenous 
creatinine clearance (calculated according to Cockcroft (5) and 
normalized for body surface area (6)). ANP and cGMP: basal values 
measured at the placebo infusion day. ρ = p-value young vs. aged: # 
p<0.05. 
parameters 
Sex ratio 
Age 
Height 
Weight 
Quetelet index 
EOC 
ANP 
cQlP 
(IVF) 
(yr) 
(on) 
(kg) -
(kgt/m2) 
(пй/тід/І. З m2) 
(pg/tal) 
(rarol/l) 
young 
(n=8) 
4/4 
23.3 ± 1.0 
175.0 ± 3.1 
68.9 ± 5.5 
22.4 ± 1.5 
109.6 ± 5.2 
34.5 ± 3.1 
20.2 ± 1.8 
Ρ 
NS 
NS 
NS 
# 
# 
NS 
aged 
(π=8) 
4/4 
75.7 ± 1.5 
165.3 ± 4.5 
67.0 ± 4.5 
24.5 ± 1.2 
48.9 ± 4.7 
49.6 ± 4.4 
19.7 ± 2.0 
ANP(pg/ml) 
1000-, УоипЯ 
Δ high 
α low 
o placebo 
100 
10 
infusion 
1 
180 60 120 180 
Time (mm) 
Figure IV-8. ANP concentrations during placebo, low dose (0.25 ßg/min) and high 
dose (2.0 ßg/min) infusion of (99-126)hANP in young (left panel) and aged (right 
panel) subjects. Values represent the mean ± SEM (η = 8). 
142 
elderly subjects. No change in ANP concentrations was observed during infusion 
of the vehicle alone (placebo infusion) (figure IV-8 and table IV-8). 
Within-person analysis did not reveal a significant difference in basal values of 
either haemodynamic or hormonal parameter during the three study days. 
Between-group analysis indicated higher blood pressure and higher noradrenaline 
values in the elderly as compared to the young subjects. 
Haemodynamic data 
Absolute values are shown in table IV—5 and table IV—7. The percentual 
changes from baseline for the various haemodynamic parameters are shown in 
figure IV-9 and figure IV-10. As during placebo infusion significant changes 
did occur, the net percentual changes during low/high dose infusion are depicted 
in table IV—6. Following placebo and low dose infusion, mean arterial pressure 
(MAP) increased significantly in both young and aged subjects In the young, this 
was mainly due to an increase in diastolic pressure (DP), while both systolic 
piessure (SP) and DP increased in the elderly Heart rate did not change 
significantly. Net percentual changes during the low dose infusion were not signi-
ficant. In contrast, during high dose infusion a significant blood pressure lowering 
effect was observed in both groups, while heart rate increased in the elderly. The 
decrease in MAP was more pronounced in the elderly, mainly due to an 
exaggerated decrease in SP. Correspondingly, heart rate increased in both groups 
but the increase was significant only in the aged group 
Forearm blood flow (FBF) decreased during placebo and low dose infusion, 
while it increased at high dose The net percentual change was significant only in 
the elderly subjects Forearm vascular resistance (FVR) being the quotient of 
MAP and FBF, exhibited an inverse pattern and increased at placebo and low 
dose infusion and decreased at high dose infusion In figure IV-11 the net per-
centual time curves (with placebo time curves subtracted) for forearm vascular 
resistance and mean arterial pressure are given. 
Haemodynamic effects had a relatively rapid onset of action, as effects were 
observed shortly (within 15 minutes) after start of high dose ANP infusion, 
consisting of a decrease in SP, DP, MAP and FVR with an increase in FBF and 
HR. As withm-group variation varied considerably, only the net percentual 
changes in SP and MAP were significantly greater in the aged group as 
compared to the young group 
During placebo infusion and low dose infusion, haematocnt and haemoglobin 
values did not change in the elderly while they increased at low dose in the 
young (figure IV—12). At high dose infusion, haematocnt and haemoglobin 
increased in both groups. Although the increase was more pronounced in the el-
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Figure IV-9. Percentual changes in systolic pressure (SP), diastolic pressure (DP) and 
heart rate (HR) during infusion of placebo (A—Δ), low (o—o) or high (·—·) rate 
ANP in young (left panel) and aged (right panel) subjects. Values are mean ± SEM 
(η = 8). 
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Figure IV-10. Percentual changes in mean arterial pressure (MAP), forearm blood 
ßow (FBF) and forearm vascular resistance (FVR) during infusion of placebo 
(L·—c\), low (o—oj or high (·—·) rate ANP in young (left panel) and aged (right 
panel) subjects. Values are mean ± SEM (η = 8). 
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Table IV-5. Effects of high dose (H), low dose (L) or placebo (Ρ) 
infusion on systolic arterial pressure (SP, mm Hg), diastolic ar­
terial pressure (DP, mm Hg), mean arterial pressure (MAP, mm Hg), 
heart rate (HR, beats/min), forearm blood flow (FBF, ml/100 ml/min) 
and forearm vascular resistance (FVR, U) in yoiing (n=8) and aged 
(n=8) subjects before, during (mean of values at 45 and 60 minutes 
of infusion) and after infusion (mean of values at 45 and 60 minu­
tes after infusion). Values are mean ± SD. 
* p<0.05 vs. baseline 
young aged 
before during after before during after 
SP 
DP 
MAP 
HR 
FBF 
FVR 
Ρ 
L 
Η 
Ρ 
L 
H 
Ρ 
L 
H 
Ρ 
L 
H 
Ρ 
L 
H 
Ρ 
L 
H 
111 ±15 
110 ±11 
113 ±11 
66 ±7 
68 ±7 
71 ±9 
Θ1 ±9 
82 ±10 
85 ±8 
70 ±6 
68 ±8 
74 ±7 
7.8 ±6.6 
6.4 ±2.6 
7.9 ±6.2 
17 ±10 
15 ±8 
18 ±11 
112 
111 
110 
71 
74 
71 
85 
86 
84 
71 
68 
77 
6.8 
6.2 
8.1 
19 
17 
14 
±15 
±12 
±10 
±7* 
±6* 
±6 
±9 
±8* 
±6 
±7 
±9 
±13 
±5.7 
±2.8 
±4.8 
±11 
±9 
±7 
115 
115 
109 
74 
75 
72 
88 
89 
85 
73 
72 
78 
6.4 
5.3 
5.8 
20 
19 
21 
±13 
±14* 
±12 
±6* 
±6* 
±6 
±8* 
±8* 
±6 
±11 
±11 
±10 
±5.2 
±1.8* 
±3.6 
±10* 
±9 
±13 
137 
133 
138 
77 
77 
80 
97 
96 
99 
62 
61 
62 
6.3 
7.1 
6.7 
21 
16 
18 
±14 
±17 
±15 
±10 
±9 
±11 
±10 
îll 
±10 
±10 
±11 
±11 
±3.4 
±3.2 
±3.5 
±14 
±6 
±8 
145 
145 
129 
80 
83 
75 
102 
103 
93 
60 
60 
67 
5.3 
6.6 
8.9 
27 
19 
12 
±17* 
±23* 
±15* 
±11 
±10* 
±11* 
±12* 
±13* 
±11* 
±10 
±10 
±12* 
±2.9 
±3.2 
±3.6* 
±19* 
±8* 
±4* 
151 ±16* 
155 ±23* 
134 ±17 
86 ±12* 
86 ±10* 
80 ±12 
108 ±13* 
109 ±14* 
98 ±12 
62 ±10 
62 ±10 
65 ±11 
4.8 ±3.1 
5.2 ±2.5 
6.9 ±4.2 
30 ±15* 
25 ±10* 
19 ±11 
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Table IV-6. Baseline values and net percentual changes (mean of 
values at 45 and at 60 minutes of infusion) of systolic arterial 
pressure (SP, mm Hg), diastolic arterial pressure (DP, ram Hg), mean 
arterial pressure (MAP, ram Hg), heart rate (HR, beats/min), forearm 
blood flow (FBF, ml/100 ml/min), forearm vascular resistance (FVR, 
U), haemoglobin (Hg, mmol/1) and haematocrit (Ht, 1/1) values 
during low dose and high dose infusion of ANP in young (n=8) and 
aged (n=8) subjects. Percentual changes during placebo infusion are 
subtracted from percentual changes during low/high dose infusion. 
Values are mean ± SD. 
ρ = p-value # p<0.05 young vs. aged 
* p<0.05 vs. baseline 
Lew dose - placebo High dose - placebo 
young ρ aged young ρ aged 
SP basal 
% etiange 
DP basal 
% change 
MAP basal 
% change 
HR basal 
% change 
FBF basal 
% change 
FVR basal 
% change 
Hb basal 
% change 
Ht basal 
% change 
110 
-0.0 
68 
-0.6 
82 
-0.2 
68 
-1.1 
6.4 
8.7 
15 
-7.7 
7.95 
3.3 
0.38 
4.0 
±11 
±9.6 
±7 
±8.0 
±10 
±8.1 
±8 
±5.6 
±2.6 
±38.9 
±8 
±37.0 
±0.73 
±3.8* 
±0.03 
±3.9* 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
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З.Э 
77 
3.5 
96 
3.4 
61 
1.8 
7.1 
6.1 
16 
-8.7 
7.99 
3.0 
0.39 
1.0 
±17 
±4.8 
±9 
±6.2 
±11 
±4.7 
±11 
±12.6 
±3.2 
±24.3 
±6 
±32.7 
±0.90 
±6.45 
±0.03 
±4.6 
113 
-3.7 
71 
-8.4 
85 
-6.2 
74 
3.2 
7.9 
27.4 
IB 
-29.6 
8.45 
4.9 
0.39 
6.6 
1 1 1
 * 
±3.6* 
± 9
 * 
±7.1* 
± 8
 * 
±4.5* 
±7 
±8.7 
±6.2 
±36.0 
±11 
±27.8* 
±0.79 
±2.7* 
±0.03 
±2.3* 
# 
NS 
# 
NS 
NS 
NS 
NS 
NS 
138 
-11.9 
80 
-10.1 
99 
-11.0 
62 
11.0 
6.7 
56.8 
18 
-57.7 
7.89 
8.8 
0.38 
9.6 
± 1 5
 * 
±6.6 
± U
 * 
±4.8* 
±10 
±4.1* 
±11 
±11.3' 
±3.5 
±41.91 
±8 
±32. ві 
±0.67 
±12.2 
±0.03 
±10.7V 
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Figure IV-11. Net percentual time curves for forearm vascular resistance (FVR) and 
mean arterial pressure (MAP) at low dose (left panel) and high dose (right panel) 
infusion of ANP in young f · — ·) and aged (o — o) subjects. Values are mean ± 
SEM (η = 8). 
derly, due to the large within-group variation in the elderly the net percentual 
changes in haemoglobin were significant only in the young subjects. 
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Table IV-7. Effects of high dose (H), low dose (L) or placebo (Ρ) 
infusion on haemoglobin (Hb, mmol/1) and haematocrit (Ht, 1/1) 
values in young (n=8) and aged (n=8) subjects before, during (mean 
of values at 45 and 60 minutes of infusion) and after infusion (60 
minutes after infusion). Values are mean ± SD. 
* p<0.05 vs. baseline 
young aged 
before during after before during after 
Ρ 
Hb L 
H 
Ρ 
Ht L 
H 
8.05 ±0.63 3.13 ±0.59 8.15 ±0.54 
7.95 +0.73 8.29 ±0.7* 8.38 +0.82* 
8.45 ±0.79 8.93 +0.60* 8.78 ±0.90 
0.39 ±0.02 0.38 ±0.02 0.38 +0.02 
0.38 ±0.03 0.39 ±0.03* 0.39 ±0.03* 
0.39 ±0.03 0.42 +0.02* 0.41 ±0.03* 
8.17 ±0.31 8.11 ±0.71 7.90 ±0.65 
7.99 +0.90 8.08 ±0.88 8.26 ±0.63 
7.89 ±0.67 8.53 ±0.47* 8.41 ±0.56 
0.38 ±0.02 0.37 ±0.03 0.38 ±0.03 
0.39 ±0.03 0.39 ±0.03 0.39 ±0.03 
0.38 ±0.03 0.41 ±0.02* 0.40 ±0.02 
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Figure IV-12. Net changes in haemoglobin (Hb) and haematocrìt (Ht) values during 
infusion of placebo (P), low (L) or high (H) dose ANP infusion in young (left panel) 
and aged (right panel) subjects. Values are mean ± SEM (η = 8). 
Hormonal data 
Figures IV-13 and IV-14 represent percentual changes in hormonal concentra­
tions, while absolute values are shown in table IV—8. The net percentual changes 
during low/high dose ANP infusion are shown in table IV-9. 
PRA decreased during placebo and low dose infusion in both groups while no 
change occurred during high dose ANP infusion. When subtracting the percentual 
change during placebo infusion from the percentual change during high dose infu­
sion, a relative increase in PRA was observed. Due to the large inter-individual 
variation, the difference was not significant. Plasma aldosterone and Cortisol did not 
change in the young, but aldosterone decreased during high dose infusion in the el-
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Figure IV-13. Percentual changes in plasma renin activity (PRA), aldosterone (Aldo) 
and cortùol (Cor) before (B), during (D) and after (A) infusion of placebo (A — A), 
low (o — о j or high (· — ·) rate ANP in young (n = 8, left panel) and aged (n = 8, 
right panel) subjects. For absolute values, see table IV-8. 
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Figure IV-14. Percentual changes in noradrenaline (NAdr), adrenaline (Adr) and cyclic 
guanosine monophosphate (cGMP) before (В), during (D) and after (A) infusion of 
placebo (A — Δ J, low (o — o) or high (m — ·) rate ANP in young (n = 8, left panel) 
and aged (n = 8, right panel) subjects. For absolute values, see table IV—8. 
152 
Table IV-8. Effects of high dose (H), low dose (L) or placebo (Ρ) 
infusion on plasma levels of PRA (nmol/l/h), aldosterone (Aldo, 
nmol/l), Cortisol (Cor, μιαοΐ/ΐ), adrenaline (Adr, nmol/1), norad­
renaline (NAdr, nmol/1), cGMP (nmol/1) and ANP (pg/ml) in young 
(n=8) and aged (n=8) subjects before, during (mean of values at 45 
and 60 minutes of infusion) and after infusion (30 minutes after 
infusion) . Values are mean ± SD. * p<0.05 vs. baseline 
young aged 
Ρ 
FRA L 
H 
Ρ 
A ldo L 
H 
Ρ 
Cor L 
H 
Ρ 
Adr L 
H 
Ρ 
Nftdr L 
H 
Ρ 
σαιρ L 
H 
Ρ 
AMP L 
H 
before 
0.87 
0.57 
0.98 
0.39 
0.53 
0.45 
0.21 
0.27 
0.24 
0.09 
0.09 
0.11 
0.69 
0.64 
0.90 
20.2 
20.2 
21.4 
34.5 
37.2 
35.1 
±0.48 
+0.35 
±0.54 
±0.28 
±0.35 
±0.25 
±0,10 
±0.11 
±0.08 
±0.04 
±0.04 
±0.06 
±0.17 
±0.13 
±0.36 
±5.1 
±5.9 
±2.5 
±8.9 
±28.3 
±17.7 
during 
0.59 
0.41 
1.02 
0.30 
0.30 
0.34 
0.20 
0.20 
0.22 
0.11 
0.10 
0.11 
0.89 
0.79 
1.17 
19.9 
26.7 
39.8 
33.1 
75.8 
570 
±0.32* 
±0.24* 
±0.55 
±0.18 
±0.09 
±0.18 
±0.09 
±0.06 
±0.08 
±0.05 
±0.04 
±0.03 
±0.21* 
±0.26 
±0.54 
±3.3 
±4.8* 
±6.8* 
+ 11.7 
±38.4* 
±237* 
a f t e r 
0.52 
0.37 
0.78 
0.26 
0.31 
0.33 
0.20 
0.20 
0.26 
0.12 
0.15 
0.16 
0.68 
0.71 
1.00 
21.1 
23.8 
27.5 
31.1 
33.7 
32.7 
+0.27* 
±0.24* 
±0.36 
±0.12 
±0.13 
±0.16 
±0.08 
±0.10 
±0.11 
±0.07 
±0.07 
±0.04 
±0.18 
±0.19 
±0.47 
±5.7 
±4.1 
±3.8* 
±12.7 
±8.2 
+4.1 
before 
0.51 ±0.41 
0.54 ±0.37 
0.55 ±0.42 
0.25 ±0.15 
0.31 ±0.16 
0.37 ±0.18 
0.21 ±0.07 
0.21 ±0.05 
0.20 ±0.06 
0.14 ±0.07 
0.13 ±0.07 
0.12 ±0.05 
1.50 ±0.37 
1.18 ±0.51 
1.53 ±0.62 
19.7 +5.7 
18.6 ±2.8 
20.8 ±4.1 
49.6 ±12.5 
54.9 ±31.3 
49.6 +14.0 
during 
0.41 ±0.25* 
0.41 ±0.21 
0.56 ±0.29 
0.28 ±0.25 
0.25 +0.09 
0.23 ±0.15* 
0.16 ±0.06* 
0.16 ±0.03* 
0.20 ±0.06 
0.11 ±0.05 
0.11 +0.07 
0.13 ±0.10 
1.64 +0.67 
1.43 ±0.57* 
1.86 ±0.65 
20.0 ±3.3 
26.6 ± 3 . 3 * 
54.5 ±14.3* 
43.8 ±9.4 
132.7 ±65.4* 
1001 ±429* 
a f ter 
0.41 ±0.20 
0.34 ±0.17 , 
0.51 ±0.25 
0.37 ±0.36 
0.24 +0.06 
0.37 +0.36 
0.16 ±0.06 
0.17 ±0.08 
0.35 ±0.24 
0.11 ±0.04 
0.12 +0.07 
0.18 ±0.13 
1.69 ±1.19 
1.10 ±0.82 
1.63 +0.46 
21.5 ±4.5 
22.2 ±3.3* 
35.6 ±10.6Y 
44.9 +10.6 
55.3 ±65.4 
53.8 ±13.3 
153 
Table IV-9. Baseline values and net percentual changes (mean of 
va lues a t 45 and a t 60 minutes of infusion) in plasma r e n i n a c t i v i ­
t y (PRA, nmol/l/h), a ldosterone (Aldo, nraol/l), C o r t i s o l (Cor, 
μπιοΐ/ΐ), adrena l ine (Adr, nmol/l), noradrenal ine (NAdr, nmol/l) , 
cGMP (nmol/l) and ANP (pg/ml) values during low dose and high dose 
infusion of ANP in young (n=8) and aged (n=7) s u b j e c t s . Percentual 
changes during placebo infusion a r e subtracted from percentual 
changes during low/high dose infusion. Values a r e mean ± SD. 
ρ = p-value # p<0.05 young vs . aged 
* p<0.05 v s . base l ine 
Lew dose - placebo High dose - placebo 
young ρ aged young ρ aged 
PRA 
% 
Aldo 
% 
cor 
% 
Adr 
% 
NAdr 
% 
cGMP 
% 
ANP 
% 
Ьаяаі 
change 
based. 
change 
hnsal 
change 
basal 
change 
hrisal 
change 
basal 
change 
basal 
change 
0.57 
3.8 
0.53 
-27.9 
0.27 
-18.2 
0.09 
-3.9 
0.64 
2.6 
20.2 
37.3 
37.2 
136.6 
±0.35 
±17.3 
±0.35 
±51.2 
±0.11 
±45.3 
±0.04 
±72.5 
±0.13 
±67.6 
±5.9 
±16.4 
±28.3 
±31.0 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
0.54 
2.6 
0.31 
-11.7 
0.21 
4.0 
0.13 
0.1 
1.18 
10.9 
18.6 
38.1 
54.9 
163.3 
±0.37 
±23.0 
±0.16 
±71.1 
±0.05 
±23.4 
±0.07 
±27.6 
±0.51 
±41.0 
±2.8 
±13.6* 
±31.3 
±37.5* 
0.98 
50.8 
0.45 
-7.6 
0.24 
1.9 
0.11 
-7.1 
0.90 
14.4 
21.4 
86.4 
35.1 
1723 
±0.54 
±75.8 
±0.25 
±31.2 
±0.08 
±83.2 
±0.06 
±38.8 
±0.36 
±93.1 
±2.5 
±32.7* 
±17.7 
±1033* 
NS 
NS 
NS 
NS 
NS 
# 
NS 
0.94 
26.6 
0.37 
-50.9 
0.20 
37.1 
0.12 
27.0 
1.53 
0.8 
20.8 
144.6 
49.6 
2044 
±1.46 
±26.9 
±0.18 
±42.3' 
±0.06 
±55.1 
±0.05 
±109. 
±0.62 
±54.1 
±4.1 
±43.9 
±14.0 
±872* 
derly while Cortisol remained constant. During low and placebo infusion however, 
Cortisol values decreased significantly in the elderly subjects. Net percentual changes 
revealed only a decrease in aldosterone in the elderly during high dose infusion. 
Adrenaline did not exhibit consistent changes neither in the young nor in the 
elderly at either infusion dose. Noradrenaline increased at steady state low dose 
infusion in the elderly and at steady state placebo infusion in the young subjects. No 
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significant net percentual changes neither at low dose nor at high dose ANP infusion 
were observed for both adrenaline and noradrenaline. 
Basal plasma concentrations of the second messenger of the ANP hormonal 
system, cyclic guanosine monophosphate (cGMP) were similar and increased during 
low dose ANP infusion to a comparable extent in young and aged subjects. When 
placebo was infused, no change in cGMP values was observed in agreement with the 
lack of change in ANP concentrations. During high dose ANP infusion, the cGMP 
increase was more pronounced in the elderly subjects. 
Side effects 
With regard to the diuretic effects of ANP, no urgency was observed during or in 
the first 30 minutes after discontinuation of placebo infusion. Following low dose 
infusion, urgency was perceived in 5 subjects (1 elderly, 4 young), following high dose 
infusion urgency was perceived in 10 subjects (4 elderly, 6 young) When urgency was 
experienced the subjects micturated instantly in the supine position. During low/high 
dose infusion of ANP no hypotension, light-headedness or bradycardia were 
observed. 
Discussion 
The higher basal ANP concentrations in elderly subjects observed in this study 
confirm the observations reported in chapter 4.1 that ANP concentrations increase 
with advancing age During infusion of both low and high dose of (99-126)hANP, the 
plasma concentrations reached at steady state were markedly higher in the elderly 
subjects as compared to the young subjects. This cannot be attributed to differences 
in height, weight or quetelet-index as these parameters were similar in both groups. 
The only difference was the lower endogenous creatinine clearance in the aged 
group As the total amount of (99-126)hANP infused was similar in both groups, the 
higher ANP concentrations reached in the elderly subjects can only be explained by a 
diminished clearance of ANP as compared to the young subjects (chapter 4.2). 
Haemodynamic data 
Low dose ANP infusion resulted in immunoreactive ANP concentrations within the 
physiological range. During this infusion dose no significant effects of ANP on 
cardiovascular parameters (blood pressure, heart rate, forearm blood flow) were 
observed. Other investigators, performing ANP infusion studies in humans, reported 
a potent blood-pressure lowering effect (49-54). The ANP concentrations reached 
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during these infusion studies however, far exceeded the normal range. In our study, 
low dose ANP infusion resulted in only slightly elevated ANP levels. Richards et al. 
(63), using low dose and intra-arterial blood pressure monitoring, observed a 
decrease in mean arterial pressure. This observation was confirmed by Shenker et al. 
(64). In contrast, Solomon et al. (65) were not able to demonstrate significant changes 
in heart rate or blood pressure. These investigators however, infused low dose ANP 
for a period up to several hours. It may well be that when ANP is infused at a dose 
sufficient to raise plasma levels only slightly, a long infusion period is necessary to 
exert biological effects while at high dose ANP infusion, effects are more rapid in 
onset. 
At high dose infusion, ANP decreased mean arterial pressure (MAP) in both 
groups, with a more pronounced decrease in the elderly. Although heart rate, as 
expected from the fall in MAP, increased in both groups, the increase was significant 
only in the elderly subjects. With blood pressure falling by an average of 6 to 11 % at 
high dose infusion, one would expect activation of the sympathetic nervous system 
resulting in reflex tachycardia. However, one should take into account that these are 
net percentual changes. The net percentual decrease in blood pressure at high dose 
resulted mainly from an increase during placebo infusion. In absolute values only a 
minor decrease in MAP was observed, which was significant only in the elderly. 
At high dose infusion, as expected from the vasodilator potency of ANP, forearm 
blood flow (FBF) increased and forearm vascular resistance (FVR) decreased. This 
is consistent with reports from other investigators (66-68). At low dose infusion, no 
change neither in FBF nor in FVR was observed. This contrasts with the findings of 
Bolli et al. (68) and Hughes et al. (66). These investigators however infused low dose 
ANP intra-arterially. Regional ANP levels and effects achieved with intra-arterial 
infusion cannot be compared with those achieved with intravenous infusion. 
In view of the vasodilating potency of ANP (66,69), one might expect an increase in 
intravascular volume with a concomitant decrease in haemoglobin and haematocrit. 
Instead, consistent with other reports (63,65,70) an increase in haemoglobin and 
haematocrit was observed during infusion of ANP, suggesting a decrease in 
intravascular volume. It has to be noted however, that in absolute values, FVR 
decreased only during high dose in the elderly. Furthermore, FVR may not accurately 
reflect total peripheral resistance (TPR). Because in our study cardiac output was not 
measured, TPR could not be calculated. Results from studies regarding TPR after 
infusion of ANP in healthy humans have not been consistent. TPR was shown to 
remain constant (71), to decrease (70,72) or even to increase (73,74). These 
inconsistent results can partly be attributed to the molecular form of ANP infused, 
the dose of ANP given, the mode of administration (e.g. bolus or constant intra-
venous infusion, or both), the duration of infusion and whether or not the study was 
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placebo-controlled. 
In rats, blood volume decreased following infusion of ANP (75,76). This decrease in 
blood volume cannot be attributed solely to increased diuresis since this phenomenon 
was also observed in anephric rats (77,78). ANP induces fluid shift from the 
intravascular fluid compartment to the interstitial space, presumably by increasing 
capillary hydraulic conductivity, increasing vascular permeation of proteins and 
elevating postcapillary resistance (75,76,79). Trippodo el al. (75) found that ANP 
decreased circulatory capacitance in rats. This was attributed to a decrease in blood 
volume and to active venoconstriction, resulting in diminished venous return to the 
heart. Indeed, infusion of ANP in humans decreases central venous pressure (73,80). 
Reducing preload decreases cardiac output, which in turn decreases arterial pressure. 
Therefore the blood pressure lowering effect of ANP can be attributed to both a 
decrease in TPR and a reduction in blood volume, which by decreasing venous 
return, diminishes cardiac output. 
Comparison of the cardiovascular data revealed a larger net percentual decrease in 
MAP during the high dose infusion in the elderly subjects. This difference was largely 
due to the more pronounced fall in SP. However, the ANP concentrations reached 
during this dose were far higher in the elderly. In view of the more pronounced 
increase in cGMP values at this dose, more exaggerated effects of ANP in the aged 
group may not come as a surprise. 
Since significant volume contraction as shown by the haematocrit and haemoglobin 
values occurred at low dose in the young but not in the elderly subjects, one can 
speculate on receptor down-regulation with diminished target-organ responsiveness 
in the elderly. Considering the greater sensitivity to ANP in promoting volume 
contraction in the young while the cardiovascular parameters were not measurably 
influenced at low dose ANP, one can hypothesize that with advancing age the 
reducing effect on intravascular volume is preferentially down-regulated. As elderly 
subjects are more prone to dehydration (32,81), it may be that this is a functional 
mechanism by which the body protects the volume of the intravascular compartment. 
In this respect it would be interesting to compare the renal effects of ANP in young 
and elderly subjects. 
Summarizing, ANP at low dose did not exert significant cardiovascular effects but 
instead induced volume contraction. Since Solomon et al. (65) did not observe any 
cardiovascular effects but instead a diuresis and natriuresis, it may well be that at low 
dose ANP exerts its effect on the cardiovascular system primarily by reducing the 
volume of the intravascular compartment (diuresis, natriuresis, extravasation of 
fluid). With higher doses ANP also exerts direct effects on the cardiovascular system 
(vasorelaxation, blood pressure lowering and hormonal effects). 
157 
Hormonal effects 
Although both basal and steady state ANP concentrations at low dose ANP 
infusion were markedly higher in the elderly, basal and steady state concentrations of 
its second messenger cGMP were similar in both groups. Only during high dose infu­
sion, when mean ANP levels were higher than 1000 pg/ml in the elderly as compared 
to 570 pg/ml in the young, did the cGMP response differ Because assessment of 
cGMP plasma levels reflect the response of the target-organs for ANP (40,41), this is 
an indication that with advancing age a down-regulation of ANP target-organ res­
ponsiveness occurs This decreased responsiveness however is offset by the higher 
ANP concentrations reached during infusion of ANP. 
In vitro, ANP has been reported to inhibit renin release from juxtaglomerular cells, 
aldosterone and Cortisol production from cultured adrenal cells and norepinephrine 
release from adrenal pheochromocytoma cells (55,56,82,83). Indeed, infusion of ANP 
resulted in some (84,85) but not all studies (49,73), in a decrease in PRA, 
aldosterone, Cortisol, and catecholamines Some investigators even observed an in­
crease of PRA and catecholamines (86,87). This may be due to the potent blood 
pressure lowering effect of ANP resulting in reflex stimulation of the sympathetic 
nervous system. Although it seems that ANP exerts some inhibitory effect on the 
sympathetic nervous system (57,88,89), with high dose of ANP the fall in blood 
pressure may trigger a strong sympathetic reflex overriding the inhibitory effect of 
ANP on the sympathetic system (73,90) 
The above mentioned effects were observed when rather high doses of ANP 
(varying from 2 ^g/min to 12 Mg/min, with or without prior bolus injection of ANP) 
were given The plasma concentrations of immunoreactive ANP reached during these 
high dose infusions far exceed the normal range, thereby raising doubt whether these 
ANP induced effects are physiological or rather pharmacological by nature 
Therefore, (99-126)hANP was infused in low dose (0 25 μg/mln) resulting in 
concentrations within the physiological range. Steady state ANP concentrations were 
reached after 45 minutes of infusion. Because during placebo infusion significant 
changes did occur, the percentual changes from baseline during placebo infusion 
were subtracted from the percentual changes during low dose infusion. However, no 
significant changes in PRA, aldosterone, Cortisol or catecholamines was observed. 
These results suggest that ANP infused at low though biologically active dose as 
shown by the increase in cGMP values, does not exert significant effects on these 
hormonal systems neither in young nor in elderly persons. Recently several investi­
gators reported that even at low dose ANP infusions (0.16 to 0 4Mg/mm) a 
natnuresis, diuresis and blood pressure lowering effect could be demonstrated 
(63-65). Also, PRA and aldosterone levels decreased These effects however were 
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reached only during infusion of low dose ANP for several hours while in our study 
infusion was continued for only 60 minutes. 
During infusion of high dose ANP plasma levels were elevated far above the 
normal range and were similar to ANP concentrations found in congestive heart fai-
lure (59,60). This resulted in a relative increase in PRA in both young and elderly 
subjects. This increase however was not significant. In absolute values, no change in 
PRA occurred during high dose infusion of ANP. 
In contrast to the rise in PRA, plasma aldosterone fell sharply in the elderly but not 
in the young subjects. This phenomenon can be explained by the observed inhibition 
of both basal and stimulated aldosterone production by ANP (58,82,91). The more 
pronounced decrease in net percentual change in aldosterone levels in the elderly can 
be attributed to greater sensitivity of the adrenal in these subjects or, more likely, to 
the more pronounced biological effect of ANP as reflected in the higher cGMP levels 
reached. As for plasma Cortisol, no significant change occurred in the young at either 
infusion mode. In the elderly Cortisol did not change at high dose infusion whereas at 
placebo and low rate infusion Cortisol decreased in the elderly. The net percentual 
change in Cortisol at high dose ANP however was, due to the large inter-individual 
variation, not significant. No changes in plasma concentrations of adrenaline were 
observed in either group indicating that ANP at this dose does not modify the 
secretion of adrenaline from the adrenal medulla. 
During high dose infusion of ANP, only a minor decrease in MAP was observed. 
This resulted in slight stimulation of the sympathetic nervous system, as shown by the 
small increase in heart rate. These changes were significant only in the elderly. In 
these subjects, noradrenaline values tended to increase although this increase was not 
significant. However, it can be questioned whether peripheral venous noradrenaline 
concentrations accurately reflect the activity of the sympathetic nervous system, 
especially when only minor changes in MAP and HR are observed. Furthermore it 
has been shown that ANP inhibits noradrenaline release (92,93). Ebert et al. (88) 
observed an attenuation of carotid baroreflex-mediated cardioacceleration by ANP 
in humans. These observations suggest that ANP may modulate the sympathetic 
nervous system. In view of the above mentioned facts, the lack of consistent changes 
in plasma levels of noradrenaline may not be surprising. 
In conclusion: the cardiovascular and hormonal effects of ANP were assessed 
during infusion of (99-126)hANP at low and at high dose. Furthermore a comparison 
was made between young and elderly subjects. In general, low dose infusion of ANP 
did not exert major cardiovascular or hormonal effects in either group. High dose 
infusion induced a fall in blood pressure and forearm blood flow, and increased heart 
rate. With regard to the hormonal parameters, only aldosterone decreased 
159 
significantly. In general, the effects of high dose infusion were more pronounced in 
the elderly group, which is reflected in the higher cGMP values (a measure of the 
biological effect of ANP) reached. The ANP concentrations reached at high dose 
however, were far higher in the elderly. Considering the similar basal cGMP values, 
the similar increase in cGMP at low dose infusion and the haemoconcentration at low 
dose occurring only in the young, we propose that down-regulation of ANP target-
organ responsiveness occurs with advancing age. This diminished responsiveness 
however is compensated by an exaggerated increase in ANP concentrations during 
infusion of ANP. 
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Part V 
STUDIES OF ANP IN 
PATHOPHYSIOLOGICAL STATES 
In the preceding parts of this thesis a method for assessment of ANP concen-
trations in human blood was developed and evaluated. In this part the method 
developed was applied to two disease states in which the atrial natriuretic 
peptide hormonal system may be involved. In general, the release of ANP is 
determined by the volume of the intravascular system. However, as ANP secre-
tion is directly related to the degree of stretch of the atrial myocytes (1,2) and 
therefore ANP values are correlated to intracardiac pressures (3), it is well 
conceivable that diseases in which the intravascular volume is not enlarged, but 
yet intracardiac pressures rise, ANP release is enhanced. One such a disease is 
pulmonary embolism. Due to obstruction of (part of) the pulmonary blood flow, 
pressures on the right side of the heart are elevated thereby causing ANP con-
centrations to increase. With dissolution of the embolus these pressures decrease 
and concomitantly ANP levels would normalize. This hypothesis was tested and 
the results are described in chapter 5.1. In chronic myocardial infarction the 
intravascular volume is increased due to the remaining cardiac dysfunction with 
resulting activation of counter-regulatory mechanisms. At this stage, elevated 
ANP levels have been measured (4,5). However, at onset of infarction no 
enlargement of the intravascular volume is present. Due to the instantaneous 
onset of infarction, one might expect a sudden increase in intracardiac pressures 
(6) and thereby an increase in ANP concentrations, which increase is related to 
the degree of myocardial dysfunction. Therefore ANP concentrations were 
measured longitudinally during two days in patients with acute myocardial 
infarction. The results are described in chapter 5.2. 
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Chapter 5.1 
Reciprocal changes in ANP and PRA during 
treatment of pulmonary embolism 
Introduction 
Pulmonary embolism is characterized by acute obstruction of part of the 
pulmonary blood flow, which regularly causes an elevation of the pulmonary 
arterial pressure and the right atrial pressure (7,8). We hypothesized that during 
dissolution of the embolus atrial natriuretic peptide levels would decrease. 
Therefore ANP levels were followed in 12 patients with proven pulmonary 
embolism. They were treated with heparin initially and oral anticoagulants 
thereafter. In addition, five patients with peripheral venous thrombosis, receiving 
the same anticoagulant regime, were followed. As peripheral venous thrombosis 
is not associated with increased atrial pressures, no change in ANP levels in 
these patients was expected. 
Besides ANP, plasma renin activity (PRA) and aldosterone were measured and 
the relations between the plasma concentrations of these three salt-regulatory 
hormones were studied. 
Patients and methods 
Patients 
Pulmonary embolism was diagnosed when patients suffered from acute 
dyspnoea, had chest pain attached to the respiration and showed clear defects on 
the technetium Tc99 perfusion lung scan. Twelve patients (5 females, 7 males, 
mean age ± SD = 47 ± 21 years) fulfilled these criteria and were enrolled in 
the study group. Five patients (3 females, 2 males, aged 41 to 75 years) with 
venous thrombosis in pelvic or upper leg veins were diagnosed clinically and by 
occlusive impedance plethysmography. On admission to the hospital none of the 
patients were hypertensive or had any other sign of cardiac or renal failure. 
Blood samples were collected (EDTA-tubes on ice) from all patients (supine 
position) on admission (day 1, before institution of anticoagulant therapy) and, if 
possible, daily thereafter at 8 a.m. for up to 11 days. Each patient was observed 
7 to 10 times. In 2 patients with pulmonary embolism and in 1 patient with 
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venous thrombosis the first sample was taken on day 2 of treatment. Treatment 
consisted in the administration of heparin by continuous intravenous infusion 
(25,000 I.U. daily) and oral anticoagulants (acenocoumarol or phenprocoumon) 
for seven days, and solely oral anticoagulants thereafter. All patients received a 
standardized hospital diet (containing 10 to 12 g NaCl/day). 
Methods 
ANP was measured using the extraction method with the S-32 antibody. 
Plasma renin activity was measured using the Phadebas Angiotensin I test 
(Pharmacia Diagnostics, Sweden), and plasma aldosterone was measured using a 
direct radioimmunoassay (9). 
Statistical analysa 
The individual data of all 17 patients were analyzed by using the two-sided 
Spearman rank correlation test. The correlation coefficients (c.c.) relating to the 
12 patients with pulmonary embolism were normalized (10) to calculate the p-va-
lue and the 95 % confidence interval (95 % C.I., for 8 degrees of freedom). Sig­
nificance was assessed at the α=0.05 level. 
Results 
Although initial values of ANP varied widely, the subsidence of clinical signs 
and symptoms of pulmonary embolism was attended with consistent changes in 
plasma ANP and PRA concentrations. Figure V—1 illustrates the changes in 
mean ANP and PRA values, the former significantly falling (p<0.01, mean c.c. 
-0.68, 95 % C.I.: -0.30 to -1.0), the latter significantly rising (p<0.01, mean 
c.c. +0.68, 95 % C.I.: +0.10 to +1.0). In eight individual patients the fall in 
ANP values reached statistical significance at the a=0.05 level. In six patients the 
rise in PRA values became significant at this level. Intra-individually, the 
decrease in ANP values was significantly related to the increase in PRA values 
(p<0.01, mean c.c. -0.51, 95 % C.I.: +0.193 to -1.0). In the five patients with 
peripheral venous thrombosis treatment-related changes could be detected 
neither in ANP nor in PRA values. Interestingly, plasma aldosterone did not 
show any consistent change during treatment neither in the one nor in the other 
group of patients (pulmonary embolism: mean c.c. +0.06, 95 % C.I.: -0.22 to 
+0.34). 
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Figure V-1. Reciprocal changes in ANP (pg/ml) and FRA (nmol/l/h) leveb (log 
scale) during treatment of pulmonary embolism. Bars denote mean ± SEM. 
Discussion 
Acute pulmonary embolism can increase the pressure on the right side of the 
heart (7,8,11,12) and thereby provide a stimulus to the secretion of ANP (3,13). 
We hypothesized that the dissolution of a pulmonary embolus will generally lead 
to restitution of normal pressures in the right atrium, and in consequence to nor­
mal values of ANP. In each patient with pulmonary embolism ANP decreased 
during anticoagulant treatment, in agreement with this hypothesis. 
One might wonder whether anticoagulant therapy, mainly its change from he­
parin to oral anticoagulants may have a significant effect on ANP levels. Indeed, 
it has been observed in the rat that ANP effects are inhibited by heparin in vivo 
(14) whereas the plasma half life of (99-126)ANP is prolonged (15). If the 
change in ANP would be caused by heparin given to our patients during the first 
seven days of their treatment, an increase rather than the observed decrease in 
ANP levels in that period would be expected. Furthermore the absence of 
consistent ANP changes in the five patients with peripheral venous thrombosis 
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receiving the same anticoagulant regime strongly indicates that the observed ANP 
changes in pulmonary embolism are not related to the treatment regime. 
The decrease in ANP values during treatment of patients with pulmonary em-
bolism was attended with a proportional rise in PRA values. The somewhat sur-
prising absence of consistent changes in plasma aldosterone indicates that on a 
dietary salt intake of about 10 gram sodium chloride sensible changes in sodium 
economy did not occur. The reciprocal changes in ANP and PRA in pulmonary 
embolism is another demonstration of the potency of the former peptide system, 
even in concentrations within the physiological range, to inhibit the activity of the 
renin angiotensin system (16,17). It remains to be elucidated if this inhibition 
occurs at the renal level. A more provocative explanation for the observed 
reciprocal changes would be that the intra-atrial pressure by itself may be a 
controlling factor of both ANP and PRA. 
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Chapter 5.2 
ANP after myocardial infarction 
Introduction 
Immunoreactive atrial natriuretic peptide (ANP) concentrations are elevated in 
patients with congestive heart failure and correlate with intracardiac pressures 
(3,18). Little is known about changes in ANP concentrations after acute myocar-
dial infarction (AMI). To determine whether there are any consistent changes, 38 
patients with AMI who were treated succesfully were followed. Infarct size was 
assessed using the maximum creatine kinase value and left ventricular systolic 
function by gated blood pool scintigraphy in the acute (2 to 4 days) and the 
chronic phases (10 to 14 days) after infarction. In 24 patients who were cathe-
terized, ANP was measured in the femoral vein, the femoral artery and the right 
ventricle and correlated to left ventricular pressures. 
Patients and methods 
Patients 
Thirty-eight patients who were succesfully treated after acute myocardial infarc-
tion were studied. The patients (32 males, 6 females, mean age ± SD = 55.1 ± 
9.1 years, range 38 to 70 years) were admitted to the hospital within 4.4 hours 
(mean ± SD = 2.3 ± 0.9 hours) after the onset of symptoms. After a diagnosis 
of acute myocardial infarction was established (based on the symptoms and the 
electrocardiogram of the patient), blood was drawn for determination of ANP 
and creatine kinase levels, and 30 E anistreplase (=APSAC, Beecham Phar-
maceuticals Ine, Bristol, Tenn, USA) and 100 mg prednisone were given intra-
venously. Subsequently the patients were given heparin (25,000 I.U. daily) and 
treated conventionally, depending on the clinical conditions, using nitrates, 
B—blocking agents, calcium antagonists, diuretics and antiarrhythmic drugs. It was 
not considered ethical by the local Hospital Ethical Committee to strictly proto-
col the conventional treatment. All patients received a low sodium diet 
(containing 3 to 4 gr NaCl/day). Blood for determination of ANP and creatine 
kinase was sampled (supine position) at the time of admission, and 3, 6, 9, 12, 
15, 18, 24, 32, 40, and 48 hours later. The left ventricular systolic function (ejec-
tion fraction) was assessed using gated blood pool scintigraphy in the acute 
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phase (2 to 4 days after infarction) and in the chronic phase (10 to 14 days after 
infarction). 
In 24 patients cardiac catheterization was performed 13.9 ± 5.5 days after ad­
mission. Blood was drawn from the femoral vein, the femoral artery, and the 
right ventricle. In addition, left ventricular systolic and end-diastolic pressures 
were monitored. 
The location of the infarct (anterior vs. inferior) was determined by means of 
electrocardiography. Early reperfusion was assessed by electrocardiography, the 
occurrence of arrhythmias and the increase in time to the maximum creatine ki­
nase value. In the 24 patients who were catheterized, the number of coronary 
vessels affected (one, two or three) was determined. 
Methods 
ANP was measured using the extraction method with the S—32 antibody. Addi­
tion of either anistreplase or heparin to plasma samples did not influence ANP 
values (results not shown). 
Statistical analysis 
The changes in ANP concentrations were studied by means of analysis of 
variance for repeated measurements followed by the paired t-test (Student). The 
influence of various factors (age, maximum creatine kinase value, infarct site, 
reperfusion, number of coronary vessels affected) on ANP concentrations were 
investigated by means of stepwise multiple-regression analysis. To establish any 
correlations between ANP values and other variables, the Spearman rank 
correlation test was used. Differences between ANP values from the femoral 
vein, the femoral artery, and the right ventricle sampled during cardiac 
catheterization were analyzed using the paired t-test (Student). Significance was 
assessed at the α=0.05 level. All values are expressed as mean ± SD, unless 
indicated otherwise. 
Results 
During the study period of 48 hours after admission, all but four patients were 
classified as stage I of the Kiilip classification for congestive heart failure (19). 
The remaining four patients were classified as Kiilip stage II during the first and 
as Kiilip stage I during the second half of the study period. Because in these 
patients the individual mean ANP concentrations measured during the first 24 
hours were not found to differ from the individual means of the concentrations 
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Figure V-2. Time course of ANP levels after admission to the hospital. Values are 
expressed as mean ± SEM. 
measured in the other patients, the data of all 38 patients were analyzed as 
relating to one group. 
Three hours after admission the mean ANP concentration (22.8 ± 17.8 pg/ml) 
was significantly lower than the mean ANP concentration at the time of 
admission (67.5 ± 44.5 pg/ml, p<0.001). Thereafter ANP levels increased steadily 
until 15 hours after admission (72.9 ± 43.1 pg/ml) (figure V-2) . The mean ANP 
concentration 48 hours after admission (89.3 ± 51.1) was significantly higher than 
the mean ANP concentrations measured at the time of admission (p = 0.04) and 
15 hours after admission (p = 0.03). Differentiation of the infarct as to size 
(small, maximum creatine kinase value < 1000 I.U./l, or large), as to site 
(anterior or inferior), and as to the occurrence of reperfusion did not influence 
the pattern of ANP concentrations. 
The ANP concentrations measured at the time of admission to the hospital 
(ANP-1) were positively correlated with the infarct size (as determined by the 
maximum creatine kinase value, г = 0.39, ρ < 0.05). The individual patient's 
8 0 -
6 0 -
4 0 -
20 • 
179 
mean ANP concentration during the first 48 hours after infarction (i.m.ANP) was 
positively correlated with both the size of the infarct and the patient's age (r = 
0.36, p<0.05 and r = 0.43, p<0.01 respectively). Neither the site of the infarct 
(anterior or inferior), nor the occurrence of reperfusion, nor the number of 
coronary vessels affected (one, two or three) influenced either the ANP-1 or 
the i.m.ANP level. Left ventricular systolic function, as assessed by gated blood 
pool scintigraphy, was negatively correlated with the i.m.ANP level in both the 
acute (r = —0.46, p<0.05) and the chronic phases (r = —0.41, p<0.05) after 
infarction. Only in the chronic phase (10 to 14 days, г = -0.43, p<0.05) did the 
ANP—1 level correlate with left ventricular function. 
During cardiac catheterization the ANP concentrations in blood drawn at any 
of the three places mentioned did not correlate with left ventricular systolic 
pressure nor with left ventricular end-diastolic pressure (table V—1). As expec­
ted, ANP concentrations in blood drawn from the femoral vein were lower than 
in blood drawn from the femoral artery or the right ventricle. A close correlation 
was observed between ANP values measured in blood from these three places of 
origin (figure V—3). 
Discussion 
The atrial natriuretic peptide hormonal system can be regarded as acting 
antagonistically to the renin-angiotensin-aldosterone system, ils main function 
Table V-1. Comparison of ANP concentrations in blood sampled during 
cardiac catheterization (n = 24) with left ventricular systolic 
pressure (LVSP) and left ventricular end-diastolic pressure 
(LVEDP). No significant correlations were found. 
femoral vein 
femoral artery 
right ventricle 
LVSP 
0.19 
0.08 
0.15 
LVEDP 
0.09 
0.27 
0.32 
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Figure V-3. ANP leveL· obtained during catheterization in the femoral vein, the 
femoral artery and the right ventricle and the correlations between these leveb. 
Values are mean ± SEM. 
being to protect the body from cardiovascular volume overload (20,21). In 
agreement with this view, high ANP levels have been observed in patients with 
congestive heart failure. ANP concentrations have been found to correlate with 
the severity of congestive heart failure and to decrease when the patients 
recovered (22-24). After myocardial infarction ANP values were found to 
correlate with maximum oxygen uptake during bicycle ergometry; this maximum 
is an index for the remaining ventricular function (25). 
The systematic changes in ANP concentrations observed in this study confirm 
an assumption which Wencker et al. (26) made considering ANP values 
measured by direct assay in only four patients with acute myocardial infarction. 
Because plasma proteins interfere in the direct assay, prior extraction of plasma 
is recommended for accurate determination of ANP levels (27,28). In our study, 
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using an extraction method for measurement of ANP levels, an initial decrease 
followed by an increase in ANP levels was observed. We do share the 
explanation offered by Wencker et al. (26) of the observed phenomena. 
Immediately after the onset of infarction, intracardiac pressures rise causing a 
massive release of ANP up to depletion of atrial storage granules. Subsequently, 
ANP synthesis increases and plasma concentrations rise. On this hypothesis the 
ANP system, which protects the body from a volume overload, functions 
inadequately during the first few hours after acute myocardial infarction. 
Therefore, during these hours, the patient should be carefully monitored for any 
signs and symptoms of heart failure. 
A different explanation of the changes in ANP concentrations might be that 
the initial surge of ANP is the result of release of ANP from ischaemic cardiac 
tissue. On this assumption higher ANP concentrations are to be expected in 
inferior than in anterior infarction, since in the former the atria are more often 
ischaemic than in the latter. However, results of multiple-regression analysis 
indicated that neither the site of the infarct (nor the occurrence of reperfusion) 
significantly influenced ANP levels at the time of admission (ANP—1) nor the 
individual mean ANP level during the first 48 hours (i.m.ANP), which is a 
measure of the release of ANP during this period. 
In accordance with the hypothesis that release of ANP is determined by the 
severity of the infarction, both ANP—1 and i.m.ANP levels appeared to correlate 
with the maximum creatine kinase value, which is an index of the severity of the 
infarction, and with left ventricular function as assessed by gated blood pool 
scintigraphy. Individual mean ANP levels also correlated with patient age. As 
ANP values rise with advancing age (chapter 4.1), the observed correlation 
between the i.m.ANP level and the age of the patient indicates that after 
myocardial infarction the i.m.ANP level is a measure of ANP production rather 
than of ANP release due to ischaemic cardiac tissue. 
Interestingly, although individual ANP values varied widely, the mean ANP 
levels ranged from 23 to 89 pg/ml. These values are considered to be in the 
normal range with the measurement method used (chapter 2.1). The absence of 
increased mean ANP levels in the patients without congestive heart failure is in 
agreement with observations of other investigators, who reported that mean ANP 
levels are not above normal in patients classified as class I according to the New 
York Heart Association (NYHA) Functional Classification (22,24,29). 
Phillips el al. (30) reported that the mean ANP level in patients with acute 
myocardial infarction treated with streptokinase was not elevated as compared 
with the mean ANP level of patients treated without streptokinase. These investi-
gators attributed this finding to the beneficial effect of streptokinase in 
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preserving the myocardium and myocardial function. The findings of normal 
mean ANP levels in our patients treated with anistreplase support and streng-
then their view. 
The weak but significant correlation between ANP values and cardiac function 
and the absence of elevated mean ANP levels in our study group of well re-
covered patients indicates that ANP may be useful to assess cardiac function only 
in cases of acute myocardial infarction complicated by overt congestive heart fail-
ure. 
The absence of a significant correlation between ANP and left ventricular pres-
sures during cardiac catheterization may come as a surprise. Cardiac catheteriza-
tion was performed several days after infarction and at that moment all patients 
were classified as Killip stage I for congestive heart failure. Several investigators 
have reported a positive correlation between ANP values and intracardiac pres-
sures (3,18,31). However, their observations were based on a wide range of intra-
cardiac pressures. The absence of a correlation between ANP values and left 
ventricular pressures in our study group indicates that in these haemodynamically 
well-recovered patients, other factors may influence release of ANP and thereby 
obscure the relationship with intracardiac pressures. 
In conclusion: ANP levels were studied after acute myocardial infarction. After 
the sudden onset of the infarct, ANP is released from atrial storage granules. 
Subsequently, depletion of these granules occurs causing a relative "hypo-ANP-
ism". The weak relationships of infarct size and left ventricular function with, on 
the one hand, the ANP concentration on admission and, on the other hand, the 
individual mean ANP concentration during the first 48 hours after admission, 
mean that ANP can be of only limited value in assessing cardiac function after 
acute myocardial infarction. 
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Part VI 
SUMMARY AND CONCLUSIONS 
The discovery by deBold and colleagues in 1981 (1) that the heart besides ac-
ting as a pump has an endocrine function roused world-wide interest. The newly-
discovered hormone, called after its provenance, function and chemical structure 
atrial natriuretic peptide (ANP) can effect substantial diuresis, natriuresis and 
lowering of blood pressure. Within a few years' time its chemical structure was 
elucidated and its synthesis achieved, so that it became possible to develop 
methods for its assessment in plasma. A large number of publications on the 
atrial natriuretic peptide hormonal system have since appeared. 
Part I of this thesis is a survey of the present state of knowledge about the 
novel hormonal system. The issues addressed in the present study can be sum-
marized as follows: 
- the evaluation of the reliability of a radioimmunoassay for ANP using in-house 
reagents including antisera and radioactive ligands, 
- a study of material and physiological conditions which may influence the assess-
ment of ANP concentrations, 
- an analysis of the physiological relevance of the higher ANP values measured 
in aged subjects as compared to those measured in young subjects, 
- an assessment of the involvement of atrial natriuretic peptide in pulmonary 
embolism and myocardial infarction 
In Part II the results of the studies performed in connection with the first issue 
are presented. To establish a method for the measurement of ANP in plasma 
two sheep were immunized with synthetic (99-126)hANP. Thus two antibodies 
specific for the non-oxidized form of (99-126)hANP were obtained. Comparison 
with a commercially available antibody turned out in favour of the first-
mentioned two antibodies. The results obtained with these three antibodies 
correlated well. With the two home-made antibodies two methods for measuring 
ANP concentrations were developed, a direct method and a method requiring 
prior extraction of plasma on Seppak C-18 columns. Although the direct method 
is considerably less laborious than the extraction method, its inaccuracy especially 
in the lower range of ANP concentrations, disqualifies it for reliable measure-
ment of ANP values. 
Using high pressure liquid chromatography (HPLC) analysis circulating forms 
of immunoreactive ANP in human plasma were studied. Both in normal subjects 
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and in patients with congestive heart failure three ANP immunoreactive forms 
were found. The main circulating form corresponds to (99-126)hANP. Whether 
the other two immunoreactive forms represent precursor or degradation products 
of (99-126)hANP and whether they are of physiological relevance remains to be 
elucidated. Stimulation of ANP release by ergometrie bicycle exercise or volume 
loading predominantly stimulates the release of (99-126)hANP. This is an indica-
tion that this molecular form is the most important circulating ANP immuno-
reactive form in human blood (2,3). Cyclic guanosine monophosphate (cGMP) 
functions as the second messenger for ANP. Therefore cGMP values in plasma 
or urine reflect the biological effectiveness of ANP (4,5). A method for 
measuring cGMP concentrations in plasma is described in chapter 2.5. Combined 
assessment of ANP and cGMP concentrations is an effective way to study both 
the release and the effect of the atrial natriuretic peptide hormonal system. 
In Part III a number of studies on the effects of various factors which may 
influence ANP values found in blood obtained from normal subjects are des-
cribed. A study of different blood sampling procedures revealed that sampling in 
EDTA-tubes kept on ice and centrifuged within one hour gives the most reliable 
results. Platelets contain receptors for ANP and according to Richards et al. (6) 
their number in plasma can therefore influence the ANP concentration. The 
application of different modes of centrifugation, which yielded different amounts 
of platelets, did not, however, significantly influence ANP values. As storage of 
plasma at - 2 0 ^ as well as repeated thawing decreases ANP immunoreactivity, it 
is recommended to store plasma at —80oC and prevent it from thawing more 
than once. 
Neither venepuncture stress nor the phase of the menstrual cycle influence 
ANP values. ANP concentrations are higher in the early morning. The ensuing 
decrease in ANP may be explained by the decrease in venous return due to 
pooling of blood in the lower extremities. Like many other hormones, ANP con-
centrations are subject to endogenous variations. These variations cannot be 
entirely attributed to assay variations and therefore can stand in the way of a 
correct interpretation of the values found. 
As the secretion of ANP is dependent on venous return to the heart, its values 
are higher in the supine than in the upright position. Ergometrie bicycle exercise 
stimulates cardiac ANP secretion, which is of physiological significance because 
plasma levels of cGMP, the second messenger for ANP, rise proportionately. 
Using the extraction method reference values for ANP were determined under 
standardized conditions in 66 healthy volunteers recruited from the general 
population. In these subjects ANP concentrations ranged from 8.3 to 86.8 pg/ml 
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(mean ± SD = 35.3 ± 16.2 pg/ml). A positive correlation between the ANP 
value and age was found. 
In Part IV a few studies dealing with age-related change in ANP concentra­
tions are described. A study of the kinetic parameters of ANP revealed a similar 
plasma half-life but a markedly decreased total body clearance and consequently 
a decreased distribution volume of ANP in elderly subjects as compared to 
young subjects. This decreased distribution volume may contribute to the higher 
ANP values found in the elderly. The correlation observed in the elderly between 
ANP clearance and endogenous creatinine clearance, a measure for the number 
of functioning nephrons, is an indication of the important role of the kidney in 
ANP clearance. The higher ANP values in the elderly do not seem to be attrib­
utable to different circulating forms of ANP, as by means of HPLC analysis 
similar ANP immunoreactive profiles were observed in one young subject and 
one aged subject. 
Dehydration induced by restriction of fluid intake to 25 % of normal did not 
cause significant changes in ANP levels either in young or in aged subjects. In 
contrast, volume loading (750 ml 0.9 % NaCl in 60 minutes) caused a pro­
nounced increase in ANP values in the aged whereas no change occurred in the 
young. Although basal ANP values were higher in the elderly, basal plasma 
cGMP values were similar and rose to a comparable extent during volume 
loading. These findings point to decreased responsiveness of the ANP target-
organs with advancing age. This hypothesis is supported by the results described 
in chapter 4.5. 
Infusion of (99-126)hANP resulted in far higher concentrations of ANP in the 
elderly than in the young. On the other hand, basal plasma cGMP values, reflec­
ting the biological effectiveness of ANP, were similar, and during low dose 
infusion (0.25 /xg/min ANP) cGMP values rose to a comparable extent in both 
groups. At high dose infusion (2.0 μg/min ANP), cGMP rose more in the elderly. 
It may well be that this greater rise is due to the higher ANP concentrations 
reached during infusion in this group. 
Low dose infusion did not result in significant haemodynamic effects in either 
group. A reduction in blood volume, as reflected in the haematocrit values, was 
observed in the young. Blood pressure fell and both heart rate and forearm 
blood flow rose at high dose ANP infusion, which is consistent with reports from 
other investigators (7-9). The effects were more pronounced in the elderly, 
which is also reflected in the greater rise in cGMP values. 
Low dose ANP infusion did not produce consistent changes in plasma renin 
activity (PRA), aldosterone, Cortisol, adrenaline or noradrenaline levels in either 
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group. During high dose ANP infusion a relative increase in PRA in both groups 
was observed, while aldosterone decreased only in the aged. No effect of ANP 
on Cortisol and adrenaline was observed in either group. The lack of sympathetic 
stimulation as reflected in the noradrenaline values during infusion of the high, 
blood pressure lowering, dose of ANP is an indication that ANP modulates the 
sympathetic nervous system (10). 
In general, the effects of high dose ANP infusion were more pronounced in 
the elderly. During infusion at this dose the ANP concentrations were, however, 
far higher in this group, which may explain the stronger effects. This is also 
expressed in the higher cGMP values that were reached in this group at high 
dose ANP infusion. 
In view of 
- the similar increase in cGMP in both groups during volume loading in contrast 
with a rise in ANP occurring only in the elderly, 
- the similar basal cGMP values despite the higher basal ANP concentrations in 
the elderly, 
- the comparable increase in cGMP during low dose ANP infusion despite the 
higher ANP concentrations reached in the elderly, and 
- the fact that haemoconcentration - a measure for volume contraction - at low 
dose infusion was found only in the young, 
it is plausible that with advancing age the responsiveness of the ANP target 
organs diminishes. This diminished responsiveness is compensated by a stronger 
response of the ANP hormonal system both to stimulation (e.g. by volume 
loading) and to infusion of exogenous ANP. Thus the system is capable, in the 
young and the old, to respond with similar potency to volume changes. At least 
part of this stronger response of the ANP hormonal system can be ascribed to a 
decreased clearance of ANP in the elderly. 
In Part V two studies are described in which ANP concentrations were 
measured serially in patients with pulmonary embolism or myocardial infarction. 
In pulmonary embolism the obstruction of the pulmonary blood flow causes 
pressures in the right side of the heart to rise. As ANP values are correlated to 
atrial pressures, one may expect initially elevated ANP concentrations, which will 
fall back to normal as the pulmonary embolus dissolves under anticoagulant 
medication. Although in a group of twelve patients with pulmonary embolism the 
mean ANP concentration on admission was not elevated, it did decrease during 
anticoagulant therapy. Concomitantly, plasma renin activity increased. These 
phenomena were absent in a control group consisting of patients with venous 
thrombosis. These findings support the hypothesis that pulmonary embolism 
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causes a relative increase in ANP concentrations. 
To follow ANP concentrations after myocardial infarction, ANP was measured 
during 48 hours in 38 patients with acute myocardial infarction. The concen-
trations decreased initially, but rose subsequently till 15 hours after admission. 
The initial ANP concentrations on admission as well as the individual mean ANP 
concentrations during the first 48 hours after admission correlated weakly, though 
significantly, with the size of the infarct and the left ventricular function. Neither 
the site of the infarct nor the occurrence of reperfusion nor the number of 
coronary vessels affected influenced the ANP concentration. The observed 
changes in ANP concentrations after infarction may be explained as follows. 
Acute myocardial dysfunction after infarction, by raising atrial pressures, causes a 
release of ANP from atrial storage granules. The ensuing decrease in ANP 
concentrations is attributable to depletion of these storage granules. At this 
stage, circulating ANP concentrations will decrease despite increased intracardiac 
pressures. Subsequently ANP is produced at greater rate causing its concen-
trations in the blood to rise again. The weak correlations of infarct size and left 
ventricular function with, on the one hand, the ANP concentration on admission 
and, on the other hand, the individual mean ANP concentration during the first 
48 hours after admission, mean that ANP can be of only limited value to assess 
cardiac function after acute myocardial infarction. 
To conclude: in this thesis the evaluation of a sensitive and reliable method for 
the measurement of ANP concentrations in humans is described. In addition, a 
number of factors to which attention should be paid when interpreting ANP 
values were studied. The ANP measurement method developed was used to 
study the physiological significance of the higher ANP levels observed in elderly 
subjects. Determination of ANP concentrations can be of value in studying 
certain pathophysiological phenomena associated with cardiovascular diseases, 
such as pulmonary embolism and acute myocardial infarction. 
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SAMENVATTING EN CONCLUSIES 
De ontdekking in 1981 door deBold en collega's (1) dat het hart naast een 
pompfunctie tevens een endocriene functie bezit, wekte wereldwijde interesse op. 
Het nieuw ontdekte hormoon, naar zijn plaats van productie, functie en che-
mische structuur, het atrieel natriuretisch peptide (ANP) genoemd, kan een forse 
diurèse, natriurese en bloeddrukdaling teweegbrengen. Binnen een paar jaar tijd 
werd de chemische structuur ontrafeld en het hormoon gesynthetiseerd, waardoor 
de mogelijkheid ontstond om een bepalingsmethode voor dit hormoon te ontwik-
kelen. Sindsdien is een groot aantal publicaties over het atrieel natriuretisch 
peptide hormonaal systeem verschenen. 
In deel I van dit proefschrift wordt een kort overzicht gegeven omtrent het 
huidige begrip over dit nieuwe hormoonsysteem. De studies beschreven in dit 
proefschrift kunnen als volgt worden samengevat: 
- de evaluatie van een radioimmunoassay voor ANP opgezet met zelf-ontwik-
kelde reagentia inclusief antiserum en radioactief ligand 
- het bestuderen van factoren en fysiologische condities die de meting van ANP 
waarden kunnen beïnvloeden 
- het bestuderen van de fysiologische betekenis van de hogere ANP waarden ge-
vonden bij oudere mensen in vergelijking met jongere mensen 
- het bestuderen van de betrokkenheid van het atrieel natriuretisch peptide bij 
longembolie en myocardinfarct 
In deel II van dit proefschrift worden de resultaten van de studies uitgevoerd 
naar aanleiding van de eerste vraagstelling, beschreven. Teneinde een methode 
voor meting van het ANP in plasma op te zetten, werden twee schapen geïmmu-
niseerd met synthetisch (99-126)hANP. Hiermee werden twee antilichamen ver-
kregen die specifiek zijn voor de niet-geoxideerde vorm van het (99-126)hANP. 
Vergelijking met een commercieel verkrijgbaar antilichaam viel in het voordeel 
van de eerste twee genoemde antilichamen uit. De resultaten zoals verkregen 
met deze drie antilichamen correleerden onderling goed met elkaar. Met de twee 
opgewekte antilichamen werden twee methoden ontwikkeld om ANP concentra-
ties te bepalen, namelijk een directe methode en een methode die gebaseerd is 
op voorafgaande extractie van het plasma op Seppak C—18 kolommen. Hoewel 
de directe methode veel minder bewerkelijk is dan de extractie methode, is door 
het gebrek aan betrouwbaarheid met name in het lagere gebied van ANP waar-
den, deze methode ongeschikt voor een betrouwbare meting van het ANP gehal-
te. 
Gebruikmakend van hoge-druk vloeistofchromatografie (HPLC) werden de 
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circulerende vormen van het immunoreactief ANP in menselijk plasma bestu-
deerd. Zowel in plasma van normale personen als in plasma van patiënten met 
decompensatio cordis werden drie ANP-immunoreactieve vormen gevonden. De 
voornaamste vorm komt overeen met (99-126)hANP. Het dient nog nader onder-
zocht te worden of de andere twee ANP-immunoreactieve vormen, voorloper- of 
afbraak-produkten van (99-126)hANP zijn en of zij enige fysiologische betekenis 
hebben. Stimulatie van ANP secretie door inspanning (fiets-ergometrie) of door 
volume expansie stimuleerde voornamelijk de (99-126)hANP vorm. Dit kan erop 
wijzen dat deze vorm de meest belangrijke circulerende ANP-immunoreactieve 
vorm is bij de mens (2,3). Cyclisch guanosine monophosphate (cGMP) func-
tioneert als de cellulaire boodschapper voor het ANP. Derhalve weerspiegelt de 
cGMP waarde in plasma of urine het biologische effect van ANP (4,5). In 
hoofdstuk 2.5 wordt een methode voor het meten van cGMP waarden in plasma 
beschreven. De gecombineerde bepaling van zowel ANP als cGMP is een 
doeltreffende manier om zowel de afgifte als het effect van het atrieel 
natriuretisch peptide hormonaal systeem te bestuderen. 
In deel III worden verschillende studies beschreven met betrekking tot het 
effect van verschillende factoren die de ANP waarde in bloed van normale 
personen kunnen beïnvloeden. Studie van verschillende bloedafname-procedures 
wees uit dat bloedafname in EDTA-buizen op ijs en gecentrifugeerd binnen een 
uur de meest betrouwbare resultaten oplevert. Bloedplaatjes bevatten receptoren 
voor ANP en derhalve zou volgens Richards et al. (6) de hoeveelheid bloed-
plaatjes aanwezig in plasma de ANP concentratie kunnen beïnvloeden. Het 
gebruik van diverse centrifugatie-methoden die verschillende hoeveelheden 
bloedplaatjes in het plasma opleverden beïnvloedde de ANP waarde echter niet. 
Omdat zowel opslag van plasma bij — 2QPC als het herhaald ontdooien van 
plasma de ANP-immunoreactiviteit vermindert, wordt aanbevolen om plasma bij 
—80PC te bewaren en om meer dan eenmalig ontdooien van plasma te voor-
komen. 
Noch de stress tengevolge van het aanprikken van een bloedvat noch de fase 
van de menstruele cyclus beïnvloeden de ANP concentratie. In de vroege 
ochtend worden hogere ANP concentraties gemeten. De hiernavolgende daling in 
ANP waarden zou verklaard kunnen worden door een daling van de veneuze 
terugvloed naar het hart als gevolg van stase van bloed in de onderste 
extremiteiten. Zoals veel andere hormonen, zijn ook de concentraties van het 
ANP aan endogene variaties onderhevig. Deze variaties kunnen niet volledig 
toegeschreven worden aan de bepalings-methodiek en kunnen derhalve de 
interpretatie van ANP waarden bemoeilijken. Omdat de secretie van het ANP 
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afhankelijk is van de veneuze terugvloed naar het hart, worden hogere ANP 
waarden gemeten in de liggende positie in vergelijking met de waarden gemeten 
in de staande positie. Inspanning op een fietsergometer stimuleert de ANP 
secretie uit het hart, wat van fysiologische betekenis is omdat ook de spiegels 
van het cGMP, de cellulaire boodschapper van het ANP, parallel met het ANP 
stijgen. Gebruikmakend van de extractie-methode werden referentie-waarden 
voor het ANP bepaald bij 66 gezonde vrijwilligers uit de bevolking. In deze 
personen varieerden de ANP concentraties van 8,3 tot 86,8 pg/ml (gemiddelde en 
standaard-deviatie = 35,3 ± 16,2 pg/ml). In deze groep werd een positieve cor-
relatie gevonden tussen de ANP waarde en de leeftijd. 
In deel IV worden enkele studies beschreven met betrekking tot de leeftijds-
afhankelijke verandering van het ANP gehalte in plasma. Bij bestudering van de 
kinetische parameters van het ANP bleek dat oude personen eenzelfde plasma 
halfwaardetijd maar een verminderde klaring en derhalve ook een verminderd 
distributie-volume van het ANP hebben in vergelijking met jonge personen. Dit 
verminderde distributie-volume zou kunnen bijdragen aan de hogere ANP waar-
den gevonden bij ouderen. De gevonden correlatie bij de ouderen tussen de 
ANP klaring en de endogene creatinine klaring, een maatstaf voor de hoeveel-
heid functionerende nephronen, onderstreept het belang van de nier bij de 
klaring van ANP. De hogere ANP waarde bij de oudere personen kan waar-
schijnlijk niet toegeschreven worden aan andere circulerende vormen van het 
ANP omdat, gebruikmakend van HPLC analyse, een soortgelijk ANP-immuno-
reactief profiel werd gevonden bij een jonge en bij een oude persoon. 
Dehydratie door restrictie van de vloeistof-inname tot 25 % van normaal 
veroorzaakte geen significante verandering in de ANP waarde noch bij jonge 
noch bij oude personen. Volume expansie (750 ml 0,9 % NaCl in 60 minuten) 
daarentegen veroorzaakte een forse stijging van de ANP waarde bij de ouderen 
terwijl geen verandering werd gevonden bij de jonge personen. Hoewel de basale 
ANP concentraties hoger waren in de oude personen, waren de plasma cGMP 
waarden hetzelfde en het cGMP steeg in gelijke mate gedurende de volume 
expansie. Deze bevindingen duiden op een verminderde respons van de doelwit-
organen voor het ANP met het vorderen van de leeftijd. Deze hypothese wordt 
ondersteund door de resultaten beschreven in hoofdstuk 4.5. 
Infusie van (99-126)hANP resulteerde in veel hogere ANP concentraties in de 
ouderen in vergelijking met de jonge personen. De plasma cGMP waarden, een 
weerspiegeling van het biologische effect van ANP, waren basaal hetzelfde, en 
stegen evenveel in beide groepen bij een lage dosering ANP (0,25 jtg/min ANP). 
Bij hoge dosering ANP (2,0 /¿g/min ANP) steeg het cGMP meer in de oudere 
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groep. Het is heel goed mogelijk dat deze sterkere stijging veroorzaakt wordt 
door de hogere ANP concentraties die in deze groep tijdens infusie bereikt 
werden. 
Lage dosering ANP veroorzaakte geen significante hemodynamische verande-
ringen in beide groepen. Bij de jongeren verminderde het circulerend volume, 
zoals weerspiegeld in de hematocriet-waarden. Bij de hoge dosering ANP daalde 
de bloeddruk en stegen zowel de hartslag als de bloeddoorstroming in de 
onderarm. Deze resultaten komen overeen met de resultaten zoals gevonden 
door andere onderzoekers (7-9). De effecten waren meer uitgesproken bij de 
ouderen, zoals tot uitdrukking komt in de sterkere stijging van cGMP waarden. 
Lage dosis ANP veroorzaakte geen consistente veranderingen in plasma renine 
activiteit (PRA), aldosteron, Cortisol, adrenaline of noradrenaline in beide 
groepen. Gedurende hoge dosis ANP werd een relatieve stijging van de PRA in 
beide groepen gevonden terwijl het aldosteron alleen bij de ouderen daalde. In 
geen van beide groepen beïnvloedde het ANP de Cortisol of adrenaline waarden. 
Het gebrek aan activatie van het sympatisch zenuwstelsel zoals weerspiegeld in 
de noradrenaline waarden gedurende infusie van de hoge, bloeddrukverlagende 
dosis ANP is een aanwijzing dat het ANP het sympatische zenuwstelsel kan 
beïnvloeden (10). 
In het algemeen waren de effecten tijdens infusie van de hoge dosis meer 
uitgesproken bij de ouderen. Gedurende infusie van deze dosis waren de ANP 
concentraties echter veel hoger in deze groep, wat de sterkere effecten kan 
verklaren. Dit wordt ook weergegeven in de hogere cGMP waarden bereikt in 
deze groep bij de hoge dosis ANP. 
Gezien de: 
- gelijke stijging van het cGMP in beide groepen in vergelijking met de ANP stij-
ging alleen bij de ouderen gedurende volume expansie 
- dezelfde basale cGMP concentraties ondanks de hogere basale ANP concentra-
ties bij de ouderen 
- vergelijkbare stijging van het cGMP gedurende infusie van lage dosis ANP 
ondanks de hogere ANP concentraties bij de ouderen 
- hemoconcentratie, wat duidt op volume contractie, bij lage dosis ANP wat 
alleen bij de jongeren werd gevonden 
wordt een verminderde gevoeligheid van de doelwit-organen voor ANP met het 
vorderen van de leeftijd aannemelijk gemaakt. Deze verminderde gevoeligheid 
wordt echter gecompenseerd door een sterkere respons van het ANP hormonale 
systeem, zowel op stimulatie (b.v. door volume expansie) als op infusie van exo-
geen ANP. Hierdoor is dit hormonaal systeem in staat om zowel bij jongeren als 
bij ouderen met eenzelfde capaciteit te reageren op volume veranderingen. Ten-
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minste een gedeelte van de sterkere respons van het ANP hormonaal systeem 
kan toegeschreven worden aan de verminderde klaring van het ANP bij oude 
personen. 
In deel V worden twee studies beschreven waarbij ANP concentraties opeen-
volgend werden gemeten in patiënten met een longembolie of met een myocard-
infarct. Door de obstructie van de longdoorbloeding bij longembolie stijgen de 
drukken aan de rechterkant van het hart. Daar ANP concentraties gecorreleerd 
zijn met de atriële drukken, verwacht men aanvankelijk verhoogde ANP concen-
traties die dalen wanneer de longembolus wordt opgelost door antistollings-
therapie. Hoewel de gemiddelde ANP spiegel bij opname in een groep van 
twaalf patiënten met longembolie niet verhoogd was, daalde het ANP gedurende 
antistollings-therapie. Tegelijkertijd steeg de plasma renine activiteit. Deze 
bevindingen werden niet gevonden in een groep patiënten met veneuze throm-
bose. Dit ondersteunt de hypothese dat longembolie een relatieve stijging van de 
ANP concentraties veroorzaakt. 
Om het verloop van ANP concentraties na een myocardinfarct te bestuderen, 
werd ANP gemeten gedurende 48 uur bij 38 patiënten met een acuut myocard-
infarct. Het ANP daalde aanvankelijk, maar steeg daarna tot 15 uur na opname 
in het ziekenhuis. Zowel de individuele ANP concentratie gemeten bij opname 
als de individuele gemiddelde ANP waarde gedurende de eerste 48 uur na 
opname, correleerden met de grootte van het infarct en met de linker-ventrikel-
functie. Noch de plaats van het infarct noch het optreden van reperfusie noch 
het aantal coronairvaten getroffen, beïnvloedden de ANP concentraties. De 
waargenomen veranderingen in ANP concentraties na een infarct kunnen als 
volgt worden verklaard. Na een infarct treedt er een acute dysfunctie van het 
hart op die, door verhoging van de atriële drukken, een afgifte van het ANP uit 
de atriële granula teweegbrengt. De hierop volgende daling van het ANP kan 
toegeschreven worden aan een uitputting van deze granula. In deze fase zullen 
de ANP concentraties in het circulerende bloed dalen ondanks de verhoogde 
drukken in het hart. Vervolgens wordt het ANP met een grotere snelheid 
aangemaakt waardoor de concentraties in het bloed weer zullen stijgen. De 
zwakke correlaties tussen de grootte van het infarct en de linker-ventrikel-functie 
aan de ene kant en de ANP waarde bij opname en de gemiddelde ANP waarde 
gedurende de eerste 48 uur aan de andere kant, duiden erop dat het ANP 
slechts van beperkte waarde kan zijn om de hartfunctie na een myocardinfarct te 
bepalen. 
Samenvattend: in dit proefschrift wordt een gevoelige en betrouwbare methode 
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om ANP concentraties bij mensen te bepalen, geëvalueerd. Tevens worden 
enkele factoren beschreven waarop gelet dient te worden wanneer men ANP 
waarden interpreteert. De meetmethode voor ANP werd gebruikt om de fysio-
logische betekenis van de hogere ANP waarden bij oudere personen te bestu-
deren. Bepaling van ANP concentraties kan van waarde zijn bij het bestuderen 
van bepaalde pathofysiologische verschijnselen samenhangende met cardio-
vasculaire ziektebeelden zoals longembolie en myocardinfarct. 
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» 
STELLINGEN 
Behorende bij het proefschrift 
ATRIAL NATRIURETIC PEPTIDE 
In het openbaar te verdedigen op 
dinsdag 12 december 1989 
des namiddags te 1.30 uur 
precies 
door 
Adriaan C.I.T.L. Tan 
STELLINGEN 
1. Het bestaan van zowel een cardiaal hormoon 'atneel natriuretisch peptide', 
een (veronderstelde) neurotransmittor 'brein natriuretisch peptide' en een 
paracnen hormoon 'urodilatine' wijst op de aanwezigheid van een 
'natriuretisch peptiderg systeem' in de regulatie van de water- en zout-
balans. 
2 In menselijk bloed circuleren naast (99—126)hANP ten minste nog twee 
andere ANP-immunoreactieve stoffen. 
dit proefschrift 
3. De procedure van afname en behandeling van bloed is van wezenlijke 
invloed op het immunoreactieve ANP-gehdlte. 
du proefrclmft 
4. De endogene ANP-spiegel kan intra-individuele variaties vertonen die niet 
volledig verklaard kunnen worden door intra-assay-vanaties 
du proefschrift 
5 De hogere ANP spiegels in het bloed van oudere mensen is tenminste voor 
een deel toe te schrijven aan het verminderde verdelingsvolume bij deze 
personen. 
dit proefschrift 
6. Met toenemende leeftijd vermindert de gevoeligheid van de doelwit-organen 
voor ANP. Deze verminderde gevoeligheid wordt echter gecompenseerd 
door een sterkere stijging van de ANP-spiegel als reactie op zowel 
endogene als exogene stimuli. 
du proefschrift 
7 De daling van de ANP-spiegel na een acuut myocardinfarct wordt 
veroorzaakt door een depletie van de atriele granula. 
du proefschrift 
8 Zowel de concentratie van ACTH als de concentratie van Cortisol in bloed 
stijgt met het vorderen van de leeftijd. 
eigen waarneming 
9. Wanneer men het 'oproepsein' van de arts beschouwt als een draagbaar 
telefoonapparaat, wordt het de hoogste tijd een draagbaar automatisch 
antwoordapparaat te ontwerpen. 
10 Wanneer de huidige tendens zich voortzet kan de term 'openbaar vervoer' 
beter worden vervangen door Verplicht vervoer'. 
11. »Gezien de praktijk in het ziekenhuis zou de benaming 'co-assistent' dienen 
te worden vervangen door 'sub-assistent' 
12. De term 'voetbal-vandalisme' kan beter worden vervangen door 'stadion-
oorlog'. 
13 De uitdrukking 'hagelstenen zo groot als duive-eieren' zegt meer over de 
grootte van hagelstenen dan over de grootte van duive-eieren 
14. In tegenstelling tot 'post-partum depressie' kan aan het bestaan van een 
'post-promotie depressie' ernstig getwijfeld worden 


